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General introduction
Optimizing initial dyspepsia management

O ptim izing initial dyspepsia m anagem ent
Dyspepsia
Derived from the Greek words ‘Qua’ (dus = bad) and ‘nenTeiv’ (peptien = to 
digest), dyspepsia literally refers to symptoms supposed to result from disordered 
digestion of food, or indigestion. Since this encompasses symptoms that find 
their etiology in very different processes from chewing to defecation it is a very 
non-specific term . 1 Dyspepsia is therefore better regarded as a complex of 
symptoms that has its origin in the upper gastrointestinal tract. Following this 
broad definition, epigastric pain or discomfort, heartburn, acid regurgitation, 
nausea, vomiting, belching, bloating, early satiety, and postprandial fullness are 
symptoms that might be regarded as part of the symptom complex. 1,2
Numerous definitions of dyspepsia and derived terms (e.g. organic, functional, 
non-ulcer, ulcer-like, motility-like or reflux-like dyspepsia) are found in the 
literature. 1,3,4 They evolved concurrent with the changing understanding of this 
disorder and the developments of methods and techniques for better 
understanding and management of patients with dyspepsia. 1,3,5 Since the 
etiology of dyspepsia remains poorly understood, the definition continues to 
provoke controversy, especially regarding the duration of symptoms, as well as 
the in- or exclusion of predominant heartburn. According to specially designed 
and revised Rome I-III criteria, the latter should be excluded and considered to 
be gastro-oesophageal reflux disease (GORD) .5,6 However, in clinical practice, 
predominant reflux and upper abdominal symptoms often cannot be reliably 
distinguished, because there is a major overlap between these symptoms and
7 10symptom patterns change over time in the majority of patients. - Therefore, we 
(and many others) believe that heartburn is an integral part of the dyspeptic 
symptom complex in primary care patients with new onset dyspepsia.2,11-15
Disease burden
Dyspepsia is very common in Western populations. Approximately 20 to 40% 
of the general population frequently suffers from dyspeptic symptoms. Variation 
in reported prevalence estimations is principally explained by the absence of an
10 16 17unequivocal definition.10,16,1' Overall, dyspeptic symptoms are being relatively 
short-lived, but recur often. Consequently, the majority is treated in primary care. 
Roughly 25% of the people with dyspeptic symptoms seek medical attention, 
accounting for approximately 3% of all general practitioner consultations.13,18 
Less than 5% of the patients consulting for dyspepsia is referred to a specialist. 
Depending on the type, severity and duration of the symptoms an endoscopy is
performed in 10 to 25% of the patients eventually.4,10,13 Many of the patients that
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Figure 1: Management o f dyspepsia (Dutch guideline)
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Treatment is associated with considerable health-care costs. In 2001, in The
Netherlands more than 400 million euro (13% of the total pharmaceutical budget)
20was spent on drugs prescribed for the treatment of dyspeptic symptoms alone.20 
An additional 15 million euro was spent on over-the-counter medication, let alone 
costs for consultations, diagnostics and interventions, such as endoscopy. Apart 
from the burden on health-care resources, dyspepsia can substantially impair a 
patients’ quality of life. As many dyspeptic patients are still in the occupational 
age, it also has a considerable socio-economic impact due to work absenteeism
10 21 04
and productivity loss. , - 
Diagnosis
Several organic causes for the dyspeptic symptoms have been identified, such 
as peptic ulcer, inflammation, altered motility, and upper gastrointestinal 
malignancies.4,6,25 Moreover, the clinical presentation of patients with dyspeptic 
symptoms is highly variable and consists primarily of non-specific symptoms. The 
pathogenesis of dyspepsia is multifactorial, including secretory (gastric acid 
hyper secretion), motor (gastrointestinal motility and sphincter function), and 
sensory (mucosal sensitivity) pathways, and is not yet fully understood. A variety 
of factors, such as Helicobacter pylori (Hp), medication, lifestyle habits, but also 
genetic predisposition and psychological factors, are thought to also be involved
in the pathogenesis.26-28
As few symptoms are discriminatory, it is difficult to make a firm clinical 
diagnosis on the basis of gastrointestinal symptoms alone.3,26 Upper 
gastrointestinal endoscopy is the golden standard for an objective clinical 
diagnosis. However, in 52-87% of the patients with new onset dyspepsia, clinical 
assessment and investigation fail to identify any abnormality to which the 
symptoms can reasonably be attributed.10,29,30
Management of dyspepsia
A variety of diagnostic and therapeutic approaches has been proposed and 
evaluated for the management of dyspepsia.6,14,31-34 Evidence based 
management guidelines largely agree that the combination of (empirical) acid- 
suppressive therapy, H pylori test-and-treat, and (prompt) endoscopy should be 
used to manage dyspepsia in order to reduce dyspepsia-related health-care 
expenses. However, guidelines are inconsistent regarding the order in which 
these interventions should be used for optimal management. 11-13,35-37 Some of 
these differences might arise from differences in health-care systems 
(availability, funding) or population characteristics (H pylori infection, ulcer or 
upper gastrointestinal malignancy prevalence).
13
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Perspective General health service Gastroenterology Gastroenterology
Dyspepsia definition all upper GI symptoms, 
including reflux
Rome II* Rome II*






age >55 years with new 
onset dyspepsia; 
progressive dysphagia; 
GI bleeding; anemia; 
vomiting; unexplained 
weight loss or anorexia; 
abdominal mass; 
lymphadenopathy; 
early satiety; family 
history of upper GI 
cancer; history of 
peptic ulcer; previous 
gastric surgery or 
malignancy; 
odynophagia; jaundice








loss; palpable mass or 
lymphadenopathy; 





• empirical antacid or 
H2RA combined with 
lifestyle advice as initial 
option for all patients 
with new onset 
dyspepsia
• empirical PPI for 
patients with reflux 
predominant persistent 
symptoms
• PPI for endoscopi- 
cally confirmed 
oesophagitis
• H2RA in patients with 
FD
• empirical PPI therapy 
as initial option in low 
(<10%) Hp-prevalence 
area.
• in high Hp- 
prevalence areas, 
empirical PPI in 
patients with persisting 
symptoms after Hp 
test-and-treat
• empirical PPI therapy 
as initial option in low 
(<10%) Hp-prevalence 
area.
• in high Hp- 
prevalence areas, 
empirical PPI in 
patients with persisting 
symptoms after Hp 
test-and-treat




• for endoscopically 
confirmed ulcers
•  if Hp-prevalence 
>10% as initial option
• if Hp-prevalence 
<10% after empirical 
PPI fails
•  if Hp-prevalence 
>10% as initial option
• if Hp-prevalence 
<5% after empirical PPI 
fails
• if Hp-prevalence 5­
10% strategy uncertain
Endoscopy • alarm features (any 
age)
• consider if there is 
need for diagnostic 
assurance when 
symptoms persist (after 
PPI and Hp test-and- 
treat failed)
• age >55 or alarm 
features (any age)
• consider after Hp- 
eradication and/or PPI 
in those <55 years with 
persisting symptoms
• age >55 or alarm 
features (any age)
• consider after Hp- 
eradication and/or PPI 
in those <55 years with 
persisting symptoms
GI: gastrointestinal; H2RA: H2-receptor antagonist; PPI: proton pump inhibitor; Hp: Helicobacter pylori.
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Perspective Primary care Primary care General health service
Dyspepsia definition all upper GI symptoms, 
including reflux
all upper GI symptoms, 
including reflux
Rome II*
Alarm features dysphagia; evidence of 












loss; abdominal mass; 
suspicious barium meal
dysphagia; evidence of 
GI bleeding; persistent 
vomiting; unexplained 




• empiric acid 
suppression (PPI,
H2RA) as initial option if 
heartburn is the 
predominant problem
• empiric acid 
suppression (PPI,
H2RA) if symptoms 
persist after Hp test- 
and-treat
• first line choice is left 
to the individual 
preference, either 
empirical PPI or Hp 
test-and-treat. If one 
fails try the other
• H2RA if symptoms 
persist after Hp test- 
and-treat
• consider empirical 
antacid or H2RA 
combined with lifestyle 
advice as initial option 
in uncomplicated 
dyspepsia
• empiric PPI when Hp- 
eradication fails
Hp  test-and-treat • if epigastric pain is 
the predominant 
problem as initial option
• first line choice is left 
to the individual 
preference, either 
empirical PPI or Hp 
test-and-treat. If one 
fails try the other
• all patients with 
persisting or recurrent 
symptoms
Endoscopy • age >50 or alarm 
features (any age)
• consider after Hp- 
eradication and/or PPI 
in those <50 years with 
persisting symptoms
•  age >55 or alarm 
features (any age)
• consider after Hp- 
eradication and/or PPI 
in those <55 years with 
persisting symptoms
• alarm features (any 
age)
• consider referral to 
secondary care if >55 
years with persisting 
symptoms after Hp 
test-and-treat
* Rome II definition: Dyspepsia refers to pain or discomfort centred in the upper abdomen (including upper 
abdominal fullness, early satiety, bloating, belching, nausea, retching and/or vomiting).
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The Dutch guideline (figure 1) is based on the opinion that the majority of 
patients can be managed in primary care without extensive initial diagnostic 
work-up, since dyspepsia is uncomplicated in most of the patients. An early 
objective diagnosis is only indicated for patients presenting with alarm symptoms 
(table 1 ), since these might indicate serious underlying causes, such as 
malignancy, complicated ulcers, or stenosing reflux-oesophagitis. Treatment of 
patients with new onset dyspepsia is primarily focused on relieving symptoms, 
using antacids or H2-receptor antagonists (H2RA) combined with lifestyle advice. 
Diagnostic approaches such as ‘PPI-trial’ (a short course (1 to 4 weeks) of 
normal- to high-dose proton pump inhibitor (PPI) therapy to establish whether 
there is a rapid symptomatic response, which is commonly considered to be 
indicative for GORD)38, and H pylori test-and-treat are indicated when symptoms 
persist, based on symptom predominance. Endoscopy might be considered in
13,19persisting symptoms necessitating diagnostic assurance. , For comparison, a 
summary of similarities and contrasts of the Dutch and major international 
dyspepsia management guidelines is presented in table 1.
The guidelines differ to some extent regarding the perspective from which it is 
developed and definition of the target population. However, they all agree that 
individuals of any age with alarm symptoms should have a prompt endoscopy to 
rule out serious disease, although the predictive value of these alarm symptoms 
is poor.39,40 The American, Canadian, and British guideline also recommend 
prompt endoscopy for patients older than 50 or 55 years of age with 
uncomplicated dyspepsia, based on increasing incidence of upper 
gastrointestinal malignancies in these patients. Furthermore, endoscopy should 
be considered as subsequent option in patients with persistent symptoms if H 
pylori eradication and/or PPI therapy fails.
In young patients with uncomplicated dyspepsia, either empirical acid 
suppression therapy or H pylori test-and-treat is recommended as initial strategy 
by all guidelines. These approaches are more cost effective than prompt 
endoscopy and it is not feasible to investigate all patients with dyspepsia.41-45 
Consistent with the Dutch guideline, only the Scottish guideline considers 
empirical antacid or H2RA combined with lifestyle advice as initial strategy. The 
Canadians differentiate between empirical acid-suppressive therapy (with PPI or 
H2RA) and H pylori test-and-treat based on symptom predominance, while 
according to the American guidelines, the choice between empirical PPI-therapy 
and H pylori test-and-treat should be based on the H pylori-prevalence in the 
population. The British guideline indicates that there is insufficient evidence of 
superiority of these methods and leaves the choice to individual preference.46
Regardless of the strategies used, actual treatment basically comes down to 
acid-suppressive drugs and H pylori-eradication therapy34, which is a
16
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combination of a PPI and antibiotics, if 
tested positive. Several single drug 
comparisons have been reported, but 
stepwise acid-suppressive treatment 
strategies - as recommended in the 
Dutch guidelines (figure 2) - have 
received scant attention. Initial treatment 
with PPIs has become a common 
approach among general practitioners 
worldwide, because of its presumed 
superior (cost-)effectiveness.14,47,48 
However, these drugs are rather 
expensive in comparison to H2RA and 
whether this actually results in less 
primary care visits and significantly 
reduce work absenteeism and 
productivity loss remains unclear.
Aims and outline of the thesis
Dyspepsia is a major health problem.
However, in spite of consensus 
statements and guidelines, controversy 
exists regarding the etiology and the Figure 2: Outline o f acid suppressive ther- 
appropriate management of patients apy w ith in  the Dutch guideline
with (new onset) dyspepsia. Due to
increasing attention for health-care costs, not only the effectiveness, but also the 
efficacy of disease management should be considered. A management strategy 
should make balanced use of diagnostic as well as therapeutic interventions. 
Although many important questions concerning treatment strategies for 
managing dyspepsia were addressed in several reviews and meta-analysis, 
there is only limited information on patients with uninvestigated dyspepsia. The 
majority of these patients receive acid binding or suppressing drugs, but the 
effect of type and order of these drugs on treatment success and cost- 
effectiveness has received scant attention.
Therefore, the aim of this thesis was to evaluate the empirical acid-suppressive 
treatment of new onset dyspepsia in primary care according to the Dutch 
guidelines in order to optimise management of patients with dyspeptic symptoms. 
We performed a large pragmatic primary care based randomised controlled trial, 
the DIAMOND-study, to compare the stepwise acid-suppressive treatment 
strategy - recommended in the guidelines for the management of dyspepsia by
1 1
| new onset |
■ dyspepsia ■









the Dutch College of General Practitioners for patients with new onset dyspepsia 
- with a strategy starting with a PPI, which is increasingly being used in general 
practice.
Chapter one describes the methodological challenges in designing and 
conducting the DIAMOND-study and discusses the rationale behind the choices 
made. In chapter two  and three we present an effectiveness and economical 
evaluation of the stepwise acid-suppressive management strategies from a 
societal perspective. Because the perspective used to evaluate the effectiveness 
of treatment might result in different treatment preference, we used a patients’ 
perspective to assess the impact of dyspepsia and treatment of dyspepsia on 
health-related quality of life in chapter four. In the last two chapters we studied 
predictors for treatment success (chapter five) and the surplus value of a pre­
treatment diagnostic test of gastric mucosal status (chapter six) with the 
intention to look for more individualised options to optimize treatment. In the 
general discussion, all the findings are discussed in the light of the aim of this 
thesis.
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Chapter 1
ABSTRACT
Background  Pragmatic randomised controlled trials are often used in primary 
care to evaluate the effect of a treatment strategy. In these trials it is difficult to 
achieve both high internal validity and high generalisability. This article will 
discuss several methodological challenges in designing and conducting a 
pragmatic primary-care-based randomised controlled trial, based on our 
experiences in the DIAMOND-study and will discuss the rationale behind the 
choices we made. From the successes as well as the problems we experienced 
the quality of future pragmatic trials may benefit.
Discussion  The first challenge concerned choosing the clinically most relevant 
interventions to compare and enable blinded comparison, since the interventions 
had very different appearances. By adding treatment steps to one treatment arm 
and adding placebo to both treatment arms both internal and external validity 
were optimized. Nevertheless, although blinding is essential for a high internal 
validity, it should be warily considered in a pragmatic trial because it decreases 
external validity. Choosing and recruiting a representative selection of 
participants was the second challenge. We succeeded in retrieving a 
representative relatively large patient sample by carefully choosing (few) 
inclusion and exclusion criteria, by random selection, by paying much attention to 
participant recruitment and taking the participant’s reasons to participate into 
account. Good and regular contact with the general practitioners and patients 
was to our opinion essential. The third challenge was to choose the primary 
outcome, which needed to reflect effectiveness of the treatment in every day 
practice. Although standardized treatment is usually preferred in trials, we also 
designed our protocol to follow every day practice as much as possible. The 
purpose of this was to facilitate our fourth challenge: to limit the number of 
protocol deviations and increase external validity.
Summary It is challenging to design and conduct a pragmatic trial. Thanks to 
thorough preparation, we were able to collect highly valid data. To our opinion, a 
critical deliberation of where on the pragmatic - explanatory spectrum you want 
your trial to be on forehand, in combination with consulting publications 
especially on patient recruitment procedures, has been helpful in conducting a 
successful trial.
DIAM OND study design
BACKGROUND
Pragmatic trials are designed to investigate how effective a treatment strategy 
is in everyday practice.1 The hypothesis and study design in pragmatic trials are 
developed specifically to answer questions of decision makers and should 
compare new with existing interventions in the indicated population using 
relevant health outcomes.2,3 Researchers face a number of methodological 
challenges and need to make several choices in the design and conduct of 
pragmatic trials. This is especially true for primary-care-based trials where the 
broad spectrum of disease presentation and early clinical stage challenges the 
selection of an adequate study population. Though these challenges greatly 
influence the external and internal validity as well as the eventual significance of 
the study results, most publications do not elaborate on the choices made. This 
paper discusses several challenges in designing and conducting pragmatic 
primary-care-based trials we experienced in a large scale multicentre 
randomised trial on dyspepsia. This might be helpful for other researchers 
especially in the planning stage of new trials. Our objective is to contribute to 
quality improvement of pragmatic primary-care-based trials.
This paper will discuss three challenges in designing a study: choosing the 
right intervention and blinding treatment allocation, choosing an appropriate 
study population, and choosing the essential outcome measures. Subsequently 
the challenges in conducting a study will be discussed focusing on recruitment of 
participating general practitioners (GPs) and patients, and on dealing with 
protocol deviations. Each section will start with a brief introduction of pitfalls in 
general, followed by the rationale behind the choices made within the DIAMOND- 
study and a speculation of the consequences of our choices. The paper will end 
with conclusions describing the consequences of our choices for the expected 
usefulness and relevance of the DIAMOND results.
The DIAMOND-trial
The Dutch study of Initial Management Of Newly diagnosed Dyspepsia 
(DIAMOND) investigates the effectiveness of two treatment strategies for 
dyspepsia: the step-up treatment strategy and the step-down treatment. The 
step-up treatment starts with antacids and, if  the symptoms persist or recur, 
builds up to stronger medication, while the step-down treatment starts with the 
strongest drug (proton pump inhibitor (PPI)) and reduces stepwise to H2-receptor 
antagonists (H2RA) and antacids as long as the symptoms persist or recur. In 
table 1.1, 1.2, 1.3, 1.4 and figure 1.1, 1.2 the design and research questions of 
the DIAMOND-study are described. The protocol of DIAMOND is registered on 
ClinicalTrials.gov (identifier: NCT00247715)4 It is a pragmatic, large multicentre
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Table 1.1: The primary and secondary aims o f DIAMOND 
P rim a ry  a im  o f  D IAMOND:
•  To investigate which treatment strategy, ‘step-up' or ‘step-down‘ treatment, was the most (cost-) 
effective initial management strategy for patients with a new episode of dyspepsia in primary care.
S econdary  a im s o f  D IAMOND:
•  To investigate which factors influence the severity of the GI complaints.
•  To investigate which factors determine compliance with dyspepsia medication prescriptions and 
compliance with advised lifestyle changes.
•  To investigate which factors influence treatment success.
randomised controlled trial in primary care running from 2003 till 2007, in which 
664 patients with dyspepsia were included and more than 300 GPs participated. 
The study is conducted with the joint expertise of three academic research 
centres from both primary and secondary care. While within DIAMOND besides 
effectiveness also cost-effectiveness will be analysed, this paper will focus on the 
evaluation of clinical endpoints. Economic evaluation trials are facing specific 
methodological challenges, which are described for instance by Ramsey et al. 
and Tunis et a l3,5
Table 1.2: Inclusion and exclusion criteria o f DIAMOND
1. Patients are included when they visit their GP for complaints of which the GP thinks that they 
originate from the upper GI tract and for which acid-suppressive medication can be effective.
2. Patients are included when they are 18 years or older.
3. Patients are excluded when they have used prescribed acid-suppressive medication in the last 
three months before inclusion.
4. Patients are excluded when they have had a gastroscopy in the year prior to inclusion.
5. Patients are excluded when they have alarming symptoms.
6. Patients are excluded when there are contraindications for prescribing acid-suppressive 
medication, such as pregnancy, liver or kidney malfunction.
7. Patients are excluded when they are not able to fill out (Dutch) questionnaires, for example 
because of language problems.
DISCUSSION
Challenges in designing a study 
Choosing the righ t intervention and blinding treatment allocation
Pragmatic trials evaluate the beneficial effect of a treatment strategy for clinical 
practice when applied by any clinician to any patient with the disorder studied. 
The intervention must be relevant and feasible to be generalised to clinical 
practice and it must be compared to the best available usual care (reference 
care). Randomisation and blinding caregivers, participants, and investigators for
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treatment allocation are used in trial settings to increase the internal validity and 
aims to ensure that an effect is solely caused by the intervention.6 Inadequate 
blinding in trials proved to result in 30% lower odds ratios than adequate 
blinding.7 However, in every day practice treatment is not blinded, and may be 
influenced by prejudices of GPs or patients. While blinding is important to 
increase internal validity, it may limit the generalisability of results. Furthermore, 
blinding treatment allocation is often difficult to achieve in pragmatic trials, 
because of differences in the appearance of treatment (for instance operation 
versus medication) or differences in the consultation scheme.
Table 1.3: DIAMOND inclusion and treatment protocol
1. When a patient visits the GP, the inclusion and exclusion criteria are checked.
2. When the patient meets the criteria, the GP informs the patient about DIAMOND. When the 
patient wants to participate, he or she provides an informed consent.
3. The GP hands out the patient the medication for step 1. The medication is packed in boxes and 
is provided to the GP at the start of the study. Each box contains all the medication steps for one 
patient. The patient numbers on the boxes are linked to the numbers on the randomisation list in 
a sealed envelope kept at the researchers' office.
4. A blood sample is taken.
5. The patient receives the first questionnaire from the GP to fill out at home. Other questionnaires 
are sent to patients (tab le 1.4).
6. The patient is treated according to the treatment protocol (see figu re  1.1 and 1.2). If the 
symptoms continue or relapse within eight weeks after starting the medication step, the patient 
starts with the next treatment step. It is possible to shorten the treatment steps into less than four 
weeks, for instance when the patient suffers from side effects. The patient and GP are advised to 
schedule a follow-up visit at four weeks, which should be cancelled when the complaints are 
resolved.
7. When symptoms continue or relapse after medication step 3, the GP can treat the patient 
according to their own judgement.
8. The GP and the patient are informed six months after inclusion about the treatment allocation 
and the test results from the blood sample (whether the patient was infected with H  pylori).
One possible solution is cluster randomisation,6 where one group of caregivers 
exclusively prescribes the experimental treatment and another exclusively the 
reference treatment. When all physicians within one centre are allocated to the 
same treatment arm, contamination will be reduced and all patients within one 
centre get the same treatment. Nevertheless, prejudices of caregivers, patients 
or researchers might still cause observation bias, for instance if the treatment is 
terminated preliminarily when physicians or patients do not expect the treatment 
to work. Although this reflects every day practice and might not be a problem in 
pragmatic trials (as long as patients are still included in analyses), observation 
bias decreases internal validity. Furthermore, because differences between 




Table 1.4: Measurements 
P rim a ry  hea lth  ou tcom e:
•  Adequate symptom relief at six months according patients.
S e conda ry  hea lth  ou tcom es:
•  Severity of the GI complaints at six months (at two weeks and after each treatment step).
•  Quality of life at six months (at two weeks and after each treatment step).
A d d it io n a l research  ques tions  inves tig a te d :
•  The cost-effectiveness of both treatment strategies.
•  The association between genetic determinants and dyspepsia and treatment success.
•  Compliance with prescribed medication advices and lifestyle advices and which factors influence 
compliance.
•  The association between psychosocial determinants and dyspepsia and treatment success. 
S e lf-adm in is te red  ques tionna ires  used:
•  General questionnaire to measure effect of the treatment, costs, work absenteeism, 
demographical determinants, co-medication used and lifestyle.
•  Gastrointestinal Symptoms Questionnaire; EuroQol 5D; SF36; Compliance Questionnaire; 
SCL90; Health Hardiness; Utrechts Coping List; Major Life Events.
The rationale behind our choices
The DIAMOND-study was designed to compare a step-up treatment strategy 
(which is advocated in recent Dutch guidelines, figure 1.1) with PPI-treatment 
(which is practised by many GPs). The appearances o f both strategies differ too 
much to be suitable for blinding. Therefore, we decided to compare the step-up 
treatment strategy with a step-down treatment strategy, in which the PPI- 
treatment is followed by two treatment steps (figure 1.1). Both treatment 
strategies were now made comparable in drug distribution and appearances by 
using placebos (figure 1.2). This had several advantages; first, this design 
enables to investigate whether patients experience symptom relief on other (non- 
PPI) acid-suppressants when initial PPI-treatment fails. Second, PPIs can have a 
known rebound effect. In the step-down group it is possible to investigate 
whether patients, who initially responded well on PPIs but got a relapse, respond 
equally well on other (cheaper) acid-suppressants. Third, when patients needed 
all three medication steps, both groups received the same medication, only in a 
different order, so the influence of the order o f medication on for example patient 
satisfaction can be investigated.
Our design also had some disadvantages. Our organisation of ‘step-down’ 
treatment does not reflect usual care, which might affect generalisability. Some 
argued it is unethical to 'step-down' when the strongest drug is not effective. 
However, in our opinion patients can safely try the other two kinds of medication, 
before further investigation is established. Furthermore, in both groups patients
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Figure 1.1: DIAMOND treatment strategies
If the symptoms persisted the patient continued with the next treatment step. If the symptoms initially were relieved but relapsed within four weeks after stopping the 
treatment step, the patient also started the next treatment step. Otherwise (in case of a relapse after four weeks), the GP could treat the patient to their own judgement. 










had to use a placebo along with normal treatment. This can be a burden, since it 
means taking extra pills in step 1 and step 3, and it differs from everyday practice 
too.
Figure 1.2: DIAMOND: B linding o f the treatment strategies
Antacids (Algedrate-Magesiumoxide); H2 RA: H2-receptor antagonist (Raniditine); PPI: Proton Pump Inhibitor 
(Pantozole).
Although heavily aimed for, we were not able to find completely identical 
placebos. However, patients would not be able to tell their treatment allocation 
and to ensure that GPs would not recognize the pills, non-transparent medication 
jars packed in sealed paper bags were used. Clustered randomisation as 
discussed above could have induced more bias as the treatment allocation would 
have been recognized easily by GPs after completing the first patient in their 
cluster.
We chose to disclose treatment allocation at six months, just after measuring 
primary outcome. We reached high internal validity at the cost of decreasing 
external validity. Primary outcome (adequate symptom relief according to the 
patient) was measured at six months, which could be three to four months after 
prolonged prescription of any medication chosen by the GPs after completing the 
trial. In usual care the GP would repeat prescription of the most effective on 
recurrence of the symptoms. However, because of the ‘late’ disclosure of 
treatment allocation in DIAMOND, our GPs may have assumed that symptom 
relief may have occurred during the use of PPI and prescribed this after the trial 
medication was finished, while maybe the patient responded on the antacid. 
Consequently, blinding might have caused convergence of treatment after trial 
medication in both strategies, which decreases differences in measured 
effectiveness.
Infection with Helicobacter pylori (H pylori) can influence the effectiveness of
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treatment as well as relapse rates of symptoms. Therefore blood samples for 
serology were taken at baseline. The H pylori test results were also disclosed at 
six months to avoid the treatment or costs to be influenced by H pylori 
management before measuring primary outcome. Incidentally GPs requested to 
disclose H pylori test results earlier, in which case, the (theoretical) costs of H 
pylori testing were included for the cost evaluation of treatment. The medical 
ethics committee agreed with postponed disclosure since H pylori infection takes 
place early childhood and has no imminent association with the onset of 
symptoms. Early H pylori testing in this trial may have caused GPs to be more 
aware of H pylori infection and may have urged them to inform about the test 
results more often than in normal practice. However, the alternatives, drawing 
blood samples only when a test is requested by the GP or after follow-up is 
completed, would have caused more drop-outs. The choice to communicate H 
pylori test results at six months and take theoretical costs into account when 
requested sooner is a clear example of a way to control the treatment, while it 
probably decreases the external validity.
Our choices may all influence treatment effects. We believe that blinding the 
treatment allocation and the use of placebo led to more comparable treatment 
strategies, which probably led to a smaller difference between the true effects of 
both treatment strategies than in every day practice would exist.
Choosing an appropriate study population
Regarding internal validity, according to Kleinbaum et al. selection bias is a 
distortion in the estimate of effect resulting from the manner in which subjects are 
selected from the target population.8 Within DIAMOND all patients were randomly 
allocated to either the step-up or step-down treatment strategy, which makes 
selection bias unlikely.
Regarding external validity, it is very important that the investigated population 
should represent the target population, but how can optimal representation be 
achieved? First, the target population needs to be clearly defined by using 
inclusion and exclusion criteria. Second, the method of patient selection greatly 
influences representation (see ‘Patient recruitment’). The best way is to select 
patients randomly, but this is very challenging because it is difficult to avoid self­
selection. Responding to an advertisement is a clear example of self-selection. 
Also GPs may be self-selected if they responded to an invitation letter to 
participate. This can be a problem when the participation of the GPs is 
associated with certain patient characteristics (educational level, co-morbidity).
A representative patient sample must reflect all patients in the target 
population, including patients from minority groups, especially when treatment 
effects are supposed to be influenced by population characteristics. Translated
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questionnaires should enable immigrants to participate. Consideration should 
always be given to motivate patients expected to have low participation rates, for 
instance by tailoring patient information to gender or age.
There are several practical or judgemental reasons (lack of time, symptoms, 
preference, willingness) for a patient not to be included although eligible. 
Therefore, registration of all eligible patients and monitoring reasons for non­
inclusion is preferred, to be able to judge inclusion selection. However, this is 
time consuming and researchers still would question the completeness of the 
registration. When available, electronic medical records might be helpful in 
estimating the proportion of non-included eligible patients. However, routine 
electronic medical records might also lack data to check eligibility (e.g. duration 
of symptoms) and won't always provide insights in the reasons for non-inclusion.
The rationale behind our choices
We chose to focus on ‘adult patients with a new episode of dyspepsia’, 
because the most effective treatment for these patients was unknown. Careful 
consideration with all the experts in the research board led to a limited number of 
inclusion and exclusion criteria to define these patients. The criteria were based 
on recent guidelines and were judged to be feasible and clear (table 1.2). 
Regarding the representation of minority groups, it was not possible to make all 
relevant language adjustments, but translation from Dutch into English was 
provided. Some participating immigrants who spoke other languages had help 
from their relatives to fill out the questionnaires.
Patients were recruited by participating GPs. We invited as many GPs as 
possible within our geographic boundaries, resulting in 312 participating GPs 
distributed over the Netherlands (figure 1.3). It is possible that especially GPs 
with a special interest in the gastrointestinal (GI) field were responding. This can 
be a problem if  participation of the GPs is associated with effect modifying patient 
characteristics. However, it is likely that the heterogeneous group of participating 
GPs (GPs from urban as well as rural regions with solo, duo, or group practices) 
has resulted in a heterogeneous patient sample, which represents the primary 
care population.
To investigate initial treatment of patients with a ‘new’ episode of dyspeptic 
symptoms, patients who used prescribed acid-suppressive drugs in the last three 
months were excluded. However, since patients with mild symptoms are more 
likely to be without medication for more than three months than patients with 
severe symptoms, this might have resulted in a patient sample with 
overrepresentation of patients with mildly severe dyspepsia. Moreover, maybe 
the GPs only invited patients with mildly severe dyspepsia, because they did not 
want to risk patients with more severe complaints to be treated with the step-up
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treatment strategy. Finally the representativeness of our sample will be 
investigated by comparing several relevant patient characteristics to results from 
other (preferably population based) studies.
Hypothetically, the difference in treatment effect between PPIs and antacids 
might be smaller in patients with mild symptoms. As a consequence the 
difference between the two treatment strategies might have been smaller than in 
every day practice where also patients with more severe complaints are treated.
-► 150 GPs in 127 practices have recruited one or more patients
Figure 1.3: GP Recruitment
Choosing the essential outcome measurements
The value of study results is greatly determined by the definition of the primary 
outcome and choice of measurements. When the primary outcome is an
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objective measure, e.g. survival, it is easy to measure and define it. However, the 
outcome of many diseases in primary care needs more subjective evaluation, 
and selection and definition of the outcome may prove to be difficult. A proper 
definition can be based on literature or expert opinion. Furthermore, it needs to 
reflect what decision makers want to know. The endpoint also needs to be clear, 
and preferably comparable with other studies.
Concerning the measurements, the validity and reliability should always be 
critically assessed. To increase response rates questionnaires must be as short 
as possible. This is challenging, especially when several additional research 
questions are investigated as in our study (see table 1.4). The additional value of 
every question in the questionnaire needs to be critically judged and a pilot study 
is preferred to estimate the feasibility and burden for GPs and patients.
The rationale behind our choices
Choosing the primary outcome measure for DIAMOND was not easy because 
the presence or absence of ‘dyspepsia’ cannot be measured objectively.9 
Furthermore, dyspepsia is characterized by periods of remission followed by 
symptom relapse. We used ‘adequate symptom relief at six months, according to 
the patient’ as primary outcome, following expert recommendations (Rome II 
criteria) and because this reflects the decision to stop or continue treatment in 
every day practice. It is generally accepted that symptomatic response can be 
used in dyspepsia because this is what GPs have to rely on in clinical practice. 
Besides, more objective measurements (e.g. endoscopy) poorly correlate with 
symptom severity. To enable a comparison with results from other studies we 
analysed the change in severity of the gastrointestinal symptoms and quality of 
life as secondary outcomes.
Additionally, choosing the right timing o f the measurement o f the primary 
outcome in a study with multi-step treatment strategies is difficult. Choosing a six 
month time interval is convenient for policy makers and feasible in trial practice. 
But the downside is that patients received trial medication for variable periods of 
time. Good responders may only have had the first treatment step, and if  they 
remained symptom-free for four weeks after finishing treatment they did not start 
with the second treatment step. In case of relapse after four weeks or after 
finishing treatment step 3 treatment was left up to the GP. As mentioned above, 
primary outcome might be influenced more by the GP prescribed medication than 
study medication at the time of six months. This may have decreased differences 
between the treatment strategies at six months. We also measured short term 
outcomes (at two weeks, four weeks, etc.) to be able to determine the short-term 
efficacy o f the individual treatment strategies.
We investigated the validity o f the questionnaire for the severity of
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gastrointestinal complaints.10,11 A pilot study among non-experts to investigate 
the burden o f filling in our questionnaires showed that at baseline as well as at 
follow-up 15 to 30 minutes were needed for a complete response. This was 
judged to be acceptable and patients were informed of this time estimation 
before providing informed consent to participate.
Challenges in conducting a study 
Patient recruitment
Many studies fail to recruit enough patients which compromise statistical
power. A review by Mc Donald showed that only 31% of randomised controlled
12trials were able to reach their goals concerning patient recruitment. There are 
several ways to recruit patients: from medical records, by advertisement or 
during consultation. The usage of medical records increases effective recruitment 
because it does not depend on patient presentation to recruiters during the 
inclusion period. However, this method cannot be used when incident cases are 
required. Sellors et al. found barriers such as the availability of electronic medical 
records, the experience of office staff and GPs to produce patient sampling
13frames and ethical considerations. Another method is patient recruitment via 
advertisements in (local) media or via flyers at the GP's office. However, patients 
responding to such advertisements may differ from patients not responding which 
leads to selection bias and hampers external validity. The conventional way to 
recruit patients is by the GP during consultation (incident cases). This way of 
recruitment approximates routine practice the most, which increases external 
validity. However, it poses a huge burden on the GP and is not always 
successful. There might simply be a lack of eligible patients or trial procedures 
can be too restrictive. According to Van Der Windt et al. the main reasons for not 
referring eligible patients to the research centre by participating GPs were: busy 
surgery hours, forgetfulness, or the conviction that a patient would benefit more
14from a specific intervention. De Wit et al. found that successful patient 
recruitment in a dyspepsia trial was determined more by the motivation of GPs by 
the research group than by financial incentives, research topic, or research
15experience. Foy et al. investigated in a meta-analysis the impact of 
interventions on patient recruitment and concluded that organisational 
characteristics (e. g. strong trial infrastructure) seemed to be important. 16 
Furthermore, many interventions on patient recruitment were not evidence-based 
but based on the experience of the investigator. 16
Additionally, successful patient recruitment depends on the patients' 
motivation. Chang et al. found that the reasons for patients to participate could 
be divided into six general categories: 1] benefit to self; 2] benefit to others; 3]
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gratitude to the physician; 4] positive comments by the trusted professional; 5] 
the appearance, personality, manner and gender of the recruiter; 6 ] monetary
17compensation. We agree with Chang that the most effective recruitment
17involves a direct and personal approach. Patients appeared to enjoy being 
noticed and sorted out for something presented to them as important and special. 
The patient information and the GP need to address possible reasons and 
advantages for patients to participate.
The rationale behind our choices
Since we focused on patients with a new episode of complaints, we chose to 
recruit incident cases during consultations by the GP. To our experience 
successful patient recruitment depends on: 1] Close monitoring of recruitment 
statistics and extra measures to boost recruitment if  necessary; 2] flexibility of the 
research protocol: it must be possible to adapt the protocol when GPs cannot 
use it in practice or when selection criteria are not clear or too strict; 3] good and 
regular contact with the GP or an assistant (preferably face-to-face or by 
telephone), which enables to remind and motivate them and notice and resolve 
difficulties. We visited the GPs after each new included patient to collect the 
patient's blood sample and provide new materials. The purpose of this visit was 
to reinforce the patient inclusion, but not to discuss how the included patient was 
treated to avoid an extra educational intervention. Furthermore, a monthly 
newsletter was sent to the GPs to remind them and to keep them posted. We 
tried to minimize the burden for the GPs and the assistants (for instance by 
taking blood samples ourselves when necessary) and answered questions 
promptly implying easy accessibility. Despite these efforts to motivate and assist 
the GPs, only 48% of the participating GPs recruited one or more patients (figure 
1.4). We can only speculate on the reasons for this disappointing number: maybe 
the inclusion and treatment was expected to be too time-consuming or maybe 
these GPs simply forgot to invite eligible patients despite o f several reminders. 
Social desirability may have caused GPs to participate who were less motivated 
to include patients. Although ultimately successful, patient recruitment was very 
time consuming and needed sufficient budget for recruitment personnel. The 
intended inclusion period of two years had to be prolonged in October 2005 to 
include the desired number of patients. Only GPs who were expected to include 
several patients before the end of 2005 (‘promising’ GPs) were invited to 
continue patient recruitment. This explains the sudden fall in participating GPs in 
figure 1.4. Interestingly, this did not decrease the patient inclusion in the last 
months, which suggests that it may be more efficient to only include highly 
motivated and ‘promising’ GPs. Exclusion of reluctant GPs may hardly decrease 
inclusion rates but does decrease the workload for the researchers.
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Figure 1.4: Patient recruitment and number o f (successful) GP participants.
GP recruitm ent
Patient recruitment in primary-care-based trials often depends on the 
cooperation of GPs. Since the demand on GPs to participate in research is 
growing and it is hard to keep the balance between research participation and
15daily practice, GPs must be very critical in their decision to participate. Factors 
known to influence the physician's decision to participate include: 1 ] a personal 
interest in the research topic; 2] the relevance of the research question; 3] the 
personal connection with the researchers; 4] the collective ownership of the 
project; 5] the support of stakeholders or respected members of the professional 
community; 6 ] the revenue of costs associated with research participation; 7] the 
simplicity of protocols with low interference with patient care; 8 ] the availability of 
practice staff to assist the enrolment; 9] the timeliness of patient recruitment; 10] 
the satisfaction with study participation.18-20 Van Der Windt et al. also mentioned 
that (accredited) postgraduate training is a reason for GPs to participate, and
14involvement in too many other studies is a reason not to participate.
A strategy for approaching primary care settings as proposed by Murphy et al. 
and Kocken et al. recommends identification of stakeholders and regional opinion 
leaders, using support letters by relevant professional organisations and
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supplying adequate, but concise, information. 18,21 It is important to consider and 
address the reasons for GPs to participate during the recruitment.
The rationale behind our choices
For GP recruitment we wanted to invite as many GPs as possible within our 
geographical boundaries to gather a large heterogeneous GP sample. We 
retrieved the addresses of all eligible primary care settings from a registration at 
the three participating universities. The GPs received an invitation letter with 
information about the research together with a recommendation letter from the 
Dutch College of General Practitioners and the Dutch Institute for Healthcare 
Improvement. A reply form was offered to respond by fax. In case of non­
response the GP was invited again by means of a telephone call. After an 
informal appointment at the GP's office, the GP decided whether or not to 
participate. For practical reasons the GP recruitment was spread out over the 
first period of patient inclusion. The results of GP recruitment are given in figure  
1.4. To our experience, however ultimately successful, the GP recruitment was 
very time consuming because of the many phone calls and visits. Although 
difficult, personal contact with the GP more positively influenced participation 
than leaving a message with the assistant. Spreading out the GP recruitment 
period gave us the opportunity to adjust the information letters and to approach 
more GPs to boost patient recruitment when the inclusion lagged behind. Our 
method of GP recruitment probably has resulted in a heterogeneous and 
representative relatively large GP sample, which is likely to have a positive 
influence on the generalisability of the results.
Protocol deviations
Protocol deviation or protocol non-adherence by patients, GPs or researchers 
is common. Examples of protocol deviations are: drop-out, inclusion of ineligible 
patients, not receiving the allocated treatment, unplanned interruption or abortion 
of treatment; and not taking the trial medication as prescribed. Drop-outs are 
patients who stop their trial medication but remain available for follow-up.22 
Patients can also be ‘lost to follow-up’, when they are no longer accessible to the 
investigators.22 Eligibility errors are relatively common.22 Objective eligibility 
criteria are less prone to error than subjective ones. If eligibility is checked before 
randomisation, the consequences of such errors will be minimal. However, in 
pragmatic trials commonly the eligibility is checked e.g. with blood measurements 
or patient self reports, which are often only available after randomisation.
Bias can be introduced when protocol deviation affects both treatment groups 
differently.22 Researchers therefore investigate whether the protocol deviation is
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caused by systematic or random errors, and whether it causes differences 
between both treatment groups. When protocol deviation is associated with one 
treatment arm (e.g. if the experimental treatment has more side-effects), it is 
important to take this into account because protocol deviations will also happen 
in every day practice. In a per-protocol analysis all patients with a protocol 
deviation will be excluded, which contrasts with the purpose of conducting a
23pragmatic trial. Exclusion of patients can result in bias when the patients that 
stay included are no longer representative for the study population. Therefore, a 
per protocol analysis is less suitable than an intention-to-treat analysis for 
pragmatic trials. Some pragmatic trials perform a per-protocol analysis 
additionally to an intention-to-treat analysis, but difficulties arise when both 
analysis produce different results. Whereas the results of a per-protocol analysis 
may provide additional insights in why a treatment has (or lacks) effect in every 
day practice, in pragmatic trials the intention-to-treat analysis is the way to 
determine the overall effect.
Protocol deviations can partly be prevented by writing simple and clear 
protocols, providing proper patient information, and by closely monitoring GPs 
and patients during a pilot study and adjusting the protocol if required.
The rationale behind our choices
To reflect every day practice as much as possible we chose to write a flexible 
treatment protocol, in which for instance the GP was free to decide when patients 
could return for consultation (after four weeks was recommended) or how the 
consultation was done, by phone or personal. This has probably minimized our 
number of protocol deviations. We can only present some preliminary data at this 
moment, since not all analyses have yet been finished. No non-eligible patients 
were included. Eleven patients gave an informed consent but changed their mind 
shortly after and they did not start using our trial medication. One patient did not 
use medication step 1 for unknown reasons, but started medication step 2 
approximately two weeks after baseline. Table 1.5 shows the questionnaire 
response rates and suggests that number of patients ‘lost to follow-up’ was 
limited. For the intention-to-treat analysis, preliminary results indicate that for 
98% of the patients the primary outcome at six months is present. We are able to 
achieve such a high response rate by contacting all non-responders or drop-outs 
by phone or via the GP (except for patients indicating not to be willing/able to 
participate anymore) and asking them to answer the question: has symptom 
relief been adequate since the start of the treatment? Most patients are willing to 
answer this single question.
Some patients do not return the initial six month questionnaire, because they 
think that when their complaints are resolved they do not need to return
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questionnaires. To prevent this bias we send reminders pointing out the 
importance of always returning the questionnaire and contact non-responders by 
phone or via their GPs. The preliminary response rates for all questionnaires are 
given in table 1.5. The response rates slowly decrease in time as can be 
expected. The length of the baseline questionnaire (T0) and the high number of 
questionnaires during the first month caused several patients to stop their 
participation. Although tested in a pilot study and explained in the patient 
information, this could not be completely prevented. Maybe in the near future 
easier ways to monitor complaints and retrieve important data (e.g. via the 
internet) will become accessible and can facilitate patient cooperation and 
prevent drop-out.
Table 1.5: Prelim inary results: the patient questionnaire response rates






step 3# 6 months 1 year
Sent out 664* 613* 643* 595* 587* 659* 566*
Returned 629 543 525 474 454 646 373
Response rate 95% 86% 82% 80% 77% 98% 66%"
* Not all follow-up questionnaires were sent out, for instance when patients started step 2 within two weeks, 
or patients reported they no longer wished to receive questionnaires. # if medication of this step was not 
started according to protocol, questionnaires were sent out at two resp. three months. In case of non­
response a reminder is sent out after all questionnaires except after one year, since this is an additional 
measurement to the original research protocol. This explains the low response rate.
The consequences of our choices for the usefulness and relevance of the 
DIAMOND results
The results of this study are useful/relevant for policy makers, patients, GPs 
and researchers because a large population of well defined patients, which is 
generalisable to the Dutch population of patients with a new episode of dyspeptic 
symptoms. The study has a high internal validity because of the random 
treatment allocation, and the concealment of treatment allocation/blinding, which 
increases the value of the results for policy makers. However, the external 
validity is decreased by the use of step-down treatment instead of PPI treatment 
(which is more common in every day practice) and by the blinding. Consequently, 
it is difficult to say what the effect of both treatment strategies will be if performed 
in every day practice.
In order to adapt the study protocol to routine daily practice, a multistep 
protocol was designed. Although this resembles everyday practice it makes 
analysis more difficult, because not all patients are in the same treatment step at 
a certain point in time, and because the period of time between finishing the trial
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medication and registration of the primary outcome may vary from patient to 
patient. In case this period is long, the primary outcome may be influenced by 
follow-up treatment chosen by the GP. This may decrease any differences 
between the treatment strategies, but on the other hand the primary outcome 
does provide essential information about the effectiveness of actual primary care 
treatment for dyspepsia. Furthermore, the differences between the two treatment 
strategies can be analyzed in more detail by analyzing the secondary endpoints 
(at four weeks, three months, etc...). Therefore, the trial design as presented will 
provide important insights in various strategies for treatment of dyspepsia in 
primary care.
SUMMARY
Pragmatic trials must ensure a high generalisability without compromising 
internal validity, which is very challenging.24 Therefore, a critical appraisal of the 
planned design and method to conduct the trial before actually starting to collect 
data is essential. When several publications on patient recruitment or other 
pitfalls in designing/conducting a pragmatic trial are consulted, one may increase 
the likelihood of conducting a successful trial. Furthermore, it is very important to 
set priorities beforehand where on the 'spectrum from explanatory to pragmatic 
you want your trial to be: do you want to know the ‘unbiased’ effect of the 
treatment (as in explanatory trials) or are you more interested in the effects in 
daily primary care (as in pragmatic trials)? For instance, we chose to blind 
treatment allocation because otherwise prejudices of GPs, patients and 
researchers might have biased the results, although blinding contrasts with the 
purpose to reflect every day practice in pragmatic trials. On the other hand, we 
chose to use flexible treatment protocol to reflect every practice, what again 
might contrast with using standardized treatment in explanatory trials.
This paper shows that while we did not compare the two most frequently used 
treatment strategies in the DIAMOND-study, we were still able to collect highly 
valid data because of the blinded randomised treatment, the randomly selected 
heterogeneous patient sample and the research protocol that closely fits to 
normal practice. Although it is very difficult to recruit as many GPs and patients 
as needed, success can be determined by careful consideration of how the GPs 
and patients will be optimally recruited and what their reasons to participate or to 
refuse participation will be. Our experiences with the DIAMOND-study give an 
indication of what success rates regarding GP and patient recruitment and 
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Effect and cost-effectiveness of step-up versus step-down 
treatment with antacids, H2-receptor antagonists, and proton 
pump inhibitors in patients with new onset dyspepsia 






Background  Substantial physician workload and high costs are associated with 
the treatment of dyspepsia in primary health care. Despite the availability of 
consensus statements and guidelines, the most cost-effective empirical strategy 
for initial management of the condition remains to be determined. We compared 
step-up and step-down treatment strategies for initial management of patients 
with new onset dyspepsia in primary care.
M ethods  Patients aged 18 years and older who consulted with their family doctor 
for new onset dyspepsia in the Netherlands were eligible for enrolment in this 
double-blind, randomised controlled trial. Between October, 2003, and January, 
2006, 664 patients were randomly assigned to receive stepwise treatment with 
antacid, H2-receptor antagonist, and proton pump inhibitor (step-up; n=341), or 
these drugs in the reverse order (step-down; n=323), by use of a computer­
generated sequence with blocks of six. Each step lasted four weeks and treatment 
only continued with the next step if symptoms persisted or relapsed within four- 
weeks. Primary outcomes were symptom relief and cost-effectiveness of initial 
management at six months. Analysis was by intention to treat (ITT); the ITT 
population consisted of all patients with data for the primary outcome at six 
months. This trial is registered with ClinicalTrials.gov, number NCT00247715.
Results  332 patients in the step-up, and 313 in the step-down group reached 
an endpoint with sufficient data for evaluation; the main reason for dropout was 
loss to follow-up. Treatment success after six months was achieved in 238 (72%) 
patients in the step-up group and 219 (70%) patients in the step-down group 
(odds ratio 0.92, 95% CI 0.7-1.3). The average medical costs were lower for 
patients in the step-up group than for those in the step-down group (€228 vs 
€245; p=0.0008), which was mainly because of costs of medication. One or more 
adverse drug events were reported by 94 (28%) patients in the step-up and 93 
(29%) patients in the step-down group. All were minor events, including (other) 
dyspeptic symptoms, diarrhoea, constipation, and bad/dry taste.
Conclusions Although treatment success with either step-up or step-down 
treatment is similar, the step-up strategy is more cost effective at six months for 
initial treatment of patients with new onset dyspeptic symptoms in primary care.
Effect and cost-effectiveness after six months
INTRODUCTION
The initial management of dyspepsia remains a challenge. The high prevalence 
of the condition substantially increases the workload for physicians and has 
detrimental effects on patient quality of life, as well as important socioeconomic 
consequences.1,2 Unfortunately, solid evidence on which to base the best initial 
management strategy is still lacking.3,4 Most studies to date have reported on 
single drug comparisons and mainly involved patients with persisting dyspeptic 
symptoms referred to secondary care. Several meta-analyses and reviews have 
been done to address important questions concerning treatment strategies for 
patients with dyspeptic symptoms.5-9 A Cochrane review showed that only a few 
studies - mostly of inadequate methodology - dealt with initial management of 
dyspepsia. The investigators concluded that large gaps in knowledge on the 
most cost-effective management strategy for uninvestigated dyspepsia exist. 
Consequently, guidelines for management of dyspepsia are inconsistent.
The American Gastroenterological Association (AGA) and Canadian guidelines 
recommend empirical proton pump inhibitor treatment for patients with 
predominant gastro-oesophageal reflux disease (GORD), and Helicobacter pylori
(H pylori) test-and-treat followed by empirical proton pump inhibitor treatment for
10 11all others. , According to the AGA guidelines, empirical proton pump inhibitor 
treatment is also an initial option in a population with low H pylori prevalence. UK
guidelines state that there is currently insufficient evidence to guide which of
12these two options should be offered first. Scottish guidelines adopt the ROME II
13definition for dyspepsia, necessitating initial endoscopy for diagnosis. They 
advise treating functional dyspepsia with antacids or H2-receptor antagonists, 
followed by H pylori test-and-treat when symptoms persist. By contrast, Dutch 
guidelines recommend empirical treatment with antacids or H2-receptor 
antagonists for all patients with new onset dyspepsia, and reserve proton pump 
inhibitor treatment for patients with persistent predominantly GORD symptoms, 
and H pylori test-and-treat for all other patients with persistent symptoms (step-
14up strategy). Direct endoscopic diagnosis is only indicated for patients 
presenting with alarm symptoms. Initial treatment with proton pump inhibitors is 
used widely because of its presumed superior cost-effectiveness. To improve 
our insight into the best treatment for initial management of dyspepsia in primary 






From October, 2003, to January, 2006 a representative sample of 312 Dutch
15family doctors (general practitioners) agreed to include patients in the 
DIAMOND-study (Dutch study on Initial Management Of Newly diagnosed 
Dyspepsia). The methodological aspects of the trial are outlined here, and details
15have been described elsewhere.
Patients aged 18 years and older who consulted their general practitioner for 
new onset dyspepsia were eligible. Dyspepsia was defined as pain or discomfort 
centred in the upper abdomen (epigastria), judged by the physician to originate in 
the upper gastrointestinal tract, which might be accompanied with symptoms 
such as regurgitation, heartburn, nausea, or bloating.16,17 Because patients 
present to clinical practice with varying durations of symptoms, no length of time 
of the dyspeptic symptom period was defined. To ensure symptoms were new 
onset, patients were excluded if they had a gastroscopy within the previous year 
or used prescribed acid-suppressive medication in the previous three months. 
Further exclusion criteria were alarm symptoms (dysphagia, unintended weight 
loss, anemia, hematemesis), pregnancy, or insufficient knowledge of the Dutch 
language.
The protocol of this randomised double-blinded trial in primary care was 
approved by the ethics committees of the University Hospitals of Nijmegen, 
Utrecht, and Maastricht. All participants gave written informed consent.
Procedures
Consultations, including lifestyle instructions, were done according to the
14physician’s standard practice. Additionally, patients received information on the 
trial. Eligible patients were randomly assigned to step-up or step-down treatment 
(figure 2.1), by means of opening one of several identically wrapped randomised 
medication boxes present at the general practice, containing separately wrapped 
medication packages for each treatment step. The randomisation sequence was 
computer-generated with blocks of six on a 50/50 basis, and concealed from 
patients, investigators, and study personnel. CJvM wrote an SAS program to 
generate the randomisation sequence. Medication boxes were assembled before 
the study based on this sequence by CJvM, SM, GAJF, MGHvO, and by 
colleagues who were not involved in the rest of the trial. CJvM, SM, and GAJF 
were unaware of the randomisation sequence during wrapping and distribution of 
the medication boxes.
At the inclusion visit, a blood sample was drawn, a 4-week follow-up visit
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Figure 2.1: Overview of study design










scheduled, and the step 1 medication and a self-report questionnaire on 
symptoms and quality of life handed out.18-20 Patients were instructed to fill out 
this questionnaire before starting the treatment. For the other baseline 
assessments a questionnaire was sent by mail directly after inclusion was 
reported. If follow-up visits were not common practice for the general practitioner, 
patients were instructed to cancel the appointment when they were free of 
symptoms to reduce protocol-generated extra consultations. Nonetheless, 
unused drugs were returned for pill counts. Treatment was only continued with 
the next step if symptoms were not adequately relieved or relapsed within the 
next four weeks, based on the combined judgment of patient and general 
practitioner. If symptoms relapsed at a later time, the general practitioner treated 
according to standard practice. Patients were allowed to proceed to the next 
treatment step earlier if symptoms worsened or unpleasant side-effects occurred. 
During the follow-up period of six months, questionnaires were sent at two 
weeks, at the end of each treatment step, or - if treatment was no longer required 
- at intervals of four weeks, and at six months. If symptoms relapsed within the 
first four weeks after ending a medication step, an additional questionnaire was 
sent to assess the symptom status at the beginning of that treatment step. The 
double-blinding of the treatment was maintained for six months after 
randomisation.
Each treatment step provided medication for four weeks and consisted of acid- 
suppressive medication with increasing acid-affecting capacity:5 1 ] antacids four 
times daily (aluminium oxide 200 mg/magnesium hydroxide 400 mg); 2] H2- 
receptor antagonist twice daily (ranitidine 150 mg); and 3] proton pump inhibitor 
once daily (pantoprazole 40 mg) for step-up and in the reverse order for step- 
down. To maintain blinding, antacids were accompanied by a proton pump 
inhibitor placebo once daily and proton pump inhibitor by antacid placebo four 
times daily.
Before initiating treatment, type and severity of gastrointestinal symptoms - i.e., 
regurgitation, heartburn, epigastric pain, nausea, and bloating - were assessed 
on a valid seven-point adjectival scale,18 and quality of life was assessed by use 
of the EuroQol-5D.19,20 Furthermore, demographics, lifestyle habits, work and 
income, medical history, and drug use at baseline were assessed with the 
additional self-report postal questionnaire at inclusion. H pylori status was 
determined by IgG antibody-titre assay (Pyloriset EIA-GIII, Orion Diagnostica, 
Espoo, Finland) in a venous blood sample. H pylori was tested in batches during 
the trial to minimise assay variability. Both patient and investigator were blinded 
to the results of the H pylori test until six months after inclusion.
During follow-up measurements, patients were asked to report adequacy of 
symptom relief, type and severity of gastrointestinal symptoms,18 quality of
50
Effect and cost-effectiveness after six months
life, 19,20 lifestyle habits, work absenteeism, out-of-pocket costs, and medication 
use. A case record form was used to assess general practitioner consultations, 
adverse events, diagnostics, and referrals. Completeness and correctness of 
these forms were verified retrospectively for all patients by use of the general 
practitioners’ electronic information system at the end of follow-up.
The financial estimates used in our study were based on the cost to society 
according to 2006 prices. The societal viewpoint was deemed relevant because 
health-care interventions are not confined to the health-care system itself, but 
also influence societal factors. We used a quantity-and-price approach to 
estimate total costs in Euros, based on primary data from this randomised trial.
Direct medical quantities, assumed relevant, include acid-related medication, 
consultations, diagnostic tests, and referrals. Non-medical quantities include 
productivity loss of paid and unpaid work, and out-of-pocket expenses. Valuation
of costs was undertaken according to Dutch guidelines for (pharmaco-)economic
21evaluations in health care. Costs of medication were based on average retail 
prices for antacids, and standard cost prices for H2-receptor antagonists and 
proton pump inhibitors.22,23 For the H2-receptor antagonist and the proton pump 
inhibitor, an additional cost of €6.71, representing the Dutch prescription charge, 
was added per prescription. This was not done for antacids, which are only 
available over-the-counter in the Netherlands. General practitioner consultation 
costs were based on a single consultation of 10 min. For diagnostic tests, a
weighted mean tariff of all tests was calculated based on costs derived from a
21database on tariff s for medical interventions from 2003. Standard cost prices 
were used for referrals and hospital admission assuming equal distribution over
general and university hospitals. Productivity losses were calculated according to
21the friction cost method. Out-of-pocket expenses, including transportation, and 
dietary changes were reported on the questionnaire. All prices were indexed to 
2006 where necessary.
The primary endpoints were effectiveness (adequate symptom relief) and cost- 
effectiveness of initial management at six months. Secondary endpoints were 
change in symptom severity (by use of a sum score of upper gastrointestinal 
symptoms severity ranging from 0 to 72) and quality of life (by use of a visual 
analogue scale [VAS] to measure patients’ overall subjective health status 
ranging from 0  [worst imaginable] to 1 0 0  [best imaginable]) between baseline 
and six months. Treatment success was defined as adequate symptom relief at 
six months, indicated by a ‘yes’ or ‘no’ answer.15 The patient’s subjective 
judgment was chosen because it would, in normal clinical practice, inform the 
decision to continue treatment. Data were analysed on an intention-to-treat basis, 
excluding only patients without data for the primary outcome at six months. 
However, all randomised patients were used in the cost calculations, since data 
on costs were available at least up to the time of loss to follow-up.
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341 participants assigned 323 participants assigned
334 treatment as assigned 
7 did not start treatment Step 1
319 treatment as assigned 
4 did not start treatment
139 received step 1 only i 1 153 received step 1 only
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1 study load j 1 study load
1 side effects 1 : 1 symptom free
1 unknown i 1 1 moved
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136 entered follow-up 1 : 3 unknown
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i .........................................................
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202 treatment as assigned Step 2 17 D treatment as assigned
57 received step 1 and step 2
3 lost to follow-up
2 symptom free 
1 unknown 
54 entered follow-up
118 treatment as assigned Step 3 11 treatment as assigned 
—i----------------------------------
118 received all three steps
3 lost to follow-up
1 death gastric cancer 
1 symptom free 
1 moved 
115 entered follow-up _ r
332 primary endpoint Endpoint 313 primary endpoint
at 6-months* reached at 6-months*
Figure 2.2: Trial profile
Study load=patients withdrew from the trial because of the number o f questionnaires to be completed or the 
number o f pills to be taken. Symptom free=patients w ithdrew from the trial because they became symptom 
free (it is unknown whether these patients remained symptom free or had a relapse because the endpoint at 
six months was not available). *All randomised patients except those lost to follow-up are included in the 
intention-to-treat population. #Number of questionnaires returned/number sent out (%). The number of 
questionnaires sent out declines because several patients asked not to be sent them as the trial progressed. 
A fter explaining the importance of the questionnaires, some patients only agreed to complete the 6-month 
questionnaire.
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Statistical analysis
The calculated sample size was based on the 
assumptions of 40% treatment effectiveness at six 
months in both groups and an actual difference of 
0% .24,25 To be able to demonstrate equivalence with a 
reliability a=0.05, 80% power (p=0.20), and a 
maximum difference in effectiveness of 1 0 % between 
the treatment strategies, we calculated that at least 
297 patients needed to be randomised to each 
treatment group.
Outcomes were compared between the groups 
using chi-square tests and Kaplan-Meier analysis. 
Mann-Whitney U test was used to compare costs 
between the treatment strategies. To describe the 
association between costs and treatment success, an 
incremental analysis was undertaken on the two 
strategies, with step-up as reference. One-way 
sensitivity analyses were done to study the effect of 
varying costs on the average total costs of the two 
strategies. All calculations were done by use of SAS 
software (version 8.2). All p values calculated were 
two-tailed and the alpha level of significance was set 
at 0.05. This trial is registered with ClinicalTrials.gov, 
number NCT00247715.
Role of the funding source
The funding organisation had no involvement in 
study design, collection, analysis, and interpretation of 
data, writing of papers, nor in the decision to submit 
the paper for publication. All authors had full access to 
the data, and CvJM, JBMJJ, and RJFL had final 
responsibility for the decision to submit for publication.
RESULTS
15150 (48%) of the participating general practitioners recruited 664 patients. 
The trial profile is shown in figure 2.2. 332 (97%) of 341 patients in the step-up, 
and 313 (97%) of 323 patients in the step-down group reached an endpoint with 
sufficient data for assessment. 19 patients (step-up n=9, step-down n=10) did not
Questionnaires returned #
Baseline
Step-up 332/341 (97%) 
Step-down 311/323 (96%)
Step 1
Step-up 274/330 (83%) 
Step-down 251/313 (80%)
Step 2
Step-up 243/305 (80%) 
Step-down 231/290 (80%)
Step 3





Table 2.1: Baseline characteristics according to treatment assignment
Step-up n/N (%)* Step-down n/N (%)*
Gender
Male 157/341 (46%) 147/323 (46%)
Female 184/341 (54%) 176/323 (54%)
Age (years)
< 40 years 120/341 (35%) 108/323 (33%)
40 - 55 years 118/341 (35%) 108/323 (33%)
> 55 years 103/341 (30%) 107/323 (33%)
Ethnicity
White 317/341 (93%) 306/323 (95%)
Work
Paid job 196/311 (63%) 173/295 (59%)
Smoking
Current smokers 96/324 (30%) 79/303 (26%)
Number of smokes per day
0 - 9 22/88 (25%) 20/77 (26%)
10 - 19 38/88 (43%) 30/77 (39%)
> 20 28/88 (32%) 27/77 (35%)
Alcohol intake
Current drinkers 226/324 (70%) 234/303 (77%)
Number of glasses per week
0 - 7 152/217 (70%) 153/229 (67%)
8 - 14 43/217 (20%) 56/229 (24%)
> 15 22/217 (10%) 20/229 (9%)
H py lo ri status
Positive 124/330 (38%) 107/315 (34%)
Symptoms*
Regurgitation 201/306 (66%) 212/296 (72%)
Heartburn 216/307 (70%) 207/294 (70%)
Epigastric pain 215/290 (74%) 204/271 (75%)
Nausea 118/309 (38%) 134/293 (46%)
Bloating 215/306 (70%) 208/293 (71%)
Predominant symptom* (severity dyspepsia / reflux)
Dyspepsia 159/311 (51%) (4.2 [1 ]/1 .8  [1]) 161/297 (54%) (4.0 [1 ] /  1.8 [1])
Equal for dyspepsia and reflux 98/311 (32%) (3.7 [1]) 85/297 (29%) (3.7 [1])
Reflux 54/311 (17%) (2.5 [1 ]/3 .9  [1]) 51/297 (17%) (2.8 [1 ]/4 .1  [1])
Quality o f life®
EQ-5D score 0.76 (0.19) 0.79 (0.17)
EQ-5D VAS 54 (25) 54 (25)
VAS=visual analogue scale. 'Denom inators depend on the number o f patients who provided an answer for a 
specific question in the questionnaire. tSymptom severity >2 on a seven-point adjectival scale ranging from 
0 to 6. *Mean (SD) severity score of the most bothersome dyspeptic and reflux symptom within the predomi­
nant symptom groups (severity dyspepsia/reflux). §Mean (SD).
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reach an endpoint (figure 2.2). Baseline characteristics are shown in table 2.1. 
During the study period, 139 (41%), 84 (25%), and 118 (35%) of 341 patients 
assigned to the step-up treatment group, and 153 (47%), 57 (18%), and 113 
(35%) of 323 patients in the step-down group received one, two, or three 
treatment steps, respectively. Seven patients in the step-up group and four 
patients in the step-down group did not use any medication. One or more 
adverse drug events were reported by 94 (28%) patients in the step-up and 93 
(29%) patients in the step-down group (table 2.2). All were minor events, 
including (other) dyspeptic symptoms (n=125; 59 step-up vs 6 6  step-down), 
diarrhoea (n=39; 24 vs 15), constipation (n=27; 15 vs 12), flatulence (n=20; 12 vs 
8 ), bad/dry taste (n=24; 4 vs 20), headache (n=15; 5 vs 10), and rash/itch (n=13; 
6  vs 7). In one patient (female, 60 years, without alarm symptoms) who showed 
no response to 12 days of step 1 medication and 7 days of step 2 medication, 
incurable gastric cancer was diagnosed during the trial period 47 days after 
inclusion (figure 2.2).








Yes 238/332 72% (66-77%) 219/313 70% (64-76%) 0.63
No 94/332 28% (19-37%) 94/313 30% (21-39%)
By H pylori status
Negative 142/201 71% (63-78%) 142/203 70% (62-77%) 0.88
Positive 89/122 73% (64-82%) 72/104 69% (59-80%) 0.54
Symptoms*
Regurgitation 70/256 27% (17-38%) 77/244 32% (21-42%) 0.30
Heartburn 90/253 36% (26-45%) 86/240 36% (26-46%) 0.95
Epigastric pain 54/246 22% (11-33%) 60/237 25% (14-36%) 0.38
Nausea 39/256 15% (4-27%) 40/245 16% (5-28%) 0.74
Bloating 93/257 36% (26-46%) 92/245 38% (28-47%) 0.75
Quality o f life
Worsened (VAS) 36/235 15% (4-27%) 41/220 19% (7-31%) 0.53
Unchanged (VAS) 44/235 19% (7-30%) 35/220 16% (4-28%)
Improved (VAS) 155/235 66% (59-73%) 144/220 65% (58-73%)
Adverse events
Step 1 70/334 21% (11-30%) 65/319 20% (11-30%) 0.85
Step 2 18/202 9% (0-22%) 30/170 18% (4-31%) 0.01
Step 3 21/118 18% (1 -34%) 20/113 18% (1-34%) 0.98
Number of patients 94/341 28% (19-37%) 93/323 29% (20-38%) 0.73
(continues on next page)
55
Chapter 2
(table 2.2 continued) Step-up Step-down p value
n/N %(95% CI) n/N %(95% CI)
Direct medical quantities
Prescribed trial medication
Antacid 341/341100% (100-100%) 113/323 35% (26-44%) <0.0001
H2-receptor antagonist 202/341 59% (52-66%) 170/323 53% (45-60%) 0.09
Proton pump inhibitor 118/341 35% (26-43%) 323/323100% (100-100%) <0.0001
Number o f patients taking additional drug treatments
Antacid 54/341 16% (6-26%) 59/323 18% (8-28%) 0.40
H2-receptor antagonist 22/341 6% (0-17%) 30/323 9% (0-20%) 0.17
Proton pump inhibitor 98/341 29% (20-38%) 93/323 29% (20-38%) 0.99
H pylori eradication 6/341 2% (0-12%) 6/323 2% (0-13%) 0.92
Prokinetics 10/341 3% (0-13%) 6/323 2% (0-13%) 0.37
Other gastrointestinal 25/341 7% (0-18%) 26/323 8% (0-19%) 0.73
Number o f consultations#
General practitioner* 752 719 0.97"
Gastroenterologist 15 16 0.73a
Other 4 2 0.45"
Number o f diagnostic tests#
H pylori test 37 31 0.97a
Endoscopy 35 35 0.64a
Upper abdominal ultrasound 19 13 0.44a
Radiograph of oesophagus 
or stomach
2 4 0.38a
Other 17 13 0.90a
Number o f admissions#
Hospital 8 2 0.69a
Indirect quantities
Absenteeism
Number of patients 30/313 10% (0-20%) 30/293 10% (0-21 %) 0.79
Number of days# 205 200 0.91a
Productivity loss unpaid work
Number of patients 147/313 47% (39-55%) 142/293 48% (40-57%) 0.71
Number of days# 1889 2135 0.78a
Out-of-pocket expenses1
Number of times reported# 39 52 0.57a
VAS=visual analogue scale. Denominators depend on the number of patients who provided an answer on a 
specific question in the questionnaire. tSymptom severity >2 on a seven-point adjectival scale ranging from 
0 to 6. Total number of times this item was counted within a treatment group. Denominators are not 
available, since one patient could have been counted more than once, whereas others were not counted at 
all (eg, if a patient was admitted to the hospital tw ice, he/she was counted tw ice, whereas most patients 
were not admitted to the hospital and therefore not counted). ^Excluding first consult. "Mann-Whitney U test 
p value, comparing numbers per patient between treatment groups. ^Out-of-pocket expenses include 
transportation and costs for changed diet.
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Treatment success after six months was reported by 238 (72%) of 332 patients 
in the step-up group and 219 (70%) of 313 patients in the step-down group (odds 
ratio [OR] 0.92, 95% CI 0.7-1.3; table 2.2 and figure 2.3A). After only one 
treatment step, adequate symptom relief was sustained for up to six months in 80 
(24%) of 332 step-up patients and 78 (25%) of 313 step-down patients; in 44 
(13%) and 26 (8 %) patients after two steps; and in 24 (7%) and 20 (6 %) patients 
after all three steps, respectively. The other 90 (27%) patients in the step-up 
group and 95 (30%) patients in the step-down group with adequate symptom 
relief at six months received additional treatment (any additional drug treatment, 
consultation, diagnostic test, or hospital admission that a patient received other 
than prescribed trial medication and general practitioner consultations for step 1 , 
step 2, and step 3 according to protocol; table 2.2) during the study period or 
were still using acid-suppressing drug at six months.
During the initial study period, treatment effect was reported in significantly 
more patients in the step-down group than in the step-up group at two weeks 
(step-up 42%, 95% CI 36-47%; step-down 55%, 95% CI 50-61%) and one month 
(step-up 55%, 95% CI 50-61%; step-down 6 6 %, 95% CI 61-71%; figure 2.4A). 
The number of patients with symptom relapse did not differ (p=0.15) between the 
step-up (104 [34%] of 306 patients) and step-down (113 [40%] of 285 patients) 
groups, and nor did the relapse period (p=0.16, figure 2.4B). At the end of the 
trial, 111 (17%) of the 645 patients were on proton pump inhibitors (step-up 
n=58, step-down n=53; p=0.84). More patients reporting inadequate symptom 
relief than patients with adequate symptom relief at six months were taking 
proton pump inhibitors (51 [27%] of 188 patients vs 60 [13%] of 457 patients, 
respectively; p<0.0001). Proton pump inhibitor use at six months did not differ 
between the treatment strategies (p=0.80). During the assessment period of six 
months, only 12 patients received H  pylori-eradication therapy (table 2.2). After 
six months, when the H  pylori status was unblinded to the general practitioner 
and the patient, at least another 8 6  patients (total 98; 42% of all 231 who tested 
positive) are known to have received eradication therapy.
Symptom patterns and severity score (overall mean sum score 20.8, SD 9.1) at 
baseline were similar between step-up and step-down groups. When 
discriminating between gastro-oesophageal reflux and dyspeptic symptoms, 470 
(77%) of 608 patients reported reflux as well as dyspeptic symptoms, eight (1%) 
of 608 reported reflux symptoms only, and 130 (21%) of 608 reported dyspeptic 
symptoms only. Reflux symptoms were predominant in 54 (17%) of the 311 step- 
up and 51 (17%) of the 297 step-down patients (table 2.1). Treatment success 
after six months was lowest in patients with predominant reflux ( 6 8  [65%] of 104 
patients), followed by patients with equal dominance (125 [70%] of 178), and 
patients with predominant dyspepsia (229 [73%] of 312), but the p value was not
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Figure 2.3: Costs and effectiveness o f treatment strategies
Mean costs and effectiveness (SE) according to (A) treatment assignment and (B) treatment assignment and 
predominance of dyspepsia or reflux
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significant (p=0.28). Post-hoc subgroup analysis also suggests that patients with 
predominant reflux, by contrast with the overall population (figure 2.3A) and 
patients with predominant dyspepsia (figure 2.3B), respond more effectively to 
the step-down (treatment success in 35 [69%] of 51 patients) than to the step-up 
(33 [62%] of 53 patients) approach (OR 1.33, 95% CI 0.6-3.0), although not 
significantly so. Over time, symptom severity between baseline and six months 
improved by a mean sum score of 10.3 (95% CI 9-11) for patients in both the 
step-up and the step-down groups (p=0.99). Symptom improvement (mean sum 
score) was significantly higher in patients with adequate symptom relief (overall 
12.3, 95% CI 11-13; step-up 12.1, 95% CI 11-13; step-down 12.5, 95% CI 11-14) 
compared with patients without (overall 5.0, 95% CI 4-6; step-up 4.9, 95% CI 3-7; 
step-down 5.1, 95% CI 3-7; all p<0.0001). Quality of life improved by 20 (95% CI 
16-24) points and 19 (95% CI 15-23) points on the VAS scale for patients in the 
step-up and step-down groups, respectively (p=0.70). Again, improvement was 
higher in patients with (overall 25.0, 95% CI 22-28; step-up 24.5, 95% CI 20-29; 
step-down 25.5, 95% CI 21-30) compared with patients without (overall 5.7, 95% 
CI 1-10; step-up 7.4, 95% CI 0-15; step-down 4.2, 95% CI -2 to 10) adequate 
symptom relief (all p<0 .0 0 0 1 ).
Medical consumption differed between the strategies only with regard to 
prescribed medication (table 2.2). The mean calculated medical costs were 
lower for patients in the step-up group than in the step-down group, which was 
solely caused by the difference in use of acid-suppressing medication (table 2.3). 
The costs associated with productivity loss and out-of-pocket expenses did not 
differ between the strategies (p=0.56, table 2.3). Combined (direct medical and 
indirect) mean costs were lower for patients in the step-up group than for patients 
in the step-down group (€426 vs €460; p=0.02). Medical costs accounted for 
more than half of the total expenses in the step-up (€77 671/€145 185 for 
treatment of 341 patients) as well as step-down (€79 140/€148 664 for treatment 
of 323 patients) groups. The higher total costs and non-significant lower success 
rate for the step-down strategy resulted in a dominant incremental cost- 
effectiveness ratio for step-up treatment (figure 2.3).
The cost-effectiveness of the dyspepsia treatment strategies was sensitive to 
the price of medication. When cost calculations were done using cost prices 
(excluding prescription costs) of generic drugs22,23 (antacid € 1 2 .0 0 , H2-receptor 
antagonist €12.32, and proton pump inhibitor €11.98 per month) instead of 
branded drugs (antacid €16.80, H2-receptor antagonist €15.27, and proton pump 
inhibitor €38.59 per month), the difference in medication costs remained 
(p=0.003), but mean medical costs (p=0.12) and overall mean costs (p=0.90) 
were no longer significantly different between the strategies.
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Figure 2.4: Time to adequate symptom relief after in itiation o f treatment strategies and 
relapse after in itia l treatment success
(A) Time to adequate symptom relief. (B) Time to symptom relapse after initial success
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DISCUSSION
Ideally, dyspepsia treatment should quickly and conveniently alleviate patients’ 
symptoms while also reducing the use of health-care resources to a minimum. 
We have shown that a step-up strategy starting with antacids is more cost 
effective than a step-down strategy starting with proton pump inhibitors in the 
initial management of dyspepsia in primary care. Compared with the step-down 
approach, the step-up regimen resulted in slightly lower medical and overall 
costs with equal clinical effectiveness - measured as treatment success at six 
months, symptom severity, and quality of life. The total costs of each treatment 
strategy were mainly dependent on prices of medication. If calculations are 
based on generic acid-suppressive drugs, the difference in cost-effectiveness 
between the treatment strategies is reduced (assuming that a generic proton 
pump inhibitor gives the same effectiveness as a branded proton pump inhibitor 
and that the prices of the antacids and H2-receptor antagonists remain 
unchanged). In that case, our finding that treatment success was reported 
significantly earlier in the step-down strategy might shift preference towards initial 
treatment with generic proton pump inhibitors.
Studies comparing stepwise management strategies have been published 
before.26-30 However, the results of our study do not completely concur with the 
existing literature. First, initial proton pump inhibitor treatment strategies were 
judged to be better for patients with dyspeptic symptoms in most other studies on 
stepwise management.26-28,30-32 Second, by contrast with our findings, proton 
pump inhibitors are generally thought to be less effective in relieving symptoms in
33patients with dyspepsia than in patients with GORD. These contrary results 
most likely occur because of differences in patient population; previous studies 
were largely based on patients with predominant heartburn or dyspeptic 
symptoms referred for endoscopy or secondary care. Our findings in primary- 
care patients with new onset dyspepsia should therefore be considered as an 
addition to the existing literature. Consistent with the CADET-HN study,34 our 
study indicates that heartburn is an integrated part of the dyspeptic symptom 
complex in uninvestigated primary-care patients and only predominant in a very 
small part of our population. Although the CADET-HN study did single drug 
comparisons in H pylori-negative patients instead of stepwise treatment, cost- 
effectiveness analyses showed that differences between H2-receptor antagonist 
and proton pump inhibitor treatment were non-significant, but slightly in favour of 
H2-receptor antagonists.34
Dyspepsia is a complex of symptoms originating in the upper gastrointestinal 
tract, including gastro-oesophageal reflux symptoms (heartburn and 
regurgitation). Despite substantial overlap between reflux symptoms and
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Table 2.3: Mean costs according to treatment assignment
Cost valuations in €* Mean cost per patient in € (SE) p value
Step-up (n=341) !Step-down (n=323)
Direct medical costs
Prescribed trial medication
Antacid23 0.14 per tablet 23.51 (0) 8.22 (0.62) <0.0001
H2-receptor antagonist22 0.25 per tablet1" 13.02 (0.59) 11.57 (0.61) 0.09
Proton pump inhibitor22 1.29 per tablet1 15.68 (1.17) 45.30 (0) <0.0001
Additional medication
Antacid23 0.14 per tablet 1.74 (0.29) 1.76 (0.29) 0.46
H2-receptor antagonist22 0.25 per tablet1 1.13 (0.28) 1.88 (0.35) 0.15
Proton pump inhibitor22 1.29 per tablet1 22.05 (2.44) 25.74 (3.02) 0.82
H pylori eradication22 146.131 3.59 (1.67) 2.84 (1.15) 0.93
Total medication (mean) 80.71 (3.91) 97.31 (3.88) <0.0001
Consultations21
General practitioner 21.03 67.41 (1.85) 67.84 (1.99) 0.97
Gastroenterologist 65.62 2.77 (0.88) 3.12 (0.94) 0.73
Other 65.62 0.74 (0.37) 0.39 (0.28) 0.45
Total consultations (mean) 70.92 (2.42) 71.36 (2.63) 0.95
Diagnostic tests21
H pylori test 29.90* 3.24 (0.58) 2.87 (0.49) 0.97
Endoscopy 515.59 55.09 (9.38) 58.16 (9.30) 0.64
Upper abdominal ultrasound 131.47 7.63 (1.79) 5.51 (1.50) 0.44
Radiograph of oesophagus 
or stomach
207.78 1.22 (0.86) 2.57 (1.28) 0.38
Other 179.90* 8.97 (2.90) 7.24 (1.97) 0.90
Total diagnostic tests (mean) 76.14 (11.75) 76.35 (10.84) 0.83
Total m edical costs (mean) 227.77 (15.54) 245.01 (14.93) 0.0008
Indirect costs§
Productivity loss21
Paid work Age dependent 146.71 (33.16) 161.69 (43.08) 0.92
Unpaid work 8.64 per h 64.70 (4.91) 72.19 (5.72) 0.57
Out-of-pocket expenses1
4.28 (2.30) 3.41 (1.23) 0.57
Total ind irect costs (mean) 215.70 (34.22) 237.29 (43.66) 0.56
Total costs
Mean fo r whole g ro u p 425.76 (36.70) 460.26 (43.31) 0.02
*See Methods section for explanation and references. tAdditional costs per prescription €671 not included 
in price per tablet. ^Weighted mean based on diagnostic tests reported in DIAMOND-trial. §Indirect costs 
were not available for all patients (step-up group 313 patients; step-down group 293 patients). ^Out-of- 
pocket expenses include transportation and costs for changed diet. "Calculation used indirect costs=0 for 
the 58 patients for whom data was missing.
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epigastric pain in most patients with uninvestigated dyspepsia, and the difficulty 
that patients have in describing their predominant symptom - which might change
35over time - not everyone agrees on the inclusion of predominant reflux in the 
definition of dyspepsia.8,10,13 Because of minimal selection, our population - which 
included patients with both dyspeptic and/or gastro-oesophageal reflux 
symptoms - is a more realistic representation of the patient population with new 
onset upper abdominal complaints encountered in daily clinical practice. 
Although many patients (77%) also reported reflux symptoms, the group of 
patients presenting with reflux symptoms alone was small (1%). Our post-hoc 
subgroup analysis seems to confirm superiority of clinical effectiveness of initial 
proton pump inhibitor treatment only for patients with predominant reflux, but 
numbers are too small to draw final conclusions. Additionally, we included 
patients with new onset dyspepsia, by contrast with most studies on acid 
suppression. These studies found poorer response in non-GORD patients 
because patients that did respond to acid suppression were excluded.
Our results once again show that defining the optimum strategy for 
management of dyspepsia, provided there is one for all patients, is complicated 
by the lack of an unequivocal definition, the heterogeneity of symptoms, and 
several underlying causes.8,36,37 One patient (aged 60 years) diagnosed with 
gastric cancer during the study period should ideally have been identified for 
early endoscopy; however, alarm symptoms were not present at inclusion. An
indication for early endoscopy in new onset dyspepsia after the age of 5 0  or 5 5
10-12years might have prevented the delay in diagnosing this cancer. - Even though 
gastric cancer is found earlier when symptomatic patients are promptly referred 
for endoscopy, no data are available on whether this strategy positively affects 
prognosis.38,39
By contrast with several other guidelines, Dutch guidelines reserve H pylori 
test-and-treat for patients with persistent non-GORD symptoms, because there is 
conflicting evidence as to whether this method is a better initial treatment 
strategy than empirical treatment. Indeed, the fact that H pylori test-and-treat is 
no better than empirical proton pump inhibitor treatment has recently been 
confirmed by Delaney and colleagues.40 Moreover, H pylori test-and-treat would 
interfere with our study protocol. Although only a few patients received 
eradication therapy during the study, several patients received it after H pylori 
status was unblinded. The decision for H pylori eradication at that time was 
mainly driven by the knowledge of the bacterium’s presence. The opinions of the 
general practitioners differed on whether H pylori should always be eradicated or 
only when symptoms are still present. At least 42% of all patients positive for H  
pylori were known to have received eradication therapy.
The strengths of this trial are the large sample size of 664 patients, the
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randomised, double-blinded design, the direct comparison of step-up and step- 
down acid-suppressive therapy, and the extensive outcome assessment 
including costs. In our study, the patient’s subjective judgment of adequate
15symptom relief (a ‘yes’ or ‘no’ answer) was taken as the primary outcome, since 
this judgment is the basis of the choice to stop or continue treatment in clinical 
practice. To support this outcome, and for clinical comparison, symptom severity 
was measured as a secondary outcome.18 Data were analysed according to 
intention to treat only, since by choosing a pragmatic design, per-protocol
15analysis (which excludes protocol deviations) is not indicated.
Nonetheless, this study also has its limitations. Although efforts have been 
made to design the study as pragmatically as possible in a clinical trial, 
differences between the study protocol and actual clinical practice were
15inevitable. In clinical practice, a general practitioner would probably not pursue 
a step-down approach when a patient is not responding to initial proton pump 
inhibitors, which is generally regarded as a helpful strategy to identify underlying 
reflux. Furthermore, we are unable to assess whether there has been relevant 
selection of patients, because characteristics of patients not included in the trial 
were not recorded. The number of general practitioners enrolling patients and the 
average number of patients enrolled per practice were low. Although this was 
anticipated because of the high workload in normal practice, it might to some 
extent limit generalisability. The actual success rate was considerably higher 
(70%) than the a-priori assumed success rate (40%). The latter was a 
conservative estimation, and was based on the literature, in which most studies 
comparing acid suppression involve patient populations with chronic or functional 
dyspepsia, which show lower success rates. Finally, it remains unclear if 
evaluation of cost-effectiveness over a period of six months, although longer than 
in most studies, is adequate for a chronic relapsing condition such as dyspepsia.
In conclusion, the step-up approach is more cost effective at six months in 
patients with new onset dyspepsia than a step-down approach. Nonetheless, 
patients on initial empirical treatment with proton pump inhibitor (step-down) 
show an earlier response, especially in the small subgroup with predominant 
reflux symptoms. Furthermore, the difference in cost-effectiveness declines when 
calculations are based on prices of generic acid-suppressive medication. These 
data provide important information for management protocols of patients with 
new onset dyspepsia in general practice.
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Chapter,
Step-up acid-suppressive strategy still more cost effective 
than step-down in new onset dyspepsia: one year results

Effect and cost-effectiveness after one year
Previously, we have shown that cost-effectiveness of initial stepwise 
empirical acid suppression is in favour of a step-up approach after six 
months. However, due to its chronic relapsing character, dyspepsia 
continues to cause prolonged health-care utilisation in many patients, 
making extended evaluation of (cost-)effectiveness desirable. Therefore, 
we assessed the symptom status, health-related quality of life (HRQoL) and 
medical costs one year after initial stepwise treatment of new onset 
dyspepsia in patients from the DIAMOND-study. An eminent drop in 
treatment success rates from 71 to 50% (and for sustained success: from 
42% to 21%) was seen between six months and one year. However, 1-year 
success rates were equal between the treatment strategies (p=0.75). 
Although medical expenses between six and twelve months converged 
(p=0.94), total medical expenses per patient in one year remained 
significantly higher for patients in the step-down (€349) compared to those 
in the step-up (€305, p=0.002) approach, resulting in an 1-year incremental
cost-effective ness ratio (ICERstep-down/step-up) of 26.8 €/%treatment success.
Therefore, the conclusions of the DIAMOND-study - that step-up is more 
cost-effective than a step-down strategy - are maintained after one year.
Initial treatment strategies that result in early and prolonged treatment success 
would reduce the socio-economic burden of common chronic relapsing disorders 
like dyspepsia. In 2003, we initiated the DIAMOND-study, a pragmatic primary 
care based randomised trial, aiming to address important gaps in knowledge on 
the most cost-effective initial treatment strategy for patient with uninvestigated 
dyspepsia. Patient with new onset dyspepsia were randomly assigned to 
treatment according to a step-up (antacids - H2-receptor antagonists (H2RA) - 
proton pump inhibitors (PPI) for four weeks; n=341) or a step-down (in reverse 
order; n=323) approach. The primary outcome, cost-effectiveness, was evaluated 
after six months, but numerous patients continue to use medical care thereafter. 
Therefore, we assessed whether cost-effectiveness of step-up and step-down 
acid suppressive therapy maintained after one year.
Dyspeptic patients that completed the DIAMOND-study were sent a postal 
questionnaire one year after randomisation (n=561, figure 3.1). They were asked 
to report presence of dyspeptic symptoms (‘yes/no’) and medication use during 
the preceding four weeks, type and severity of gastrointestinal symptoms, and 
HRQoL using the EuroQol-5D.1 During the extended follow-up, persisting or 
recurrent disease was treated following usual care. Health-care utilisation was 
assessed retrospectively up to one year for all patients as part of the original 
study using the general practitioners’ electronic information system. One-year 
treatment success was defined as: ‘absence of symptoms’, and was regarded as 
‘sustained’ if, after completing the study medication, there was no further health-
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Figure 3.1: Profile o f extended follow-up o f the DIAMOND-study
care utilisation for dyspepsia up to one year. Statistical analyses were identical to 
the original trial. Paired t-test was used to compare HRQoL and symptom 
severity between time points.
Treatment success was achieved in 50% (95%CI:45-55%) of the 373 (6 6 %) 
patients that completed the 1 -year questionnaire, and was equal between the 
strategies (step-up: 49%, 95%CI:42-56%; step-down: 51%, 95%CI:43-58%; 
p=0.75). However, success of initial stepwise treatment was sustained in only 
21% (95%CI:16-25%) of the patients (figure 3.2A). These success rates are
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considerably lower than at six months (overall: 71%, 95%CI:67-74%; sustained: 
42%, 95%CI:38-46%). A reduction between six months and one year was also 
seen in HRQoL (1-year EQ-5D VAS: 68.9 (SD:20.7), paired t-test, all p<0.01, 
figure 3.2B), but symptom severity did not increase (1-year mean sum score: 
10.5 (SD:8.9), paired t-test, all p>0.2, figure 3.2C). Nonetheless, both symptom 
severity and HRQoL after one year remained statistically significantly improved 
compared to baseline (paired t-test, all p<0.0001, figure 3.2B  and 3.2C).
Figure 3.2: Treatment effectiveness according to treatment assignment




During the extended follow-up from six to twelve months, PPIs were used by a 
25% (95/373) of the patients that returned the questionnaire. There were no 
statistical significant differences in PPI use (step-up: 26%, 95%CI:19-32%; step- 
down: 25%, 95%CI:19-32%; p=0.98), nor other health-care utilisation1 
(medication, consultations, and diagnostic tests: all p>0.2, figure 3.3A) between 
the strategies. Consequently, average costs per patient (overall: €111 (SE:11); 
step-up: €101 (SE:12); step-down €121 (SE:18); p=0.94) for treatment between 
six months and one year were comparable between the strategies. Since all 
treatment within the extended follow-up was according to usual care, 
convergence in treatment and cost were expected. Nonetheless, the overall 
average 1 -year health care utilisation costs per patient for treatment of dyspepsia 
remained statistically significantly higher for patients in the step-down (€349 
(SE:22), n=323) compared to patients in the step-up (€305 (SE:19), n=341; 
p=0.002) approach. Although no longer dominant, the 1-year incremental cost-
effectiveness ratio (ICERstep-down/step-up: 2 6 .8  € / %treatment success) remained in favour
of the step-up strategy. Like in the six month analyses, differences in medication 
costs (p=0.10) as well as in health care utilisation costs (p=0.73) between the 
strategies disappear when sensitivity calculations are performed with prices of 
generic instead of branded drug.
Few studies evaluating the effect of acid suppressive treatment of dyspepsia 
assess success rates at one year. In a randomised trial comparing empirical 
H2RA treatment (ranitidine 150mg b.i.d, 4-wk) with prompt endoscopy in patients 
with uninvestigated dyspepsia with an indication to start empirical treatment, 
Bytzer et al. report absence of symptoms after one year in only 22% resp. 21% of 
the patients. On the other hand, Rabeneck et al. observed higher 1-year 
(sustained) success rates in a double-blinded randomised trial, comparing a 6 -wk 
course of PPI (omeprazole 20mg b.i.d.) with placebo. Similar to our results, they 
also observed a significant drop in success rate in the PPI-group (70% at six 
weeks to 48% at one year) and also the placebo-group (55% to 41%) in a 
predominantly male population with uninvestigated dyspepsia.4 Proper 
comparison is however complicated by differences in treatment and outcome 
definition. Based on evaluation of our cost data, which were collected for all 
patients from the original DIAMOND-study, our 1-year success rate is probably 
an underestimation. Despite identical 6 -month success rates (71%, p=0.96), 
medical expenses between six and twelve months were significantly higher in the 
questionnaire responders (€111 (SE:11)) compared to non-responders (€63 
(SE:10), p<0.0001, figure 3.3A), as well as the total 1-year costs (€358 (SE:19) 
vs. €286 (SE:22), p<0.0001, figure 3.3B). Since failure to achieve success was 
also associated with considerably higher 1 -year treatment costs (average per 
patient without treatment success: €426 (SE29), n=183; with treatment success:
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Figure 3.3: Health care utilisation costs according to treatment assignment
(A) Additional health-care costs per patient between six and twelve months according to 1-year 
questionnaire response, and (B) Total 1-year dyspepsia related health-care costs per patient (average) 
according to 1-year questionnaire response and treatment success and for the whole DIAMOND
€286 (SE:26), n=181; p<0.0001, figure 3.3B), one might expect a higher 
proportion of the non-responders to have no symptoms at one year. Non­
responders were more often younger, working, male, and current smokers. The 
differences in costs between patients with and those without treatment success 
were primarily due to acid suppressive medication use (antacids: 37% 95%CI:30- 
44% vs. 15% 95%CI:10-20%, p<0.0001; H2RAs: 16% 95%CI:11-22% vs. 8 % 
95%C:4-12%, p=0.01; PPIs: 49% 95%CI:42-56% vs. 29% 95%CI:23-36%, 
p<0.0001), total number of general practitioner consultations (631 vs. 445, 
p<0.0001), and endoscopies (36 vs. 20, p=0.01). The differences in acid 
suppressive medication was seen in both strategies, except for H2RA use in the 
step-up (p=0.68). In turn, differences in number of primary care consultations, 
and endoscopies between successful and unsuccessful treatment were more 
pronounced in the step-up strategy (p=0,008 resp. p=0.05) than in the step-down 
strategy (p=0.07 resp. p=0.21).
In conclusion, after one year, step-up is still more cost-effective than a step- 
down strategy. One-year treatment costs are on average €140 higher in patients
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without treatment success compared to those with successful treatment. The 
main cost drivers for unsuccessful treatment of new onset dyspepsia in primary 
care are acid suppressive medication, primary care consultations, and 
endoscopies.
76
Effect and cost-effectiveness after one year
REFERENCES
1. Van Marrewijk CJ, Mujakovic S, Fransen 
GA, Numans ME, De Wit NJ, et al. Effect and 
cost-effectiveness of step-up versus step-down 
treatment with antacids, H2-receptor 
antagonists, and proton pump inhibitors in 
patients with new onset dyspepsia (DIAMOND- 
study): a primary-care-based randomised 
controlled trial. Lancet 2009;373:215-25.
2. Fransen GA, Van Marrewijk CJ, 
Mujakovic S, Muris JW, Laheij RJ, et al. 
Pragmatic trials in primary care. Methodological 
challenges and solutions demonstrated by the
DIAMOND-study. BMC Med Res Methodol 
2007;7:16.
3. Bytzer P, Hansen JM, Schaffalitzky de 
Muckadell OB. Empirical H2-blocker therapy or 
prompt endoscopy in management of 
dyspepsia. Lancet 1994;343:811-6.
4. Rabeneck L, Souchek J, Wristers K, 
Menke T, Ambriz E, et al. A double blind, 
randomized, placebo-controlled trial of proton 
pump inhibitor therapy in patients with 




Health-related quality of life: An evaluation of stepwise acid- 
suppression strategies for new onset dyspepsia from a 
patients’ perspective
Corine J van Marrewijk 
Martijn GH van Oijen 
Gerdine AJ Fransen 
Suhreta Mujakovic 
Jean W Muris 
Niek J de Wit 
Mattijs E Numans 
André J Knottnerus 
Diederik E Grobbee 




Background  Treatment that besides alleviating symptoms also quickly improve 
health-related quality of life (HRQoL) is beneficial for both the individual and 
society. We aim to describe the impact of empirical treatment on HRQoL in 
patients with new onset dyspepsia and identify predictors for HRQoL change 
over time.
M ethods  We conducted a multi-centre double-blinded trial that randomly 
assigned step-up or step-down acid suppressive therapy to primary care patients 
with new onset dyspepsia. Symptom relief and HRQoL (EQ-5D) were assessed 
at baseline, two weeks, after each treatment step and six months using 
uestionnaires. Repeated measures linear regression was used to compare 
HRQoL change over time between responders and non-responders and to 
identify predictors of HRQoL change.
Results  A total of 664 patients (mean age 47 (SD: 15) years, 46% males) were 
randomly assigned to step-up (n=341) and step-down (n=323) treatment. 
After six months, HRQoL was increased (EQ-VAS: from 54.3 to 74.8, p<0.0001) 
equally for both treatment groups (p=0.68). Reduction of symptom severity - the 
most discriminating predictor for HRQoL over time (p<0.001) - resulted in higher 
HRQoL. Other independent predictors were age (p<0.001), educational level 
(p=0.006), baseline psychopathology (p=0.03), and treatment success (p=0.05).
Conclusions During dyspepsia treatment HRQoL improved independent of the 
treatment strategy used. Reduction of symptoms was associated with increased 
HRQoL. Also age, educational level, baseline psychopathology, and treatment 
success were independent predictors of HRQoL change over time.
Health-related quality o f life
INTRODUCTION
The patients’ health perspective plays an increasingly important role in the 
health-care decisions as well as its evaluation in an era of pay-for-performance. 
Patient-reported outcomes, e.g. self-reported symptoms and health-related 
quality of life (HRQoL), are therefore becoming more and more important. 1 They 
reflect the patients’ perception of disease and its consequences for their well­
being and can measure the effect of health-care interventions. It provides 
valuable information that cannot be adequately captured by physiological 
measures. Furthermore, physiological measures of improvement may not 
necessarily correlate with improvements in patient-reported outcomes.2,3
HRQoL, probably the best known example of a patient-reported outcome, is a 
subjective multidimensional concept covering functional ability as well as 
physical, emotional and social well-being. Due to its comprehensiveness, it is 
increasingly recognized as an important outcome for patients with chronic 
diseases, such as dyspepsia.2,4
Dyspepsia is a non-life-threatening chronic relapsing disorder that can 
substantially impair HRQoL and consequently increase health-care utilisation.4,5 
It is characterized by a complex of non-specific upper gastrointestinal symptoms 
affecting about 20-40% of the general Western population.4,6 The majority of 
patients is managed in primary care using acid-suppressive medication primarily 
aiming to reduce symptoms, and not necessarily the underlying pathophysiology. 
The latter is generally unknown in most patients with new onset dyspepsia, since 
endoscopy - which identifies organic causes in approximately 5 0 % of the 
patients7 - is generally only indicated for patients with persisting or alarming 
symptoms. Hence, primary health-care providers mainly depend on subjective 
outcome communicated by the patient.
The objective of this study is to evaluate stepwise empirical treatment of new 
onset dyspepsia in primary care patients from a patients’ perspective. Guidelines 
and clinical studies in dyspepsia primarily focus on symptom-based measures. 
We used patient-reported outcome measures to assess symptom severity as well 
as HRQoL, since the latter represents a more generalised measure of treatment 
outcome than symptom improvement alone. We aim to describe the impact of 
dyspepsia and the effect of stepwise acid-suppressive treatment (comparing 
step-up versus step-down) strategies, on HRQoL over time in patients with new 
onset dyspepsia in primary care. Additionally, we aim to identify predictors for 




The population studied includes participants of the DIAMOND-study (Dutch 
study on Initial Management Of Newly diagnosed Dyspepsia) that randomly 
assigned primary care patients with dyspepsia to either step-up or step-down 
acid-suppressive treatment. An outline of the methodological aspects of the trial 
will be described below, but is described in more detail elsewhere.8,9 The protocol 
of this pragmatic randomised double-blinded trial was approved by the ethics 
committee of the University Hospitals of Nijmegen, Utrecht and Maastricht. The 
trial is registered by ClinicalTrials.gov as NCT00247715. All participants gave 
written informed consent.
Patients and Study Design
Patients, aged 18 years and older, consulting their general practitioner for new 
onset dyspepsia between October 2003 to January 2006 were recruited by a 
representative sample of Dutch general practitioners.8 Dyspepsia was defined as: 
pain or discomfort centred in the upper abdomen, judged by the physician to 
originate in the upper gastrointestinal tract, which might be accompanied by 
symptoms such as regurgitation, heartburn, nausea, or bloating.10,11 Patients 
were eligible if they did not use prescribed acid-suppressive medication three 
months prior to randomisation, and did not have a gastroscopy one year prior to 
randomisation. Exclusion criteria were signs or suspicion of malignancy or alarm 
symptoms (food transit complaints, unintended weight loss, anemia, vomiting of 
blood), pregnancy, insufficient knowledge of the Dutch language, or lack of 
motivation.
After written informed consent, eligible patients were randomly assigned to 
either step-up or step-down treatment. Treatment was stepwise with 1] antacids 
four times daily (aluminium oxide 200mg / magnesiumhydroxide 400mg); 2] H2- 
receptor antagonist twice daily (ranitidine 150mg); and 3] proton pump inhibitor 
once daily (pantoprazole 40mg) for step-up and these drugs in the reverse order 
for step-down. Each step contained medication for four weeks. To maintain 
blinding of treatment allocation for patients, general practitioners, and 
researchers, antacids were accompanied by a PPI-placebo once daily and PPI 
with antacid-placebo four times daily. Treatment was only continued with the next 
step if symptoms were not adequately relieved or relapsed within the next four 
weeks, based on the shared judgment of patient and general practitioner. If 
symptoms relapsed at a later time, the general practitioner treated according to 
standard practice. Patients were allowed to proceed to the next step earlier if 
symptoms worsened or unpleasant side effects occurred. The double blinding of 
the treatment was maintained up to six months after randomisation.
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Assessments
Self-report questionnaires were used to assess the predefined outcomes 
gastrointestinal symptoms, and HRQoL over time. Demographics, lifestyle habits, 
work and income, medical history, and medication use were assessed at 
baseline. Type and severity of gastrointestinal symptoms, were assessed on a 7- 
point adjectival scale, as well as a global measure of symptom severity using a 
visual analogue scale (VAS) ranging from 0 (no symptoms) to 100 (unbearable 
symptoms) . 9,12 Two validated generic questionnaires were used to measure 
general HRQoL; the EuroQol-5D (EQ-5D) 13,14 at all time points to assess HRQoL 
change over time, and the Medical Outcomes Study Short-Form 36-item survey
15(SF-36) at baseline to provide a more detailed characterisation of the patients 
HRQoL. Additionally, blood was drawn to assess H Pylori infection (Pyloriset® 
EIA-GIII, Orion Diagnostica, Espoo, Finland), but patient, treating physician, and 
investigator were blinded to the infection status until six months after inclusion.
Over a period of six months, follow-up assessments for the predefined 
outcomes were performed using self-report questionnaires at two weeks, at the 
end of each treatment step, or - if treatment was no longer required - at intervals 
of four weeks, and at six months. In case of relapse within the next four weeks, 
an additional questionnaire was sent to assess the state at the beginning of that 
treatment step. Patients were asked to report adequacy of symptom relief8,9, type
12 13,14and severity of gastrointestinal symptoms , and HRQoL (EQ-5D) , at all 
measurement times.
The EQ-5D questionnaire describes and valuates HRQoL according to five 
domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depres­
sion. Each domain has three levels of severity: ‘no problems’, ‘moderate 
problems’, and ‘severe problems’. Using Dutch coefficients for Time Trade Off 
tariffs, a continuous preference-based score ranging from -0.33 to +1 was 
calculated, with 1 indicating ‘perfect health’ and 0 representing ‘death’. Negative 
scores represent health states valued as worse than death. Additionally, it 
contains a visual analogue scale (VAS) to measure the patients’ overall 
subjective health status ranging from 0  (worst imaginable) to 1 0 0  (best 
imaginable). It is suited to calculate utilities necessary for cost-utility
13,14a n a ly s e s . 13,14
The SF-36 contains 36 items that describe eight domains: physical functioning 
(PF); social functioning (SF); role limitations due to physical health problems 
(RP); role limitations due to emotional health problems (RE); mental health (MH); 
vitality (VT); bodily pain (BP); and general health (GH); and a question measuring 
health change. From the eight domains a physical component summary (PCS) 
and a mental component summary (MCS) can be calculated. For each domain 
as well as the component summaries, a score ranging from 0  to 1 0 0  is calcula-
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Table 4.1: Baseline characteristics according to treatment assignment
Step-up (n=341)* Step-down (n=323)*
Gender
Male 157 (46%) 147 (46%)
Age (years)1"
46.9 (18-85) 47.3 (18-91)
Living situation
Alone 88 (27%) 65 (21%)
With partner/family 244 (73%) 246 (79%)
Educational level
Low 161 (49%) 151 (49%)
Average 86 (26%) 98 (32%)
High 82 (25%) 61 (20%)
Years of education5 11.0 (3.2) 11.0 (2.9)
Symptom severity§
Symptom score 20.7 (9.1) 20.9 (9.1)
VAS 54.6 (24.0) 55.0 (22.6)
SCL-90 score§
131.5 (38.5) 130.3 (36.8)
SF-36 domain§
Physical function (PF) 78.8 (20.4) 79.9 (18.8)
Social functioning (SF) 76.3 (22.1) 76.0 (22.3)
Role-physical (RP) 58.2 (40.6) 60.6 (40.3)
Role-emotional (RE) 77.3 (36.3) 78.0 (36.4)
Mental health (MH) 71.0 (18.5) 70.9 (19.1)
Vitality (VT) 55.6 (21.3) 56.7 (19.4)
Bodily pain (BP) 60.8 (20.1) 62.9 (18.6)
General health (GH) 59.2 (17.9) 60.0 (17.9)
Change 41.4 (20.2) 42.4 (20.1)
Physical component score (PCS) 64.3 (19.7) 66.0 (18.7)
Mental component score (MCS) 69.9 (19.8) 70.5 (20.1)
Health-related quality o f life
EQ-5D VAS§ 54.5 (25.4) 54.1 (24.5)
EQ-5D Dutch utility score§ 0.76 (0.19) 0.79 (0.17)
EQ-5D domains1
Mobility 51 | 2 (17%) 47 | 1 (16%)
Self-care 1 2 | 0 ( 4%) 3 | 0 ( 1%)
Usual activity 100 | 5 (35%) 87 | 3 (31 %)
Pain / Discomfort 215 | 18 (76%) 208 | 10 (75%)
Anxiety / Depression 115 | 8 (40%) 107 | 7 (39%)
VAS=visual analogue scale. *n (%), denominators depend on the number of patients who provided an answer 
for a specific question in the questionnaire. *mean (range). §Mean (SD). ^Moderate | Severe (percentage).
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ted, with a higher score indicating a better HRQoL.15
Statistical analyses
Data were analysed on intention-to-treat principles. Baseline characteristics 
were described according to treatment assignment. HRQoL (EQ-5D utilities and 
VAS score) was compared between the groups and different time points using 
Student’s t-test. Uni- and multivariable repeated measures linear regression 
models were used to assess the longitudinal association between HRQoL (EQ- 
5D VAS) and treatment success (defined as adequate symptom relief indicated 
by a ‘yes’ or ‘no’ answer), and to identify predictors of HRQoL (EQ-5D VAS) 
change over time. Treatment strategy, gender, age, H pylori status, lifestyle 
habits (current smoking, alcohol intake), living situation, educational level, 
working status, baseline psychopathology (SCL-90 score), treatment success 
(time dependent), and symptom severity (time dependent) were included in the 
regression models. All calculations were performed using SAS software (version 
8.2; SAS Institute Inc., Cary, NC, USA). Analysis of repeated measures was 
performed with PROC MIXED, using an unstructured covariance matrix. A p­
of 0.05 (2-sided) was regarded as statistically significant.






A total of 664 patients with a mean age of 47 (range:18-91) years were 
randomly assigned to a step-up (n=341) and step-down (n=323) acid- 
suppressive treatment strategy. HRQoL questionnaires SF-36 and EQ-5D were 
returned and completed at baseline by respectively 86.9% (n=577) and 91.4% 
(n=607) of the patients. Baseline demographics, gastrointestinal symptom 
scores, and HRQoL scores are shown in table 4.1. During the study period, 139 
(41%), 84 (25%), and 118 (35%) of 341 patients assigned to the step-up 
treatment group, and 153 (47%), 57 (18%), and 113 (35%) of 323 patients in the 
step-down group received one, two, or three treatment steps, respectively. 
Treatment success after six months was achieved in 238 (72%) patients in the 
step-up group and 219 (70%) patients in the step-down group (odds ratio 0.92, 
95% CI 0.7-1.3). EQ-5D questionnaires were completed at two weeks, at the end 
of step 1, step 2, and step 3, and six months in respectively 529 (80%), 524 
(79%), 466 (70%), 448 (67%), and 497 (75%) of the 664 patients. Questionnaire 
response rates did not differ between the treatment strategies, nor between 
patients with (responders) or without (non-responders) treatment success at six 
months.
During the study period, the mean HRQoL increased significantly from baseline 
(VAS: 54.3 (SD:25); Utility score: 0.77 (SD:0.2)) to six months (VAS: 74.8 
(SD:20); Utility score: 0.87 (SD:0.2), paired t-test p<0.0001). Overall, 6 6 % of
Table 4.2: Six months follow-up data according to  treatment assignment
Step-up (n=341)* Step-down (n=323)* p value
Health-related quality o f life outcomes
Health-related quality o f life
EQ-5D VAS§ 75.2 (2G.2) n=24S 74.4 (2G.5) n=233 G.6S
EQ-5D Dutch utility score§ G.S7 (G.17) n=249 G.S6 (G.1S) n=23S G.49
EQ-5D domains1
Mobility 35 j G I256 (14%) 27 j 3 I24G (13%) G.15
Self-care 6 j G I251 ( 2%) 5 j G I24G ( 2%) G.S2
Usual activity 42 j 2 I255 (17%) 4S j 1 I241 (20%) G.54
Pain / Discomfort 1G4 j 4 I254 (43%) 1G3 j 7 I24G (46%) G.51
Anxiety / Depression 4S j 6 I252 (21 %) 45 j 4 I24G (20%) G.S5
General health compared to start
Much better 91 I256 (36%) 76 I245 (31%) G.55
Slightly better 77 I256 (30%) S7 I245 (36%)
Approximately the same 77 I256 (30%) 7G I245 (29%)
Slightly / Much worse 11 I256 ( 4%) 12 I245 ( 5%)
VAS=visual analogue scale. *n (%), denominators depend on the number of patients who provided an answer 
for a specific question in the questionnaire. §Mean (SD). ^Moderate | Severe (percentage)
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the patients reported improvement in HRQoL during follow-up. There was a 
statistically significant increase from baseline to two weeks in both groups (mean 
EQ-5D VAS: step-up: from 54.5 to 67.9; step-down: from 54.1 to 67.3; paired t- 
test: p<0.0001; figure 4.1). It continued to increase during the first treatment step 
in patients in the step-down (mean EQ-5D VAS: to 71.7; paired t-test p=0.0013), 
but not in patients in the step-up (mean EQ-5D VAS: to 67.3; paired t-test 
p=0.45) strategy. HRQoL differed significantly between the treatment strategies 
at the end of step 1 (p=0 .0 2 ) in favour of the step-down strategy, but not 
thereafter (end of step 2 (p=0.59), step 3 (p=0.19) and at six months (p=0.68; 
figure 4.1 and table 4.2). HRQoL gains were more prominent in responders at 
six month compared to non-responders (figure 4.2). In contrast to the 
responders, that showed a continued increase in the mean HRQoL until six 
months, it only increased until the end of step 1 in non-responders, but 
decreased (slightly) thereafter. HRQoL improvement was most often a result of 
improvement of the EQ-5D domains: ‘Pain or Discomfort’, ‘Anxiety or 
Depression’, and ‘Usual activity’ respectively (table 4.1 and 4.2).
Figure 4.2: Health-related quality o f life change over six m onths according to treatment 
response at six months
Mean EQ-5D VAS
In univariable as well as multivariable repeated measures linear regression 
analyses there were no differences in HRQoL between the treatment strategies 
(table 4.3). Symptom severity was the most discriminating, but not the only
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independent predictor of HRQoL over time. More severe symptoms resulted in a 
lower HRQoL (figure 4.3). The other predictors that were independently 
associated with lower HRQoL VAS score over time were younger age, higher 
educational level, more baseline psychopathology and absence of treatment 
success (table 4.3).The difference in HRQoL VAS scores over time between 
responders and non-responder was no longer statistically significant (p=0.06) 
after correction for gender (NS), age (p<0.001), H pylori status (NS), educational 
level (p=0.003), baseline psychopathology (p=0.04), treatment strategy (NS), and 
symptom severity (time dependent, p<0 .0 0 0 1 ).






Treatment strategy NS NS
Gender NS NS
Age <0.001 <0.001
H pylori status 0.007 NS
Current smoking 0.05 NS
Alcohol intake NS -
Living status 0.06 NS
Educational level 0.006 0.006
Paid Job NS -
Psychopathology - baseline <0.001 0.03
- change over 6 months NS -
Treatment success (time dependent) <0.001 0.05
Symptom severity (time dependent) <0.001 <0.001
NS: not statistically significant (p>0.05). -: not included in multivariable model
The correlation coefficients between HRQoL measured with the generic EQ-5D 
VAS score and symptom severity were found to increase from baseline 
(r=-0.503) during treatment (after two weeks: r=-0.666; step 1: r=-0.673; step 2: 
r=-0.757; step 3: r=-0.763), but slightly decrease again at six months (r=-0.612; 
all p<0.0001; figure 4.3).
DISCUSSION
The patients’ perspective is a valuable source for assessing impact of 
dyspepsia and effect of treatment, especially since an objective clinical measure 
is generally lacking for patients treated in primary care. HRQoL was substantially 
impaired in our population of patients seeking care for new onset dyspepsia. 
Impairment was seen on all SF-36 domains, but especially on: vitality, role
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limitations due to physical health problems, general health, and bodily pain, and 
on all EQ-5D domains except ‘Self-care, but especially ‘Pain or Discomfort’, 
‘Anxiety or Depression’, and ‘Usual activity’ .16-18 By alleviating symptoms, 
treatment may also improve HRQoL. We studied the impact of step-up or step- 
down acid-suppressive treatment strategies on HRQoL in patients with new 
onset dyspepsia. We found a marked improvement of HRQoL, especially shortly 
after treatment was initiated, in both treatment strategies. No differences in 
HRQoL over time were seen between treatment strategies, except for a more 
prominent increase within the first month in patients in the step-down group 
(starting with a PPI). This was also found in the symptom severity scores, which 
supports an association between symptoms and health-related quality of life. 
Moreover, comparison of HRQoL over time between responders and non­
responders implies that successful treatment of dyspeptic symptoms restores the 
patients’ well-being by removing impairments.
Figure 4.3: Correlation between dyspepsia symptom severity (VAS) and health-related quality 
o f life (VAS)
VAS=visual analogue scale.
The marked improvement of HRQoL in this study after initiation of acid-sup- 
pressive treatment was comparable to findings in several other studies despite
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differences between the populations and treatment strategies studied.4,19-27 Pace 
et al. also found significantly improved HRQoL after four weeks in patient with 
non-erosive or mild GERD treated with 40mg esomeprazole, which sustained up
to six months when treatment was continued with either continuous or on-
22demand 20mg esomeprozole. In a population with heartburn predominant 
uninvestigated dyspepsia (CADET-HR) Armstrong et al. compared two step-up 
strategies and found a higher HRQoL after four weeks for initial PPI treatment 
compared to initial H2RA. Consistent with our findings, this difference in HRQoL
19between the strategies was no longer present after 16 weeks. The extent to 
which the HRQoL improvement in our study and the CADET-HR study is 
attributable to actual effect of the medication or a placebo-effect cannot be 
determined due to the lack of a placebo group. However, the CADET-HN study 
performed a head-to-head comparison between PPI, H2RA, cisapride and 
placebo in a H pylori negative population with uninvestigated dyspepsia,
excluding predominant heartburn and found a significantly increased HRQoL in
20patients using PPI compared to placebo after four weeks and six months.
Symptom severity was found to be the most discriminating, but not the only 
predictor for HRQoL change over time. This association between HRQoL and 
symptom severity21-25, as well as with psychological distress5,21,28, and 
socioeconomic factors, including age, gender and educational level28 have been 
reported previously. Systematically collected data on co-morbidity at the different 
time points would have been a valuable addition to our study, since co-morbidity 
might explain some of the variance observed using a generic HRQoL measure.
The strengths of this trial are the large sample size, the randomised, double­
blinded design, the head-to-head comparison of step-up and step-down acid- 
suppressive treatment strategies, and the extensive outcome assessment 
including the combination of self-reported dyspeptic symptoms and HRQoL. We 
have measured HRQoL at baseline using the SF-36, the most widely used 
generic HRQoL instrument, and the EQ-5D for assessment over time. The latter 
is a more compendious questionnaire which also enables economic evaluation. 
Both questionnaires are extensively validated and widely used in clinical 
research. However, these generic questionnaires might be less responsive to 
changes in health after treatment than a disease specific HRQoL instrument. In 
contrast to Raghunath et. al., we were able to show a markedly increase in 
HRQoL after acid-suppressive treatment, that was largely associated with 
symptom improvement, with the combination of our symptom questionnaire and
29the EQ-5D. Although this was seen in both EQ-5D measures, the VAS scale 
was more responsive to change than the utility score. The association of HRQoL 
with symptoms became more pronounced during treatment and diminished again 
slightly thereafter. Although several disease specific questionnaires for upper
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gastrointestinal disorders are available, the majority primarily focuses on GERD, 
and the specificity of these instruments for uninvestigated dyspepsia remains
30 31unclear.30,31 Generic measures have greater potential to measure any 
unforeseen effect or side effects of health care, can be used in all patient groups 
and in healthy individuals, and are more suitable for use in economic
32evaluation. The use of a step-down approach as comparator and the 
generalisability of our population have been discussed previously.9
Patients have an important role to play in communicating the impact of disease 
and the effectiveness of health care. In contrast to clinical care, which depends 
on subjective patient-reported outcome in new onset dyspepsia, research 
generally prefers and thus mostly present objective variables, such as upper 
gastrointestinal endoscopy outcomes. However, these variables poorly relate to 
the subjective patient-reported outcomes in dyspeptic patients due to the 
heterogeneous etiology which is still incompletely understood. For example, 
patients present to the physician with symptoms that might or might not be 
associated with underlying peptic ulcer disease. Patients require treatment for 
their symptoms, which might also be treatment of the underlying cause, but not 
necessarily. HRQoL reflects the impact of the symptoms, and might help to 
interpret partial improvement of symptoms which is often the case in dyspepsia 
treatment.4 It should therefore be considered in practice to supplement clinical 
measures of disease, such as symptoms, to gain additional information on the 
impact of disease on patients well-being that can influence treatment regimen.
In conclusion, new onset dyspepsia poses a substantial burden on a patients’ 
general well-being. Fortunately, HRQoL improves significantly shortly after 
initiating acid-suppressive therapy using either a step-up or step-down strategy. 
Although initial treatment with a PPI resulted in a quicker improvement in HRQoL 
in the first months, there were no differences in HRQoL between the treatment 
strategies thereafter. There was an inverse correlation between symptom 
severity and HRQoL. Besides symptom severity, age, educational level, baseline 
psychopathology, and treatment success were identified as independent 
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Determinants of successful acid-inhibiting treatment in 
primary care patients with uninvestigated dyspepsia
Chapter 5
ABSTRACT
Background  Although dyspepsia has been investigated intensively, evidence on 
the most adequate treatment strategy is still incomplete. On average only half of 
the dyspeptic patients respond to acid inhibiting drugs. Which patients will benefit 
most from initial acid inhibition is not well-defined. Therefore, we aim to identify 
factors associated with short-term and long-term success of acid modulating 
treatment for new onset dyspepsia in primary care.
M ethods  Data from a randomised trial comparing step-up (n=341) with step- 
down (n=323) treatment with antacids, H2RAs or PPIs (DIAMOND-study) were 
analysed. Baseline factors, including patient characteristics, symptom severity, 
health-related quality of life (HRQoL), psychopathology and adherence were 
tested against treatment outcome in uni- and multivariable logistic regression 
analysis to identify determinants of short-term and long-term success.
Results  After four weeks, success of antacid or PPI treatment was achieved in 
respectively 35% and 51% of the patients. Determinants of short-term success 
were lower symptom severity (antacid and PPI), history of psychological 
problems, and attributions concerning the stability of non-adherence (antacid), 
and intermediate educational level (PPI). After six months, 71% of the patients 
reported treatment success. Long-term success was independently associated 
with higher baseline HRQoL, and absence of reflux predominance, but also 
history of gastroenterological complaints, lower age, intermediate educational 
level, work, and low alcohol intake.
Conclusions Severity and type of dyspeptic symptoms influence short-term 
treatment response, while HRQoL, and symptom predominance influence long­
term success.
Determ inants o f treatm ent outcome
INTRODUCTION
Dyspepsia refers to a complex of symptoms thought to arise in the upper 
gastrointestinal tract including epigastric pain/dysfunction, heartburn, acid 
regurgitation, nausea, belching, postprandial fullness, early satiety and 
bloating.1,2 The prevalence of patients suffering from dyspepsia is 20-40% of the 
population worldwide.3-5 Consequently, dyspepsia has a substantial impact on 
health-care costs and quality of life.6-9 The etiology of dyspepsia is complex 
involving hyperacidity, motility problems and psychological factors, among 
others.2,10 Gastro-oesophageal reflux and peptic ulcer disease are responsible 
for dyspeptic symptoms in respectively 2 5 % and 5 -1 0 % of the patients, but at 
present, in the majority of patients no organic explanation can be found (i.e. 
functional dyspepsia) . 11
Acid-inhibiting drugs remain the first choice for therapeutic treatment of 
dyspepsia.12,13 It is mainly effective in acid related disorders, such as GERD and 
peptic ulcer disease. 14,15 Yet, in patients with functional dyspepsia the effect of 
acid inhibitors is questionable. 16,17 Age, type and severity of symptoms, H pylori 
infection, psychological factors are believed to influence response to acid- 
modulating treatment in uninvestigated dyspepsia. 16 The ability to predict a 
positive or negative response to various acid-modulating drugs will contribute to 
more cost-effective management and could support a tailor-made treatment 
advice for individual dyspeptic patients. In this paper we report determinants of 
short-term success of 4-weeks antacid or PPI treatment and long-term success 
of stepwise acid-modulating treatment strategies in patients with new onset 
dyspepsia in primary care praxis.
METHODS
Data for this analysis are derived from a prospective, multicentre, randomised 
controlled trial comparing two acid-inhibiting treatment strategies for initial 
management of new onset dyspepsia in primary care (DIAMOND-study) . 18,19 The 
protocol of this trial was approved by the Medical Ethics Committees of the 
University Hospitals of Nijmegen, Maastricht, and Utrecht, and registered by 
ClinicalT rials.gov as NCT00247715.
Patients and study design
Between October 2003 to January 2006, patients, aged 18 years and older, 
with new onset dyspepsia18 were recruited at 127 primary care centres in the 
Netherlands.19 Eligible patients18 were randomly assigned to either step-up 
treatment, starting with antacids, followed by H2-receptor antagonists (H2RA) and
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proton pump inhibitors (PPI), or step-down treatment, these drugs in the reverse 
order. If symptoms were not adequately relieved after a treatment step (four 
weeks) or relapsed within the following four weeks, treatment was continued with 
the next step. If symptoms relapsed at a later time, the general practitioner 
treated according to standard practice. Treatment allocation was blinded (up to 
six months) to patients, general practitioners, and researchers by adding 
placebos to step 1 and 3.
Assessments
Self-report questionnaires were used to assess baseline characteristics 
including demographics, working situation, lifestyle habits, medical history (i.e. 
any type of gastrointestinal complaint, and history of psychological problems in 
the past five years), and medication use, as well as psychopathology, using a
validated Dutch version of the Symptom Check List-90 (SCL-90)20, and
21adherence factors , including intention to be adherent, social influence, and self­
efficacy based on the I Change Model22, attitudes towards medicine treatment
23using the Beliefs about Medicine questionnaire (BMQ) , and attributions derived 
from the Weiner’s attribution theory24. Type and severity of gastrointestinal 
symptoms18,25, adequacy of symptom relief18,19, and health-related quality of life 
(HRQoL), using the EuroQol-5D (EQ-5D) 26,27 were assessed using self-report 
questionnaires at four weeks, and at six months. Blood samples were drawn for 
determination of H pylori antibodies (Pyloriset® EIA-GIII, Orion Diagnostica, 
Espoo, Finland).
Outcome
Both short-term and long-term treatment success were analyzed as primary 
outcome. Short-term treatment success was defined as adequate symptom 
relief18,19 after four weeks treatment with either antacids (step-up) or PPIs (step- 
down) without direct further requirement of medication. Long-term treatment 
success was defined as adequate symptom relief18,19 at six months after 
(stepwise) treatment with any acid-modulating drug. Herein three groups were 
distinguished: 1] Complete success: success without further use of acid- 
modulating medication, 2] Partial success: success while still using acid- 
modulating medication, and 3] Treatment failure. To assess whether there are 
different determinants of complete relief and effective maintenance/on demand 
treatment two dichotomised definitions of long-term success were evaluated: 1 ] 
success regardless of acid-modulating medication use at six months (partial 
success regarded as success)18, and 2 ] success without further use of acid- 
modulating medication (partial success regarded as failure).
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Statistical analyses
Patient characteristics were described according to short-term as well as long­
term treatment outcome. Socio-demographic factors, lifestyle habits, H pylori 
infection, medication use, medical history, symptom type and severity, HRQoL, 
psychopathology, and as proxy for treatment adherence, only those adherence
factors that have previously been found to be associated with pill count in the
21DIAMOND-study , were included in univariable logistic regression analysis, to 
identify potential determinants of short-term success of either antacids or PPIs, 
or for long-term success of (stepwise) acid-modulating treatment.
All factors, univariably associated with treatment outcome at p<0.10, as well as 
evidence-based factors, such as age, gender, baseline symptom severity, H  
pylori infection, and history of gastrointestinal symptoms (any that have 
previously been found to be associated with treatment outcome28-31, were 
included in a multivariable logistic regression model using backward selection 
(maximum likelihood estimate critical p-value 0.05) to identify independently 
associated risk factors with either of the treatment outcome measures.
Furthermore, dyspeptic symptoms were modelled against treatment outcomes 
using uni- and multivariable logistic regression analysis to assess the probability 
of treatment success according to severity of dyspeptic symptoms (abdominal 
pain, epigastric pain, heartburn, regurgitation, abdominal rumbling, bloating, 
empty feeling, nausea, vomiting, early satiety, postprandial fullness, belching, 
and halitosis). Odds ratios with 95% confidence intervals were calculated. All 
calculations were performed using SAS software (version 8.2; SAS Institute Inc., 
Cary, NC, USA).
RESULTS
Of the 664 participants of the DIAMOND-study, 341 patients were randomly 
assigned to initial antacid and 323 patients to initial PPI treatment, the first step 
of respectively the step-up and step-down treatment strategy. Since eleven 
patients did not use the allocated study medication18, and treatment outcome 
after four weeks was not available for 21 patients, short-term treatment outcome 
was evaluated in 632 patients. Long-term treatment outcome was available for 
645 patients. Baseline patient and clinical characteristics according to short-term 
outcome of either antacid or PPI treatment and for long-term outcome are shown 
in table 5.1.
Short-term treatment success
After four weeks, adequate symptom relief was achieved in 114 of 324 (35%)
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Step-up 114 (100%) - 210 (100%) -
Step-down - 157(100%) - 151 (100%)
Gender
Male 53 (46%) 75 (47%) 90 (43%) 64 (42%)
Age (years)
< 40 years 44 (39%) 53 (34%) 68 (32%) 48 (32%)
40-55 years 35 (31 %) 45 (29%) 80 (38%) 58 (38%)
> 55 years 35 (31 %) 59 (38%) 62 (30%) 45 (30%)
Body Mass Index (kg/m2)
< 25 55 (50%) 56 (37%) 92 (45%) 68 (47%)
25-30 43 (39%) 72 (48%) 80 (39%) 57 (39%)
> 30 12 (11 %) 23 (15%) 31 (15%) 21 (14%)
H py lo ri status
Positive 42 (39%) 56 (36%) 79 (38%) 47 (32%)
NSAIDs use
22 (19%) 29 (18%) 37 (18%) 39 (26%)
Educational level
None/ Low 55 (50%) 66 (43%) 99 (49%) 81 (55%)
Middle 30 (27%) 58 (38%) 53 (26%) 35 (24%)
High 26 (23%) 28 (18%) 52 (25%) 31 (21%)
Work
Paid job 70 (66%) 85 (57%) 123 (62%) 85 (60%)
Coffee intake
> 21 cups per week 38 (36%) 54 (37%) 72 (37%) 57 (42%)
Alcohol intake
> 10 glasses per week 19 (17%) 25 (17%) 31 (16%) 31 (21%)
Smoking
Current smokers 29 (26%) 30 (20%) 61 (31%) 47 (32%)
Gastroenterological history
54 (48%) 74 (49%) 130 (63%) 90 (62%)
Symptom severity§
Symptom score 17.7 (8.1) 19.0 (9.3) 22.2 (9.2) 22.6 (8.4)
Predominant symptom
Dyspepsia 61 (58%) 71 (49%) 96 (48%) 87 (60%)
Equal 28 (27%) 43 (30%) 67 (34%) 40 (27%)
Reflux 16 (15%) 31 (21%) 37 (19%) 19 (13%)
(continues on next page)
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197 (52%) 41 (51%) 94 (50%)
179 (48%) 40 (49%) 94 (50%)
175 (47%) 36 (44%) 84 (45%)
145 (39%) 19 (23%) 51 (27%)
124 (33%) 40 (49%) 60 (32%)
107 (28%) 22 (27%) 77 (41 %)
171 (48%) 27 (34%) 77 (42%)
143 (40%) 38 (48%) 77 (42%)
45 (13%) 15 (19%) 28 (15%)
130 (35%) 31 (40%) 65 (375%)
70 (19%) 16 (20%) 41 (22%)
171 (47%) 31 (38%) 105 (57%)
111 (31 %) 30 (37%) 36 (20%)
80 (22%) 20 (25%) 42 (23%)
222 (66%) 50 (63%) 88 (51 %)
120 (37%) 33 (42%) 69 (40%)
52 (15%) 15 (19%) 43 (24%)
94 (27%) 22 (27%) 55 (30%)
189 (52%) 53 (65%) 111 (60%)
20.2 (8.9) 20.5 (8.5) 21.7 (9.5)
202 (59%) 27 (35%) 83 (48%)
91 (26%) 34 (44%) 53 (31 %)
51 (15%) 17 (22%) 36 (21 %)
(continues on next page)
patients starting with antacids, and 
157 of 308 (51%) patient starting with 
PPIs (p<0.0001). Characteristics 
univariably associated with short-term 
success of both antacids as well as 
PPIs were lower baseline symptom 
severity, higher baseline HRQoL, and 
absence of a gastroenterological 
history (p<0.05). Moreover, success 
of PPI treatment was also associated 
with intermediate educational level, 
non-smoking, attributions concerning 
the controllability of non-adherence 
(p<0.05), and self-efficacy (p<0.10), 
and success of antacids with 
psychological history, and attributions 
concerning the stability of non­
adherence (p<0.10).
In mutivariable analysis, less severe 
baseline symptoms, presence of 
psychological problems in the past 
five years, and attributions concerning 
the stability of non-adherence were 
found to be independently associated 
with the likelihood of successful 
antacid treatment, while less severe 
baseline symptoms, and intermediate 
level of education were independently 
associated with the likelihood of 
successful PPI treatment (figure  
5.1A).
Looking at the probability of 
treatment success of the individual 
dyspeptic symptoms, lower severity of 
all symptoms except empty feeling, 
vomiting and belching were found to 
be univariably associated with 
success of either or both antacid and 
PPI treatment. However, only less
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(table 5.1 continued) Short-term
Treatment success Treatment failure
Antacid PPI Antacid PPI
(n=114)* (n=157)* (n=210)* (n=151 )*
Health-related quality o f life§
EQ-5D score 0.79 (0.2) 0.81 (0.1) 0.75 (0.2) 0.77 (0.2)
Psychological history
25 (24%) 27 (18%) 31 (15%) 36 (26%)
SCL-90 score§
127.3 (36.4) 126.6 (34.4) 134.2 (39.6) 133.9 (39.1)
Treatment adherence§
Forgetfulness 5.0 (1.7) 4.7 (1.9) 4.9 (1.8) 5.0 (1.6)
Attribution stability (adherence) 4.3 (2.1) 4.3 (2.0) 4.7 (1.8) 4.5 (1.9)
Attribution control (adherence) 4.9(1.8) 4.9 (1.7) 5.2(1.5) 5.3 (1.2)
Necessity of drug 9.4(7.9) 8.6 (7.1) 9.6 (7.9) 9.3 (6.7)
Social influence 13.6 (4.4) 13.8 (4.3) 13.9 (4.5) 14.1 (4.0)
Self-efficacy 18.0 (5.7) 16.1 (7.2) 17.5 (6.4) 17.5 (6.1)
Intention 11.3 (1.7) 11.5 (1.4) 11.4 (1.7) 11.4 (1.7)
PPI=proton pump inhibitor. *n (%), denominators depend on the number of patients who provided an answer 
for a specific question in the questionnaire. §Mean (SD).
severe heartburn (OR:0.84, 95%CI:0.7-0.9), bloating (OR:0.78, 95%CI:0.7-0.9), 
and postprandial fullness (OR:0.82, 95%CI:0.7-1.0) remained statistically 
associated with successful antacid treatment in a model including all upper 
gastrointestinal symptoms. For PPI treatment success, only less severe 
abdominal rumbling (OR:0.80, 95%CI:0.7-1.0), and postprandial fullness 
(OR:0.82, 95%CI:0.7-1.0) remained statistically significant associated in a 
multivariable symptoms model (figure 5.2A).
Long-term treatment failure
After six months, acid-modulating therapy was successful in 457 of the 645 
(71%) patients. However, 81 (13%) patients were still using acid-modulating drug 
on-demand or as maintenance therapy to control symptoms, which was regarded 
as only partial success. Lower age, intermediate educational level, having a paid 
job, alcohol intake <10 units/week, higher HRQoL at baseline (p<0.05), and lower 
symptom severity, and intention to be adherent (p<0.10) were univariably 
associated with long-term treatment success overall (regardless of medication 
use). If partial success was regarded as part of treatment failure, similar variables 
as above were found to be associated with complete long-term treatment 
success, except for educational level, symptom severity and intention to be 
adherent, while there was an association with absence of gastroenterological
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history, and absence of reflux 
predominance.
Higher baseline HRQoL, and 
absence of reflux predominance, 
intermediate educational level, having 
a paid job, lower alcohol intake 
(<10/week), were found to be 
independently associated with long 
term treatment success overall 
(regardless of medication use). For 
complete long-term success however, 
only higher baseline HRQoL, and 
absence of reflux predominance 
remained, but also lower age and 
absence of a gastroenterological 
history were found to be 
independently associated (figure  
5.1B).
In contrast to short-term success, 
only few symptoms (heartburn, 
regurgitation, postprandial fullness, and halitosis) were found to be univariably 
associated with long-term treatment success. An independent association with 
long-term treatment success in both models (complete success and partial 
success) were found for less severe heartburn (overall success: OR:0.84, 
95%CI:0.7-0.9; complete success: OR:0.77, 95%CI:0.7-0.9), and postprandial 
fullness (overall: OR:0.78, 95%CI:0.7-0.9; complete: OR:0.73, 95%CI:0.6-0.8), 
and more severe early satiety (overall: OR:1.25, 95%CI:1.1-1.5; complete: 
OR:1.43, 95%CI:1.2-1.7), while complete long-term success was also found to 
be independently associated with more severe abdominal pain (OR:1.21, 
95%CI:1.0-1.4) and less severe halitosis (OR:0.87, 95%CI:0.7-1.0) (figure  
5.2B).
DISCUSSION
Successful management of dyspepsia remains a challenge for primary care 
physicians. Knowledge regarding which patient is most likely to benefit from a 
certain acid-suppressive treatment approach would enable physicians to provide 
tailor-made treatment, and also to improve treatment outcome and save costs. 
The present analysis of the DIAMOND-study indicates that several baseline 





0.79 (0.2) 0.77 (0.2) 0.75 (0.2)
78 (22%) 11 (14%) 37 (21%)
128.7 (35.9) 128.4 (31.9) 134.3 (41.2)
4.9 (1.8) 4.7 (1.7) 5.0 (1.6)
4.4 (2.0) 4.8 (1.5) 4.5 (1.9)
5.1 (1.6) 5.3 (1.3) 5.1 (1.5)
9.0 (7.3) 10.0 (7.7) 9.4 (7.6)
13.9 (4.3) 13.4 (4.3) 13.8 (4.3)
17.5 (6.6) 17.7 (5.6) 16.9 (6.4)




Adjusted OR (95% Cl)
» Antacid treatment 
PPI treatment 
a Overall success (regardless of medication use)
_ a_  Complete success (without further medication use)
Figure 5.1: Determinants o f treatment success: results o f multivariable logistic regression 
analysis
(A) Short-term treatment success o f antacids or PPIs. (B) Long-term treatment success regardless of 
medication use or without further medication use
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with the duration of the evaluated period. We assessed determinants for short­
term (four weeks) as well as long-term (six months) success of two initial 
stepwise acid-suppressive treatment strategies in primary care patients with new 
onset dyspepsia. Although many of the main factors identified cannot easily be 
amended to favour treatment success, they might be useful to allocate a patient 
to receive the most appropriate treatment.
We identified lower symptom severity as an important determinant of short­
term response to either antacids or PPI, however not for long-term outcome of 
stepwise acid-modulating treatment. Evaluation of symptom type revealed that 
patients experiencing the more dysmotility-like symptom postprandial fullness 
were less likely to respond to a short course (four weeks) of either antacid or PPI 
therapy, nor to achieve long-term success. In fact, it has been reported 
previously that patients with dysmotility-like symptoms (Rome II) or postprandial 
distress syndrome (PDS, Rome III) do not improve on acid inhibition.28,32,33 These 
patients might profit more from other treatment options like prokinetics. 
Furthermore, patients with more severe heartburn and bloating were found to 
profit less from a short course of antacids, which is consistent with earlier 
findings that patients with reflux-like symptoms or GERD yield the least profit 
from acid-binding compared to acid-suppressing treatment.17,34 In addition, 
patients with more severe/predominant heartburn were found to be less likely to 
achieve long-term success of any acid-modulating treatment. This is consistent 
with clinical practice, where many of these patients receive maintenance or on- 
demand pharmacotherapy for prolonged periods. However, we do foresee some 
issues for use of symptom type and severity scales for prediction of success 
rates in clinical practice because symptoms overlap, and change in severity and
3 35type over time. ,
We confirmed the positive association between a history of psychological 
problems and a relatively favourable response to antacid treatment as shown by 
Holtmann et al.36 Individuals suffering from active psychological distress react 
with temporarily enhanced acid production, which might contribute to 
experiencing dyspeptic symptoms, which seem to respond well to antacid
37treatment.37 However, together with attributions concerning the stability of non­
adherence, this factor was not a determinant of long-term outcome.
The most discriminating factors for long-term success were higher HRQoL and 
absence of reflux predominance at baseline. A similar association was previously 
reported by Bolling-Sternevald et al. between HRQoL and success after 4-week 
treatment with PPI in patients with functional dyspepsia.28 We also observed this 
association for short-term treatment success univariably with either antacid or 
PPI, however, higher HRQoL was only identified as independent determinant for 
long-term treatment success. Our results imply that the (severity of) symptoms
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themselves is important for short-term outcome, whereas long-term outcome 
depends more on the impact of symptoms on a patients’ well-being. In addition to 
higher HRQoL and absence of reflux predominance at baseline, also higher age 
and presence of a gastroenterological history were found to be indicators of 
failure to achieve complete long-term success (without further medication use), 
while intermediate level of education, having a paid job, and low alcohol intake 
were associated with overall long-term success. In contrast to Blum et al. H pylori 
infection status was not identified as determinant for either short-term or long-
on
term treatment outcome.
Figure 5.2: Odds o f having treatment success according to severity o f dyspeptic symptoms: 
results o f multivariable logistic regression analysis
(A) Short-term treatment success of antacids or PPIs. (B) Long-term treatment success regardless of 
medication use or without further medication use
This is not the first study to identify determinants for treatment outcome of acid- 
modulating drugs. However, the majority only assesses predictors for short-term 
outcome, or involve specific subgroups of dyspepsia (e.g. heartburn, functional 
dyspepsia).28-31,36 Strengths of our study are that we studied a relatively 
unselected population of primary care patients with dyspepsia, and that we were 
able to evaluate predictors of long-term treatment outcome. For proper
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prediction, we studied variables measured at baseline. As a consequence, we 
were unable to study the effect of actual treatment adherence (e.g. by pill count 
during the study period), although this factor might influence treatment outcome. 
Furthermore, other studies have indicated that outcome of short-term symptom 
evaluation might itself be a useful factor to predict long-term treatment 
outcome.28,30 Nonetheless, this was not included in our evaluation of long-term 
outcome.
In conclusion, our findings suggest that several baseline factors might facilitate 
allocation of different acid-modulating drug to specific subgroups and thereby 
improve treatment outcome, but determinants vary with the period of outcome 
evaluation. Symptom severity and type primarily influence short-term outcome, 
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Background  The most effective initial treatment strategy of dyspepsia is still 
under debate. Individual biological characteristics, such as condition of gastric 
mucosa, might contribute to selection of the most appropriate acid suppression 
treatment strategy. Therefore, we aim to assess whether pre-treatment testing 
of gastric mucosal status is relevant for treatment success in an RCT comparing 
step-up and step-down therapies in newly diagnosed dyspepsia patients.
M ethods  Baseline serum samples were collected to assess gastric mucosal 
status using serum levels of pepsinogens-I&II, gastrin-17, and Helicobacter pylori 
IgA/IgG-antibodies. The 6-month treatment success was compared between 
step-up and step-down for patients with serum diagnoses: normal; gastritis; 
corpus atrophy or antrum atrophy.
Results  In all, 519 patients (M/F: 249/270, age: 47 (18-85) years, 29% H pylori+) 
were randomised to step-up (n=293) or step-down (n=226). Normal mucosa, 
gastritis and corpus atrophy were diagnosed serologically in 70%, 28% and 2% 
of the patients, evenly distributed between the strategies (p=0.65). Treatment 
success was achieved in respectively, 69%, 70% and 70% for the serum 
diagnosis groups, and did not differ between the strategies.
Conclusions Dyspepsia treatment success could not be predicted by gastric 
mucosal status. Therefore, serum diagnosis of gastric mucosal status is no 
useful tool for patient allocation to acid suppressive treatment strategies.
G astric m ucosal status
INTRODUCTION
Therapeutic management of dyspepsia, a complex of nonspecific upper 
gastrointestinal symptoms, with a heterogeneous etiology, primarily aims at acid 
suppression. Annually, more than 10% (>€400 million) of the Dutch 
pharmaceutical budget is spent on these drugs.1 However, irrespective of the 
acid suppressive drugs used, treatment success is still unsatisfactory in 
numerous patients and the long-term effectiveness is generally low. As long as 
the etiology is not fully unravelled, treatment needs to be optimized with tools 
currently available. It is perhaps possible that long-term treatment success can 
be improved by selection of the most appropriate acid suppressive treatment 
strategy based on individual biological or clinical characteristics.
Atrophic gastritis causes reduced gastric acid secretion due to loss of properly 
specialized glands in the gastric mucosa. Prevalence rates vary considerably, 
from 1.5% to 50% in most studies, depending on age, Helicobacter pylori (H  
pylori) infection, diagnostic classification and definitions used.2-4 It remains 
unclear whether patients with gastric atrophy respond to the same extent to 
gastric acid suppression. It has even been suggested that long-term use of acid 
suppressive drugs accelerates the progression of (chronic) gastric inflammation 
to gastric atrophy, particularly in H  pylori-infected patients.5-8
Histology is still the gold standard for diagnosis of gastric atrophy, necessitating 
the use of endoscopy with biopsies. However, this method is invasive and 
expensive and it has been argued that (international) guidelines for gastritis 
staging should be used for accuracy of bioptic sampling to minimize inter­
observer variation in the histological diagnosis.9-11 Several studies have shown 
that the gastric serum profile, including serum biomarkers of pepsinogens I & II 
(PGI & PGII), gastrin-17 (G-17) and H pylori-serum antibodies, is a reliable 
alternative for assessment of both morphological and functional status of the 
gastric mucosa.12-15 As the latter method only requires a simple blood test, it is 
much more suitable for screening for gastric mucosal status in patients with new 
onset dyspepsia.
Several studies have focused on the effect of longterm proton pump inhibitor 
treatment or the effect of H  pylori-eradication on gastric atrophy.16-21 However, 
whether the presence of (atrophic) gastritis influences the outcome of acid 
suppressive treatment remains unclear. Therefore, our aim was to assess 
whether gastric mucosal status at baseline determines long-term outcome of 





The population studied includes participants in a multi-centre randomised 
clinical trial investigating the most cost-effective empirical treatment strategy for 
new onset dyspepsia in Dutch primary care (DIAMOND-study). Methodological 
aspects of the trial are outlined hereunder; however, details have been described 
elsewhere.22,23 The protocol of this pragmatic randomised double-blinded trial 
was approved by the ethics committees of the University Hospitals of Nijmegen, 
Utrecht and Maastricht, The Netherlands. The trial is registered by 
ClinicalTrials.gov as NCT00247715. All participants gave written informed 
consent.
Patients and study design
Patients, aged 18 years and older, consulting their general practitioner for new 
onset dyspepsia between October 2003 and January 2006, without alarming 
symptoms (dysphagia, unintended weight loss, anemia, hematemesis), 
pregnancy, or with sufficient knowledge of the Dutch language, were eligible. 
Consistent with the Dutch guidelines, age above 50 years was not regarded as 
an indication for prompt endoscopy.23,24 New onset dyspepsia was defined as: 
pain or discomfort centred in the upper abdomen (epigastria), judged by the 
physician to originate in the upper gastrointestinal tract, which might be 
accompanied by symptoms such as regurgitation, heartburn, nausea or 
bloating25,26 and no use of prescribed acid suppressive medication for three 
months and no gastroscopy one year prior to randomisation.
At inclusion, patients were randomly assigned to either step-up or step-down 
treatment. Treatment was stepwise with 1] antacids four times daily 
(aluminiumoxide 200 mg/magnesium hydroxide 400 mg); 2] H2-receptor 
antagonist twice daily (ranitidine 150 mg); and 3] proton pump inhibitor once daily 
(pantoprazole 40 mg) for step-up and vice versa for step-down. Each step lasted 
four weeks. Treatment was continued with the next only step if symptoms were 
not adequately relieved or relapsed within the next four weeks, based on the 
shared judgment of patient and general practitioner. If symptoms relapsed later, 
the general practitioner treated according to standard practice. Treatment 
allocation was blinded for patients, general practitioners and researcher by 
adding placebos to the medication in step 1 and 3.
Baseline characteristics, including demographics, lifestyle habits, type and 
severity of gastrointestinal symptoms, were assessed using self-report postal 
questionnaires. During follow-up, patients were asked to report adequacy of 
symptom relief, type and severity of gastrointestinal symptoms, medication use, 
on questionnaires sent at two weeks, after each treatment step and at six
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months. Clinical data were collected by the general practitioners in case record 
forms. Treatment success was defined as adequate symptom relief at six months 
(yes/no).22,23
Figure 6.1: Trial profile
PPI=proton pump inhibitor. H2 RA=H2-receptor antagonist.
Gastric mucosal status
At inclusion, 10 mL of venous blood was collected in a plastic serum tube 
without additives. Serum samples were obtained by centrifugation at 2000 g for 
10-15 min and stored at -20°C until further use. A series of enzyme linked
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immunosorbent assays (ELISA) were performed in the laboratory of the 
manufacturer to determine serum levels of PGI, PGII, basal G-17 and H pylori 
IgA/IgG antibodies (Biohit GastroPanel, Helsinki, Finland). All samples were run 
at the same time to minimize assay variability and the laboratory assistant was 
blinded for treatment allocation. Reference ranges according to instructions of 
use by the manufacturer were: PGI 30-165 ^g/L, PGII 3-15 ^g/L, PGI/PGII-ratio 
3-20 and basal G-17 1-10 pmol/L. Helicobacter pylori IgA/IgG antibodies titers 
>30 IU were considered H  pylori-positive.13,27
All laboratory data determined by the GastroPanel assay, as well as the 
patients’ age, were entered into the GASTROSOFT software system (Biohit, 
Helsinki, Finland), a specially designed algorithm to calculate the gastric mucosal 
status, expressed as: normal, gastritis, predominant corpus atrophy and
13predominant antrum atrophy, from the serum values.13 General practitioners 
were not informed of the GastroPanel test results.
Statistical analysis
Patients for whom data of the GastroPanel assay as well as 6-month treatment 
success were available were included in the analyses. Overall baseline 
characteristics, gastric mucosal status and treatment success were compared 
between the two treatment regimens using chi-square tests and Student’s t-test. 
Additionally, the comparison of 6-month treatment success between step-up and 
step-down was made for the serum diagnoses of gastric mucosal status, using 
chi-square tests or Fisher-exact test, where appropriate. Kaplan-Meier analysis 
was used to compare the time to treatment success between the gastric mucosal 
status groups. All statistical calculations were performed using SAS software 
(version 8.2; SAS Institute Inc., Cary, NC, USA).
RESULTS
A total of 664 patients with new onset dyspepsia were included in the 
DIAMOND-study. We restricted our analysis to 519 (78%) patients because of 
several reasons for exclusion: 1] insufficient amounts of serum (n=56); 2] 
absence of the primary outcome (lost-to-follow-up: n=14) and 3] interfering PPI 
use, due to delayed blood collection, when treatment had already started (n=75, 
figure 6.1). The mean age of the population studied here was 47 (range: 18-85) 
years, 270 (52%) patients were female and 151 (29%) of the patients were H  
pylori-positive. Baseline characteristics were similar for the treatment groups 
(table 6.1). A majority (n=362, 70%) of the patients had a normal gastric mucosal 
status, while gastritis was found in 147 (28%) and predominant corpus atrophy in 
10 (2%) of the patients. Predominant antrum atrophy was not found in our study
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population. The distribution of gastric mucosal status did not differ between the 
treatment strategies (p=0.65, table 6.1).
Table 6.1: Baseline characteristics according to treatment assignment
Step-up (n=293)* Step-down (n=226)*
Gender
Male 142 (48.5%) 107 (47.4%)
Age (years)§
46.9 (14.3) 48.2 (13.9)
Ethnicity
White 277 (94.5%) 218 (96.5%)
Symptoms1
Regurgitation 173 (65.5%) 145 (70.1%)
Heartburn 185 (70.1%) 146 (70.9%)
Epigastric pain 184 (73.9%) 145 (75.9%)
Nausea 97 (36.5%) 92 (44.9%)
Bloating 186 (70.7%) 145 (71.1%)
H py lo ri status
IgA/IgG seropositivity 82 (28.0%) 69 (30.5%)
Serum levels§
Pepsinogen I (yg/l) 101.3 (40.8) 102.3 (56.6)
Pepsinogen II (yg/l) 11.5 ( 7.0) 11.9 (10.0)
Pepsinogen I/II ratio 9.9 ( 3.2) 9.7 ( 3.1)
Gastrin-17 (pmol/l) 7.1 (18.9) 6.8 (22.1)
Gastric mucosal status
Normal 209 (71.3%) 153 (67.7%)
Gastritis 79 (27.0%) 68 (30.1%)
Predominant corpus atrophy 5 ( 1.7%) 5 ( 2.2%)
Predominant antrum atrophy 0 ( 0%) 0 ( 0%)
*n (%), denominators depend on the number o f patients who provided an answer for a specific question in the 
questionnaire. t Symptom severity >2 on a seven-point adjectival scale ranging from 0 to 6. §Mean (SD).
During treatment, adequate symptom relief was reported earlier in patients with 
gastritis (63%, 80%, 85% and 95% after respectively one, two, three and six 
months of treatment), followed by patients with a normal gastric mucosal status 
(60%, 69%, 75% and 88%) and patients with predominant corpus atrophy (50%, 
50%, 50% and 80%). This is mainly attributable to a difference in time to 
treatment success among the three serum diagnosis groups in patients treated 
with a step-up strategy (p=0.004). Nonetheless, time to treatment success did not 
differ between step-up and step-down within each group of gastric mucosal 
status (figure 6.2). In each of the gastric mucosal status groups, 38% of the 
patients had symptom relapse after initial success and time to symptom relapse
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Figure 6.2: Time to treatment success according to treatment strategy fo r the different 
groups o f gastric m ucosal status (Kaplan-Meier)
did not differ among the three groups of gastric mucosal status (p=0.69). Despite 
differences in initial response, treatment success at 6 months did not differ 
among patients with normal gastric mucosal status (69%), gastritis (70%) and 
predominant corpus atrophy (70%, p=0.97). Neither were there any differences in 
6-month treatment success between step-up and step-down treatment overall 
(step-up: 70% (n=205); step-down: 69% (n=155); RR: 0.98, 95%-CI: 0.9-1.1), nor
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between the subgroups gastric mucosal status: normal (70% (n=146) 
respectively 68% (n=104); RR: 0.97, 95%-CI: 0.8-1.1), gastritis (70% (n=55) 
respectively 71% (n=48); RR: 1.01, 95%-CI: 0.8-1.3), or predominant corpus 
atrophy (80% (n=4) respectively 60% (n=3); RR: 0.75, 95%-CI: 0.3-1.7, figure  
6.3).
Figure 6.3: Six months treatment success according to gastric mucosal status
DISCUSSION
A majority of dyspeptic patients are treated with acid suppression, but 
irrespective of the type of acid suppressive drugs used, long-term treatment 
success is generally limited. We hypothesized that individualizing the selection of 
the most appropriate acid suppressive treatment strategy guided by gastric 
mucosal status might improve long-term treatment success in patients with 
dyspepsia. Therefore, we studied the association between baseline gastric 
mucosal status and six months success of two acid suppressive treatment 
strategies in a pragmatic randomised clinical trial. Although patients with gastritis 
showed an earlier response, no association was observed with treatment 
success at six months.
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This study focused on whether the combined use of GastroPanel and 
Gastrosoft could assist the general practitioner in clinical decision making. The 
test provides a reliable diagnosis of the morphological and functional status of 
the gastric mucosa by a simple blood test, using ELISA-techniques.12-15 When a 
patient presents with new onset dyspepsia, assessment of gastric mucosal status 
prior-to-treatment initiation identifies a small number of patients with atrophy (2%) 
who should not be treated with acid suppression. However, the hypothesized 
additional value of GastroPanel as initial test to guide patient allocation to the 
most appropriate treatment, thus improving long-term success, was not 
observed.
Gastritis and atrophy were present in respectively 28% and 2% of our 
population. Prevalence of gastritis and atrophy reported in literature varies 
considerably.4,13,28,29 The prevalence in our population, consisting of patients 
consulting their general practitioner for new onset dyspepsia, is situated in the 
lower range of the reported prevalence spectrum, probably because most 
numbers were derived from patients who underwent endoscopy, indicating higher 
a-priori pathology rates.2,3,13 Overall, treatment success at six months was 
achieved in approximately 70% of the patients, for both stepwise treatment 
strategies evaluated, as well as for patients with different gastric serum 
diagnosis. This overall success rate is consistent with that seen in other studies, 
considering differences in management strategies, definition of dyspeptic patient
30 31population and follow-up period evaluated.30,31 Although it is still unclear whether 
a (causal) relationship between H  pylori-gastritis and dyspeptic symptoms exists, 
H pylori eradication therapy has been reported to have a small but significant
32,33benefit in non-ulcer dyspepsia and leads to long-term symptom improvement. , 
The earlier response to acid suppressive treatment in patients with gastritis 
remains unexplained, but might be associated with the defence mechanism that 
H pylori needs to protect itself in the acidic environment.
This analysis is performed in the context of a large prospective double-blind 
randomised clinical trial cohort comparing two treatment strategies of acid 
suppression. Some limitations should be noted. In 75 patients, blood sample 
could not be drawn at the inclusion visit (mainly due to high workload in general 
practice), but was drawn by one of the researchers as soon as possible 
thereafter, when treatment with proton pump inhibitor might have already started. 
As PPI use influences measured serum levels and therefore interferes with the 
serum diagnosis, these patients had to be excluded for our analysis. Although 
this resulted in a higher number of exclusions in the treatment strategy starting 
with a proton pump inhibitor (step-down), we do not expect that it has influenced 
the outcome because the excluded patients did not differ from others in baseline 
characteristics. Furthermore, gastric mucosal status was diagnosed using the
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gastric serum profile instead of histology (gold standard) because the latter would 
necessitate invasive and expensive endoscopy with biopsies. As primary care 
patients with new onset dyspepsia usually do not have an indication for 
endoscopy, this would be ethically unacceptable within the DIAMOND protocol. 
Therefore, the gastric serum profile is more suited for screening in this 
population. For H pylori-status alone, a breath test or stool antigens are regarded 
as the gold standard according to the Maastricht II criteria.34 Studies have shown 
that the serum diagnosis, including serum biomarkers of pepsinogens I & II (PGI 
& PGII), gastrin-17 (G-17) and H  pylori-infection, is a reliable method (sensitivity 
ranging from 75% to 90% and specificity from 88% to 100%) for assessment of 
both morphological and functional status of the gastric mucosa compared to 
histology.1327
Even though clinical applicability as initial test to guide selection of the most 
appropriate acid suppressive treatment was not found, this test might still have 
potency for patients with persisting dyspepsia that are considered for endoscopy, 
as no underlying pathology can be found in up to 60% of the patients during 
endoscopy.2,29,35-37 Screening for gastric status prior to endoscopy, using this 
simple blood test, might identify patients who do not need an unpleasant, 
invasive and expensive endoscopy.14,29 An efficiency study comparing 
endoscopy with and without preceding serum diagnosis of gastric status might 
elucidate the feasibility and cost-effectiveness of using this test panel as part of 
dyspepsia management prior to endoscopy.
In conclusion, our study demonstrated that despite an earlier response in 
patients with gastritis, there is no additional value for general practitioners to use 
serum diagnosis of gastric mucosal status as a tool to determine which initial acid 
suppressive treatment strategy should be used in patients with new onset 
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Main findings and im plications for dyspepsia m anagem ent
Initial management of dyspepsia remains a challenge for primary care praxis. 
Since dyspeptic symptoms represent a global problem with considerable impact 
on the patients’ well-being and health care resource utilisation, numerous 
treatment options have been investigated over the last decades.1-11 Many 
important questions concerning treatment strategies for managing dyspepsia 
have been addressed and compiled into treatment guidelines.12-18 However, the 
initial management of patients with uninvestigated dyspepsia received scant 
attention. The majority of these patients are treated in primary care using acid- 
modulating drugs, but evidence on the most appropriate initial strategy for 
empirical management of new onset dyspepsia is limited.
DIAMOND: Main findings
In this thesis, attention is focussed on the evaluation of initial empirical 
treatment of new onset dyspepsia in primary care in order to optimise its 
management. In a pragmatic randomised clinical trial including economic 
evaluation (DIAMOND-study), effectiveness and costs of stepwise empirical 
treatment with antacids, H2RA, and proton pump inhibitors as recommended by 
the Dutch guidelines for management of dyspepsia (step-up) was compared to 
‘starting with a PPI’ (step-down), a strategy that gains popularity among primary 
care physicians. The DIAMOND-study showed that the step-up strategy resulted 
in lower (medical) costs and equal clinical effectiveness with regard to treatment 
success, symptom severity and health-related quality of life compared to the 
step-down strategy after six months, and after one year. Although there was an 
advantage in favour of ‘starting with a PPI’ (step-down) in the first month, equal 
success rates of approximately 70% after six months and 50% after one year 
were achieved in both strategies, and relapse rates (step-up 34% vs. step-down 
40%) were also equal. Successful treatment was associated with a more 
prominent and continuing recuperation of the substantially impaired health- 
related quality of life (HRQoL). Moreover, average 1-year medical costs per 
patient were €140 lower compared to unsuccessfully treated patients. Main cost 
drivers of unsuccessful treatment were acid-modulating medication, primary care 
consultations and endoscopies. The DIAMOND-study also showed that in 
addition to the medical costs, dyspeptic patients make considerable socio­
economic costs, as the majority of patients affected by dyspeptic symptoms are 
still at an occupational age (approximately 85% of the DIAMOND population, 
while 60% had a paid job). Furthermore, multivariable regression analysis 
showed that short-term treatment success is primarily determined by the severity 
and type of dyspeptic symptoms, while long-term success is influenced more by 
HRQoL, and symptom predominance. Moreover, pre-treatment serum diagnosis 
of gastric mucosal status was not found to predict treatment success and was
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therefore not regarded as a useful tool for patient allocation to acid-modulating 
treatment strategies.
Interpretation of the DIAMOND results
The findings reported in this thesis support the Dutch multidisciplinary 
guideline for the management of dyspepsia, which recommends initial treatment 
according to a step-up strategy for all patients with uncomplicated dyspeptic 
symptoms, and reserves PPI treatment for patients with persisting symptoms.12 
However, for proper interpretation of the results of the DIAMOND-study in the 
light of assessing the ‘most appropriate’ initial empirical treatment strategy, 
several aspects should be considered.
In the first place, the tension between ‘proper’ scientific comparison (internal 
validity) and pragmatism (external validity). In a trial setting, several concepts, 
including randomisation, and blinding of treatment allocation, are used to 
increase internal validity and to ensure that an effect is solely attributable to the 
intervention.19 However, these might hamper generalisability. In the DIAMOND- 
study for example, due to blinding, the step-down strategy did not exactly reflect 
the initial PPI strategies in current clinical practice, as a physician would probably 
not prescribe a H2RA if symptoms persist after PPI treatment. Moreover, in usual 
practice, a physician would repeat a prescription of the most effective drug on 
recurrence of the symptoms, however, due to the late disclosure of treatment 
allocation this information was not at his disposal up to six months. These, as
well as the influence of blinding on treatment adherence due to the increased
20number of pills reported by Fransen et al. might all have influenced 
effectiveness and costs.
Secondly, assessment of what is ‘most appropriate’ or ‘best’ depends on the 
perspective and individual preferences. A patient would judge a treatment which 
quickly solves (not only reliefs) their symptoms with the least side effects and 
personal expenses as ‘most appropriate’, while a physician would also take the 
necessity to treat, the amount of associated work, and medical risks in 
consideration. From a health care or societal perspective, also costs, availability 
of resources, and productivity losses play an important role in the judgment.
A third aspect that influences the outcome evaluation is time. In the DIAMOND- 
study we found different results and determinants for short-term versus long-term 
outcomes. Short-term evaluation of the two strategies resulted in higher clinical 
effectiveness for initial PPI treatment, while both strategies were equally effective 
at long-term evaluation. Moreover, situations might change over time. For 
example, due to the patent expiry of the pantoprazole (the PPI used in the 
DIAMOND-study) in Europe in May 2009, cheaper generic alternatives have 
become available. As price of medication was the main contributor to the
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difference in cost-effectiveness between the strategies, this change will influence 
interpretation of the results of the DIAMOND-study.
Implications for dyspepsia management
In light of the findings presented in this thesis, there is no reason to drastically 
change the Dutch management guidelines for dyspepsia. Nevertheless, the 
DIAMOND results combined with increased knowledge of dyspepsia in literature 
provide sufficient reasons for an update. In pursuance of the implementation of 
the DIAMOND results into clinical practice, Wevers et al. assessed views and 
support for the Dutch dyspepsia guidelines among general practitioners 
(addendum  tw o ). Their inventory sheds light on the main arguments of the 
physicians for current clinical practice regarding the treatment of dyspepsia. In 
contrast to the guideline recommendations, the majority (62%) of the responding 
general practitioners adopt an initial PPI strategy on patients presenting with 
dyspeptic symptoms for the first time. Although 83% indicated that the guidelines 
were clear, 38% think it should be changed. Evidence-base and applicability of 
the guideline need to be improved.
Value o f antacids/H2RA as a firs t step o f em pirical dyspepsia m anagem ent
According to the Dutch multidisciplinary guideline, patients with uncomplicated 
dyspepsia should get lifestyle advice and (if necessary) pharmacotherapy using 
antacids or H2RA at first presentation. The importance of lifestyle advice seems 
to be generally recognized, even though evidence-base is limited.21-24 However, 
the use of antacids or H2RA as initial step is argued to be redundant as the 
majority of patients with dyspeptic symptoms will have tried self-medication 
before consulting their general practitioner for further advice and treatment. 
However, self-medication will generally be on-demand (only when symptoms are 
present). On-demand use might be as effective as continuous use in chronic 
users25, but it would undermine the diagnostic value of an initial treatment 
course, as the cause of treatment failure cannot adequately be assessed. Failure 
to achieve treatment response (on either over-the-counter or prescribed 
medication) might be due to the fact that the drug does not (sufficiently) work, but 
it can also be caused by non-adherence or inaccurate use. Assessment of 
adherence and intake fidelity are two important issue raised by Fransen26 which 
should be stressed explicitly in the guideline in order to adequately evaluate 
effectiveness of a treatment. Whether or not antacids or H2RA are redundant 
should be based on findings regarding adherence. Therefore, it is desirable that 
practical criteria for assessing and evaluating adherence and intake fidelity are 
included in the guideline for the initial visit, but also for follow-up of a prescribed
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treatment course. In case of non-adherence it is important to determine whether 
medication is not taken because of lack of response or side effects or because 
symptoms are no longer present. As only one third of the patients were found to 
take their acid-suppressive medication in concordance with the medication 
instructions26, it is not only important that a general practitioner as well as 
pharmacists provide clear medication instructions, but the necessity of proper 
use also needs to be underlined.
Because H2RA is less effective , generally require more daily doses, and are
27now also equally or more expensive than PPIs, one can argue that there is no 
longer place for H2RA in the management of dyspepsia at all. Although 
DIAMOND can only evaluate the effect of H2RA in addition to a course of either 
antacid or PPI treatment, respectively 13% of the patients in the step-up and 8% 
of the patients in the step-down strategy were found to have sustained treatment 
success up to six months after the H2RA treatment step (2nd step). Whether this 
is actually due to the mode of action of H2RA or due to the prolonged treatment 
remains unclear.
Pros and  cons fo r in itia l PP I strategy
Higher (short-term) effectiveness, the reduction of cost differences due to the 
availability of generic PPIs, few(er) daily doses, and reimbursement are some of 
the arguments in favour of an initial PPI strategy (addendum  two). However, 
important arguments against (initial) PPIs are the rebound effect after treatment 
cessation and the long-term maintenance or on-demand use in numerous 
patients.28-30 Although, generally safe, PPI use has been associated with 
(serious) side effects, including increased risk of infectious complications, e.g. 
community-acquired pneumonia and enteric infections (i.e. Clostridium difficile), 
hip fractures, and nutritional deficiencies.27,31-35 It has also been found to 
inadvertently affect the natural human microbiota, whether this might result in a 
shift to lower gastrointestinal symptoms needs to be investigated more 
thoroughly.36-38 In contrast to expectations, the step-down strategy did not result 
in fewer consultation, nor in decreased productivity loss or absenteeism (chapter 
tw o & three). Adherence rates were found to be better for PPIs (75%) than for 
H2RA (63%) and antacids (49%) within the DIAMOND-study.26 This implies a 
greater gain in adherence might be achieved for antacids, which might diminish 
the difference in short-term effectiveness between antacids and PPIs. 
Furthermore, evidence whether generic PPIs are as effective as branded PPIs is 
still insufficient.39
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O ther aspects
In addition to the analyses presented in this thesis and the evaluation of 
treatment adherence by Fransen cited above, the DIAMOND-study also included 
an evaluation of psychological and genetic factors.40 In her thesis, Mujakovic 
concluded that despite the associations identified, psychological and genetic 
factors do not have direct consequences for clinical dyspepsia management of 
the majority of patients in primary care.40
Furthermore, several aspects in the Dutch multidisciplinary dyspepsia 
management guideline differ considerably from most international dyspepsia 
guidelines, including a] the in or exclusion of patients with predominant reflux 
symptoms; b] use of a cut-off age for prompt endoscopy; and c] the position of H  
pylori test-and-treat.
In line with the ROME criteria, most of the international guidelines recommend 
to distinguish patients with predominant reflux from those with dyspepsia, as they 
are more likely to respond to acid suppression. Although subgroup analysis 
showed that in contrast to patients with predominant dyspepsia, patients with 
predominant reflux respond better to initial PPI treatment compared to antacid 
treatment (chapter two), we do not support the opinion that such a distinction 
needs be made prior to initial treatment of patient with new onset dyspepsia in 
the Dutch guideline. First of all, there is substantial overlap between these 
symptom groups and symptoms are known to change over time.41-43 
Consequently, reliable classification of patients is difficult.44 Furthermore, new 
onset dyspeptic symptoms have a good prognosis in the majority of patients, and 
more aggressive medication is often unnecessary. In chapter five we showed 
that success of PPI and antacid treatment is determined by different symptoms 
and patient characteristics. However, the analyses do not allow firm 
recommendations for clinical practice to facilitate treatment allocation. 
Nonetheless, it may help the physicians understand why a patient does (not) 
respond to therapy.
Apart from alarm symptoms, most international guidelines also adopt an age 
criterion, i.e. over 50 or 55 years for prompt endoscopy, in contrast to the Dutch 
guideline. The observation in the DIAMOND-study of one 60-year old female 
without alarm symptoms who was diagnosed with incurable gastric cancer after 
47 days might imply that the addition of an age criterion is valuable. However, 
although the risk of gastro-oesophageal cancer is known to increase with age, 
and in the presence of alarm symptoms, gastric cancer is rare in the Dutch 
population. In an individual patient data analysis combining the data of 13,377 
patient from seven studies investigating alarm symptoms and gastrointestinal 
malignancy, Janssen et al. showed that age was an important factor, but that
45there is no clear threshold for an age cut-off. Use of an age cut-off would
133
General discussion
increase the number of endoscopies, but there is insufficient prove that earlier 
detection by prompt endoscopy would actually positively affect prognosis. 
Increased costs and resource utilisation would therefore not outweigh delayed 
diagnosis. This individual patient data analysis also showed that alarm symptoms 
are far from ideal for identifying patients with gastro-oesophageal malignancy 
(sensitivity 62.0%; specificity 70.5%; PPV 2.6%; NPV 99.3%), or other serious 
gastro-oesophageal pathology (sensitivity 34.3%; specificity 71.2%; PPV 37.6%; 
NPV 69.3%), due to the low sensitivity, and because the overall prevalence of 
alarm symptoms is high, while the prevalence of gastro-oesophageal cancer is
45low. Nonetheless, all guidelines adopt them as criterion for prompt endoscopy. 
Janssen et al. suggests that alarm symptoms should not by definition lead to 
endoscopy, but should prompt the physician to make a thorough differential 
diagnosis, including disease outside the upper gastrointestinal tract. The authors 
advise that apart from alarm symptoms, also age, H pylori infection, gender, use 
of ASA/NSAIDs, and the presence of heartburn symptoms should be taken in to 
account when estimating individual risk of serious pathology.
The position of H pylori test-and-treat in the management of dyspepsia is highly 
variable among major dyspepsia guidelines. The order in which to use empirical 
pharmacotherapy or H pylori test-and-treat is based on either H pylori prevalence
14,15 18(cut-off 5-10%) , , symptom recurrence or predominance (epigastric pain vs. 
heartburn)16, the combination of these12, or the choice is left to individual
17preference . According to the American guidelines, H pylori test-and-treat would 
be the preferred initial strategy in our population with a H pylori prevalence of 
36%. However, in a fairly recent randomised controlled trial Delaney et al. 
showed that there is no evidence that H pylori test-and-treat should be preferred 
over initial empirical acid suppression, as both strategies are equally effective 
and cost-effective after one year in a population with a H pylori prevalence of 
29%.7 In a randomised trial focussing on the order of empirical acid suppression 
and H pylori test-and-treat, Janssen et al. found no difference in treatment 
success after six months between a strategy starting with empirical acid 
suppression followed by H pylori test-and-treat in case of persisting or relapsing 
symptoms (treat-first) or initial H pylori test-and-treat followed by empirical acid 
suppression in case of persisting or relapsing symptoms (test-first). Relapse 
rates were found to be higher in H pylori positive patients, which would suggest a 
preference for initial H pylori test-and-treat. However, in the absence of a cost 
evaluation this trial is not conclusive. In his thesis, Janssen argues that 
dyspepsia management should combine empirical acid suppression and H pylori 
test-and-treat, even in patients with (predominant) reflux symptoms, and that 
eradication should be indicated for H pylori positive patients using ASA/NSAIDs, 
or prior to PPI maintenance treatment.
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Change in evidence-based medicine is however not solely achieved by revision 
of a management guideline. Compliance to guidelines also needs to be improved 
among users. This is easier said than done. Although a more evidence-based 
and applicable guideline would improve intentions to comply with 
recommendations, it may be necessary to change situations in order to support 
the guideline.46 For example, one of the situations that needs to be evaluated are 
the health care insurance issues. Reimbursement of only PPIs promotes an initial 
PPI strategy. However, no reimbursement for any of the acid-suppressive drugs 
represents a problem for chronic users. On the other hand, reimbursement for all 
three categories of acid-modulating drugs will probably result in increased 
workload for general practitioners and a shift from OTC to prescribed use. This is 
a difficult and moving field which needs attention to promote treatment in 
accordance with the guideline. It remains to be determined whether there are 
other situations that need to change to support compliance with the guideline.
In conclusion, a step-up treatment strategy remains to be the preferred 
treatment approach for patients with newly diagnosed dyspepsia. Guidelines 
should however be revised to improve applicability for general practice, and to 
better substantiate the recommendations. Practical criteria for assessment and 
evaluation of treatment adherence and intake fidelity should be included, and 
used as a tool to assess whether the initial antacid or H2RA step might be 
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This thesis concerns issues regarding the optimisation of initial management of 
patients with new onset dyspepsia (upper gastrointestinal disorders). 
Management guidelines play an eminent role in achieving balanced use of 
health-care resources. This is becoming increasingly important, especially for 
common chronic relapsing disorders, such as dyspepsia.
Although the majority of patients with dyspeptic symptoms are treated in 
primary care using acid-binding or suppressing drugs, it remains unclear what 
the most appropriate initial strategy is for empirical management of patients with 
(new onset) dyspepsia. Therefore, we performed a large pragmatic primary care 
based randomised controlled trial with economic evaluation (DIAMOND-study), to 
evaluate two stepwise empirical acid-suppressive treatment strategies for new 
onset dyspepsia. Patients were randomised to receive either a] stepwise 
treatment with antacid, H2-receptor antagonist (H2RA), and proton pump inhibitor 
(PPI) as recommended by the Dutch management guidelines (step-up), or b] 
these drugs in the reverse order (step-down) led by a strategy starting with a PPI 
which is increasingly being used in general practice. Chapter one provides 
insight into challenges in designing and conducting such a pragmatic trial, and 
the rationale behind choices made in the DIAMOND-study.
The primary aim of DIAMOND was to compare (cost-)effectiveness of the step- 
up and step-down strategies for initial management of patients with new onset 
dyspepsia after six months (chapter two  and addendum  one). Our study results 
indicate that both treatment strategies are clinically equally effective with regard 
to 6-months treatment success, symptom severity, and health-related quality of 
life (HRQoL). There was a short-term advantage in favour of starting with a PPI 
(step-down), but incremental cost-effectiveness analysis showed that the step-up 
strategy (starting with antacids) was more cost-effective after six months 
compared to the step-down strategy. Because dyspepsia continues to cause 
prolonged health-care utilisation by many patients due to its chronic relapsing 
character, extended evaluation of (cost-)effectiveness was desirable. Therefore, 
we also assessed the symptom status, HRQoL and medical costs after one year 
(chapter three). The results of this extended follow-up study showed that the 
conclusions of the DIAMOND-study - that step-up is more cost-effective than a 
step-down strategy - are maintained after one year. Acid-modulating medication, 
primary care consultations, and endoscopies were found to be the main cost 
drivers for unsuccessful treatment of new onset dyspepsia in primary care. The 
differences in number of primary care consultations, and endoscopies between 
successful and unsuccessful treatment were more pronounced in the step-up 
strategy.
The patients’ health perspective plays an increasingly important role in the 
health-care decisions as well as its evaluation in an era of pay-for-performance,
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especially when objective clinical measures are lacking. Dyspepsia is known to 
substantially impair HRQoL. Patient reported outcomes were used to investigate 
the impact of dyspeptic symptoms, as well as the effect of empirical treatment on 
HRQoL after 6 months (chapter four). HRQoL was substantially impaired in our 
population of patients seeking care for new onset dyspepsia. Fortunately, HRQoL 
improved substantially shortly after treatment was initiated, independent of the 
strategy used. Repeated measures linear regression techniques were used to 
compare HRQoL change over time between patients with and without treatment 
success, and to identify predictors for HRQoL change. The results imply that 
successful treatment of dyspeptic symptoms restores the patients’ well-being by 
removing impairments. Symptom severity was the most important, but not the 
only predictor of HRQoL change over time. Other independent predictors were 
lower age, intermediate educational level, presence of baseline psychopathology, 
and treatment success.
Identifying which patients will benefit most from initial acid inhibition might 
contribute to improve care and save costs. Multivariable regression analysis was 
used to identify factors associated with short-term as well as long-term success 
of acid-modulating treatment for new onset dyspepsia in primary care (chapter 
five). Severity and type of dyspeptic symptoms were found to influence short­
term treatment response to both antacid and PPI, while higher HRQoL, and 
symptom predominance influenced long-term treatment outcome. Furthermore, 
we studied whether pre-treatment testing of the condition of the gastric mucosa 
using a simple serologic test would be a useful tool for patient allocation to acid- 
suppressive treatment strategies (chapter six). Since dyspepsia treatment 
success could not be predicted by gastric mucosal status, we concluded that this 
was not the case.
In light of the findings presented in this thesis, there is no reason to drastically 
change the Dutch management guidelines for dyspepsia. Nonetheless, there is 
sufficient reason for an update. The guidelines should be revised to improve 
applicability for general practice. Implications of our findings for dyspepsia 







Dit proefschrift gaat over het optimaliseren van de aanvangsbehandeling van 
patiënten met beginnende maagklachten (dyspepsie). Behandelrichtlijnen spelen 
een belangrijke rol in het evenwichtig gebruik van de gezondheidszorg. Dit wordt 
steeds belangrijker, vooral bij veel voorkomende chronisch terugkerende 
aandoeningen, zoals dyspepsie.
Hoewel de meerderheid van patiënten met maagklachten door middel van 
maagzuurbindende of -remmende medicijnen wordt behandeld in de 
huisartsenpraktijk, blijft het onduidelijk wat de meest geschikte benadering is 
voor aanvangsbehandeling van patiënten met (nieuw ontstane) maagklachten. 
We hebben daarom in de huisartsenpraktijk een grootschalig praktijkgericht 
onderzoek met kostenevaluatie (het DIAMOND-onderzoek) uitgevoerd, om twee 
maagzuuronderdrukkende behandelmethoden voor patiënten met nieuw 
ontstane maagklachten te evalueren. Patiënten kregen willekeurig een 
stapsgewijze behandeling voorgeschreven met: a] achtereenvolgens een 
antacidum, een H2-receptorantagonist (H2RA), en een protonpompremmer (PPI), 
zoals wordt aanbevolen in de Nederlandse behandelrichtlijn (step-up) of b] deze 
geneesmiddelen in de omgekeerde volgorde (step-down), gebaseerd op een 
behandeling die aanvangt met een PPI, welke steeds vaker wordt gebruikt in de 
huisartsenpraktijk. Hoofdstuk een geeft inzicht in overwegingen ten aanzien van 
het opzetten en uitvoeren van zulke praktijkgerichte onderzoeken en een 
motivatie voor de keuzes die in het DIAMOND-onderzoek zijn gemaakt.
Het primaire doel van DIAMOND was om de (kosten)effectiviteit van de step- 
up- en step-downbenadering voor initiële behandeling van patiënten met nieuw 
ontstane maagklachten te vergelijken na zes maanden (hoofdstuk twee en 
addendum  een). Uit de resultaten van het onderzoek bleek, dat beide 
behandelmethoden na zes maanden klinisch even effectief waren met betrekking 
tot behandelsucces, ernst van de symptomen, en gezondheid gerelateerde 
kwaliteit van leven. Op korte termijn was er een voordeel om met een PPI te 
starten (step-down), maar uit de incrementele kosteneffectiviteitanalyse bleek dat 
de step-upbenadering (beginnen met een antacidum) meer kosteneffectief is na 
zes maanden dan de step-downbenadering. Aangezien maagklachten chronisch 
en terugkerend zijn, kan dit bij veel patiënten leiden tot langdurig gebruik van de 
gezondheidszorg waardoor een langere termijn evaluatie van de 
(kosten)effectiviteit wenselijk was. We hebben daarom de symptomen, de 
kwaliteit van leven en de medische kosten ook na een jaar geëvalueerd 
(hoofdstuk drie). Uit de resultaten van dit verlengde follow-uponderzoek bleek 
dat de conclusies van het DIAMOND-onderzoek - dat de step-upbenadering 
meer kosteneffectief is dan een step-downbenadering - overeind blijven na een 
jaar. Maagzuurmodulerende medicatie, de huisartsconsulten en endoscopieën 
bleken de belangrijkste aanleiding voor kosten te zijn bij niet succesvolle
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behandeling van nieuw ontstane maagklachten in de eerstelijns 
gezondheidszorg. De verschillen in aantal huisartsconsulten en endoscopieën 
tussen wel of niet succesvolle behandeling waren meer uitgesproken in de step- 
upbenadering.
De gezondheidsbeleving van de patiënten speelt een steeds belangrijkere rol 
in de keuzes en beoordeling van een behandeling in een tijdperk van 
marktwerking in de zorg, met name wanneer objectieve klinische uitkomstmaten 
ontbreken. Het is bekend dat maagklachten de kwaliteit van leven aanzienlijk 
kunnen beperken. We hebben door de patiënt zelfgerapporteerde uitkomsten 
gebruikt om de invloed van maagklachten en het effect van empirische 
behandeling op de kwaliteit van leven na zes maanden te onderzoeken 
(hoofdstuk vier). Kwaliteit van leven was aanzienlijk verminderd in onze 
populatie van patiënten die met nieuw ontstane maagklachten bij de huisarts 
kwamen. Gelukkig verbeterde de kwaliteit van leven aanzienlijk kort nadat de 
behandeling werd gestart en was deze onafhankelijk van de gebruikte 
behandelmethode. Lineaire regressietechnieken voor herhaalde metingen 
werden gebruikt om de veranderingen in kwaliteit van leven over de tijd te 
vergelijken tussen patiënten met en zonder behandelsucces en om voorspellers 
voor verandering in kwaliteit van leven te identificeren. De resultaten impliceren 
dat succesvolle behandeling van maagklachten het welzijn van de patiënten 
herstelt door het wegnemen van de klachten. Ernst van de maagklachten was de 
belangrijkste, maar niet de enige voorspeller van veranderingen in kwaliteit van 
leven over de tijd. Andere onafhankelijke voorspellers waren lagere leeftijd, 
middelbaar opleidingsniveau, aanwezigheid van psychopathologie en het 
bereiken van behandelsucces.
Het identificeren van patiënten die het meeste baat hebben bij initiële 
maagzuurremming zou bij kunnen dragen aan verbetering van de zorg en 
kostenbesparing. Met behulp van multivariabele regressieanalyse werden 
factoren geïdentificeerd die verband houden met het korte en ook lange termijn 
succes van behandeling met maagzuuronderdrukkende medicijnen voor nieuw 
ontstane maagklachten in de eerstelijns gezondheidszorg (hoofdstuk vijf). Ernst 
en type van de maagklachten waren van invloed op korte termijn 
behandelsucces voor zowel antacidum als PPI, terwijl betere kwaliteit van leven 
en het meest overheersende symptoom van invloed waren op lange termijn 
behandeluitkomst. Daarnaast hebben we onderzocht of een simpele 
serologische test, waarmee de conditie van het maagslijmvlies voorafgaand aan 
de behandeling wordt bepaald, een nuttig instrument is om te bepalen met welk 
maagzuuronderdrukkende medicijn de patiënt het beste behandeld kan worden 
(hoofdstuk zes). Aangezien de conditie van het maagslijmvlies geen voorspeller
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was voor het succes van de behandeling van maagklachten hebben we 
geconcludeerd dat dit niet het geval was.
Op grond van de bevindingen beschreven in dit proefschrift is er geen reden 
om de Nederlandse behandelrichtlijn voor dyspepsie drastisch te veranderen. Er 
is echter voldoende reden voor een update. De richtlijn moet herzien worden om 
de toepasbaarheid voor de huisartsenpraktijk te verbeteren. Implicaties van onze 
bevindingen voor de behandeling van dyspepsie en toekomstig onderzoek 






Bloed, zweet en tranen, maar nu is het eindelijk zover. Mijn proefschrift is af! 
Vaak heb ik uitgekeken naar dit moment.
De weg naar dit boekje was lang en heeft mij en mijn omgeving flink op de 
proef gesteld. Het was dan ook een leerzame periode op meer dan alleen 
wetenschappelijk gebied. Dank ben ik verschuldigd aan alle mensen die direct of 
indirect hebben bijgedragen aan het tot stand komen van dit proefschrift. Een 
aantal mensen wil ik in het bijzonder noemen.
Prof. Jansen, ik heb u leren kennen als een zeer correcte en deskundige man. 
Bedankt voor de klinische input, uw kritische blik, de intensieve samenwerking 
aan de Lancet revisies en het faciliteren van dit onderzoek. Leuk dat u regelmatig 
kwam buurten in de ‘kelder’.
Robert, jij hebt de basis gelegd voor dit proefschrift. Toen je me benaderde 
voor het EUROSTAR-project van dr. J Buth, heb ik niet lang hoeven nadenken. 
Gelukkig maar, want je was een fijne werkgever, een goede leermeester en 
bovendien de geestelijk vader van het DIAMOND-onderzoek. Ik heb veel 
bewondering voor je onderzoeksenthousiasme en wetenschappelijke creativiteit 
en denk met plezier terug aan de gezellige BBQs in Liempde. Dat de begeleiding 
door je opleiding geneeskunde en specialisatie MDL op een laag pitje is komen 
te staan was soms wel lastig, maar dat is goed opgevangen. Bedankt voor je 
vertrouwen en geduld. Ik weet dat ik niet altijd even makkelijk te sturen was.
Martijn, zonder jou was dit proefschrift er misschien wel niet meer gekomen. Ik 
heb je leren kennen als een geweldige en gezellige collega. Je stond altijd klaar 
om te helpen op zowel het wetenschappelijke als persoonlijke vlak. Als er iets 
was, had jij dat altijd zo in de gaten en zorgde je voor de nodige tissues en 
bemoedigende woorden. Zo ook begin 2007. Ik kan me nog goed herinneren dat
je zei: ‘Corine, hier heb je de handdoek en daar staat de ring....... Je moet hem
er wel zelf ingooien’. Zo snel geef ik me echter niet gewonnen. Het idee om jou 
te vragen mijn tweede copromotor te worden, was een belangrijk keerpunt. Ik 
was dan ook blij toen je me liet weten dat je dat wel wilde. Je hebt me geholpen 
om die enorme berg op te delen in haalbare etappes en zorgde dat ik me niet 
teveel met bijkomende zaken hoefde bezig te houden. Ik vond het fijn om tijdens 
ons regelmatige ‘PhDysp’ overleg te sparren over de stukken die ik weer had 
uitgewerkt. Het was gezellig en motiverend en vaak een bevestiging van mijn 
gedachten. Martijn, ik heb veel bewondering voor je wetenschappelijke en 
sociale capaciteiten. Je bedenkt altijd goed wat je wilt en gaat dan op je doel af. 
Voor mij ben je een bron van inspiratie en een geweldige begeleider. Helaas is
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het me niet gelukt om je eerste (co)promovendus te zijn. Maar ik zal ook zeker 
niet de laatste zijn!
Gerdine en Suhreta, nu is het cirkeltje rond en staan jullie aan mijn zijde tijdens 
de verdediging van mijn proefschrift (ons onderzoek). Vier jaar lang hebben we 
intensief samengewerkt om het DIAMOND-onderzoek tot een goed einde te 
brengen. We hebben vele kilometers gemaakt om het bloed te verzamelen. Het 
was eigenlijk altijd meer rennen dan stilstaan. We hielden elkaar scherp en 
vulden elkaar aan. Gerdine, ik heb met veel plezier met je samengewerkt aan 
zowel EUROSTAR en DIAMOND. Suhreta, ik denk nog met veel genoegen terug 
aan de gezellige avonden sporten, kletsen en thee drinken. Echt jammer dat we 
niet meer bij elkaar om de hoek wonen, want ik mis het echt.
Zonder de inzet van alle deelnemende huisartsen*, patiënten en de 
ondersteuning van de stuurgroep, in het bijzonder André Knottnerus, Jean Muris, 
Mattijs Numans en Niek de Wit, hadden we het niet voor elkaar gekregen. De 
huisartsen en patiënten hebben gezorgd voor de essentiële bouwstenen van 
DIAMOND. Terwijl de glans mede te danken is aan het slijpen en polijsten door 
de stuurgroep. Bedankt voor jullie steun en de prettige samenwerking.
Alle collega’s uit de ‘kelder’ wil ik bedanken voor de gezellige en fijne 
werksfeer, de inspirerende discussies, de helpende handen en luisterende oren. 
Hierbij wil ik in het bijzonder Leo van Rossum noemen voor het bouwen en 
ondersteunen van de database en niet te vergeten zijn overheerlijke brownies en 
Lieke van Kerkhoven voor het vervangen van Suhreta tijdens haar verlof en het 
bijspringen in drukke tijden. Daarnaast wil ik alle (ex-)medewerkers van de 
afdeling Maag-, Darm-, Leverziekten, maar met name Annie van Schaik en de 
secretaresses, bedanken voor alle hulp bij het labwerk en de post en faxen voor 
ons onderzoek. Joost Drenth, jij hebt gezorgd voor het laatste zetje. Dirk de 
Jong, ik vind het leuk om nu met je samen te werken aan het TOPIC project. Ook 
mijn huidige collega’s DNA-diagnostiek wil ik niet vergeten. Met name de 
monsterontvangst, de isolatie faciliteit en de secretaresses voor het verwerken 
van het grote aantal TOPIC aanvragen. In het bijzonder wil ik ook alle 
‘Multifactorieel’ collega’s nog noemen. Naast al jullie hulp bij het TOPIC 
onderzoek wil ik jullie allemaal bedanken voor een prettige en positieve 
werksfeer, de morele en emotionele ondersteuning. Barbara Franke en Marieke 
Coenen bedankt voor de ruimte die jullie me gegeven hebben om mijn 
proefschrift naast mijn werk af te ronden. Paul Savelkoul, bedankt voor alle tips 
voor het opmaken van mijn proefschrift en je hulp bij het maken van de kaft.
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Al mijn dierbare vriendinnen/vrienden wil ik bedanken voor de belangstelling, 
alle aanmoedigingen en het begrip dat ik gekregen heb. Sorry dat ik zo weinig 
tijd had. Veronique en Jos, jullie zijn geweldige buren. Bedankt voor alles wat 
jullie voor ons doen en alle ‘Snijbonensoep’. Ik vind het geweldig om te zien dat 
Xander zo dol is op jullie en andersom. Ik hoop dat we nog lang buren zullen 
blijven!
Sabine en Arthur, daar staat jullie kleine zusje dan. Jullie waren er altijd om me 
een hart onder de riem te steken als het weer eens tegen zat. Net als pa en ma 
hebben jullie altijd vertrouwen in me gehad. Ik waardeer het enorm dat jullie me 
zo goed hebben opgevangen toen het thuis niet zo lekker liep. Janny en Peter, ik 
had geen fijnere schoonouders kunnen hebben. Bedankt voor alle hulp in en om 
het huis en alle extra donderdagen die jullie op Xander hebben willen passen 
zodat ik aan mijn proefschrift kon werken.
Last, but zeker not least, lieve paps, mams, Marco en Xander. Dit boekje wil ik 
opdragen aan jullie vieren. Paps en mams, jullie hebben altijd voor me klaar 
gestaan en doen dat nog steeds. Jullie hebben me gestimuleerd het maximale uit 
mezelf te halen en me altijd onvoorwaardelijk gesteund. Mama, van jou heb ik 
geleerd: ‘waar een wil is, is een weg’. Het was zeker niet makkelijk om de goede 
weg te blijven volgen, maar deze wijze les heeft er mede voor gezorgd dat het nu 
klaar is. Paps, bedankt dat jij elke dinsdagochtend Xander komt ophalen voor 
een gezellig dagje bij opa en oma en je hulp bij het corrigeren van de tekst. 
Marco, lieve schat, voor jou is het zeker niet altijd even makkelijk geweest. Ik 
weet dat ik veel van je gevraagd heb, mede doordat het allemaal veel langer 
geduurd heeft dan de bedoeling was. Af en toe was je het dan ook helemaal zat 
en lukte het even niet om nog begrip op te brengen en dat snap ik ook wel. Ik wil 
je bedanken voor je geduld en de steun die je me hebt gegeven. Voor het 
overnemen van veel huishoudelijke taken en dat je ervoor zorgde dat ik ’s 
avonds niet te lang boven achter de laptop bleef zitten werken aan mijn boekje. 
Zonder jouw steun had ik de moed misschien wel opgegeven. Xander, mama’s 
zonnestraaltje, met jouw enthousiasme en charme weet je mama altijd op te 
vrolijken. Met je vriendelijke lach en je guitige blik weet je iedereen voor je te 
winnen. Sorry, dat mama niet altijd voldoende tijd en aandacht voor je kon 
maken. De laatste tijd vond je dat niet altijd makkelijk. Hoewel je al een hele kerel 
bent, ben je nog te klein om te begrijpen wat mama allemaal moest doen. Ik ben 




Alblasserdam ~ M M de Folter-Maaskant; Almere ~ O I M Geräts, L Groeneveld, H M 
Kole, R Liagre; Amersfoort ~ J Mus, I K I Jongh-Kilian, P H J Heuberger, G A Essen; 
Arnhem ~ T M C Cohen Stuart, C M D de Graaf, A M M Derks; Baarlo ~ A L M van 
Heeswijk; Bemmel ~ A D Hiddink; Berg En Dal ~ C M M Veldhoven; Best ~ R G A M 
Beumer, F J H Venema, R J Hendriksen; Beuningen (Gld) ~ R M Meijers-Koopman, G P K 
Adriaansens; Bladel ~ G M Dijkmans-Dijkman; Blaricum ~ M Y J van Daelen; Boekel ~ P 
H Weber; Boxmeer ~ B J N Wetzels-v Drunen, C Y Jongebreur; Boxtel ~ J M P M 
Janssen; Breda ~ J P M Breemen; Brunssum ~ A J Drost, C S Hoogervorst; Bunnik ~ D J 
H van Steenis; Cuijk ~ A van Riel; Culemborg ~ M J W  Knijnenburg; Diepenveen ~ A O 
Quartero; Drunen ~ J C C Engelenburg-v Dorst; Druten ~ E Oosterman; Duiven ~ S A J 
Sluijmers; Ede (Gld) ~ C Lugt, H F Engel; Eersel ~ B A M Mangnus; Eindhoven ~ R B T 
Verstegen, S T B van Bentum, N P Hoftijzer, C J Westphal-Juijn, C G J Dekkers, P J 
Dalinghaus-Nienhuys, A C de Steur, M H E Salwegter, H J C Becx; Elst (Gld) ~ M C M 
Corsten; Ewijk ~ C P Buiks; Geleen ~ J P H Dolhain, P C J Hezemans; Gemert ~ L M 
Bernsen, A J M van de Ven; Geulle ~ M van Putten, P J Zwietering, J W  M Muris; 
Groesbeek ~ P Fussenich, V M Lenglet; Haelen ~ H P L Deckers; Heerlen ~ P V H Bots, 
B T M van der Werf; Helmond ~ W  Heres, B A M Gerritsen, M M M Brueren; Hilvarenbeek 
~ J M A E Henquet, O G Ahlers; Hilversum ~ A E G M Walter, E Doorenspleet, P 
Wessels; Hulsberg ~ J J P Dellevoet, J G Nijhof; IJsselstein (Ut) ~ F A W  Hoogstraten, R 
H M Roelofs; Kerkrade ~ J M S Soomers-Turlings, F L M Soomers; Lierop ~ F J M 
Raaymakers; Maastricht ~ G G M Wolfs; Maurik ~ E F J Regtien; Meerssen ~ T J J van 
Erp; Meijel ~ L M Habets; Montfoort ~ A de Vries; Nieuwerkerk aan den Ijssel ~ R D W  
Duiverman; Nijkerk (Gld) ~ C M de Jonge-Tettero; Nijmegen ~ P J R Mesker, J J L M 
Mesker-Niesten, B T I M van der Bom, E J M Snoeren, F M Dreijerink, A A M van Erp, F B 
J Peters, L G M Janssen, O Ouwendijk, M J R Janssen, J A M van Breemen, H Scholten; 
Oosterhout (Nb) ~ R A Dingjan; Oost-West-Middelbeers ~ E J M Mutsaerts; Ospel ~ C M 
Hussaarts; Oss ~ T C Hol, J C de Bres-de Langen, G J Holten; Renswoude ~ J A M 
Dirven; Rhenen ~ F H Rutten, N J de Wit, B D Frijling, M Bosman; Rijen ~ P C J A 
Goderie; Roermond ~ A T M de Vries; Schoonhoven ~ M A Bade; Schoonrewoerd ~ C F I 
Noppe; 's-Hertogenbosch ~ G H J van Roekel; Sint Anthonis ~ P P J M Bindels; Sint 
Odilienberg ~ M G Perquin; Sint Oedenrode ~ C B van Jaarsveld, A C M van Mil, M A C M 
van Osch; Sittard ~ S O Hobma; Soerendonk ~ P J Meurs; Soest ~ E J Oudshoorn, M M 
Smits-Schaff els, L J M M Weusten; Soesterberg ~ F P Prause; Stein ~ L O V de Wolf; 
Susteren ~ J W  M Wijnhoven; Swalmen ~ H A Harms; Tegelen ~ M Reitsma; Tilburg ~ D 
L M Schraven; Utrecht ~ M E Numans, F A M van Balen, L H M Rikken; Valkenswaard ~ L 
J A L Hendrikx; Velddriel ~ E J Heemskerk; Veldhoven ~ M J A van Dooren; Venlo ~ C A 
M van Vugt; Venray ~ P P M Henkes, J B M Wittgen; Waalre ~ A J M van de Sande; 
Waalwijk ~ J E P Ongering; Weert ~ G H J M Smits, W  A M Baake; Weesp ~ H B 
Burggraaff ; Wijchen ~ B B van Drenth; Wijlre ~ S Koopmans; Winssen ~ C J H Proper- 








Corine van Marrewijk werd op 13 april 1976 geboren te Renkum. Hier genoot 
ze een fijne, zorgeloze jeugd. Een belangrijk deel hiervan bracht zij met veel 
plezier door in de turnhal. Na het behalen van haar VWO diploma aan het 
Christelijk Streeklyceum te Ede, startte zij in 1994 met de opleiding Biomedische 
Gezondheidswetenschappen aan de Katholieke Universiteit Nijmegen. 
Aansluitend bij haar passie voor sporten, lag haar interesse in eerste instantie bij 
de richting Bewegingswetenschappen. Echter, gedurende het propedeuse jaar 
merkte ze dat haar voorkeur veranderde naar Epidemiologie. In november 1998 
ging ze voor een afsluitende (extra) stage naar het ‘National Centre in HIV 
Epidemiology and Clinical Research’ aan de ‘University of New South Wales’ in 
Sydney, Australië. Eind augustus 1999 keerde zij, na haar stage en ca. zeven 
maanden backpacken door Nieuw-Zeeland, Australië, Indonesië en Maleisië 
samen met haar vriend Marco, weer terug naar Nederland om haar diploma op te 
halen.
Tussen oktober 1999 en mei 2007 was zij werkzaam bij Medical Science BV, 
waar zij onder mentorschap van dr. Robert Laheij heeft gewerkt aan 
verschillende onderzoeksprojecten, waaronder de EUROSTAR dataregistratie, 
het DIAMOND-onderzoek en het FOCUS-CT project. Sinds mei 2007 werkt ze 
onder supervisie van dr. Barbara Franke en dr. Marieke Coenen als postdoc 
onderzoeker in de onderzoeksgroep Multifactoriële aandoeningen van de 
afdeling Antropogenetica van het UMC St Radboud aan het TOPIC project. In de 
avonduren en de weekeinden heeft ze gewerkt aan het tot stand komen van dit 
proefschrift.




Zuurremmers: hoog inzetten, of juist laag? - Het DIAMOND- 
onderzoek naar effectiviteit en kosten van de step-up- en de 
step-downbenadering bij maagklachten in de eerste lijn
2. Behandeling van maagklachten door huisartsen - Visies op 
CBO-richtlijn en voorkeur van behandelmethoden vanuit de 
huisarts belicht
Dit artikel werd eerder gepubliceerd als: Van Marrewijk CJ, Mujakovic S, Fransen 
GA, Numans ME, De Wit NJ, Muris JW, Van Oijen MG, Jansen JB, Grobbee DE, 
Knottnerus JA, Laheij RJ. Effect and cost-effectiveness of step-up versus step- 
down treatment with antacids, H2-receptor antagonists, and proton pump 
inhibitors in patients with new onset dyspepsia (DIAMOND-study): a primary-care- 
based randomised controlled trial. Lancet 2009;373:215-25. Publicatie gebeurt 
met toestemming van de uitgever.
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Addendum  1
SAMENVATTING
Doel Er zijn weliswaar consensusrichtlijnen over de behandeling van 
‘maagklachten’ in de eerste lijn, maar de meest kosteneffectieve strategie moet 
nog worden bepaald. In het DIAMOND-onderzoek zijn de effectiviteit en de 
kosten van een step-upbehandeling vergeleken met die van een step- 
downbehandeling in de initiële behandeling van patiënten met een nieuwe 
episode ‘maagklachten’.
Methode Patiënten van 18 jaar en ouder die met nieuw ontstane maagklachten 
bij de huisarts kwamen, kregen willekeurig een stapsgewijze behandeling met 
achtereenvolgens een antacidum, een H2-receptorantagonist en een 
protonpompremmer (step-up), óf dezelfde geneesmiddelen in omgekeerde 
volgorde (step-down). Elke stap in dit dubbelblinde, gerandomiseerde 
gecontroleerde onderzoek duurde vier weken. Een volgende stap werd alleen 
genomen als de klachten aanhielden of binnen vier weken terugkwamen. De 
primaire uitkomsten - symptoomverlichting en kosteneffectiviteit na zes maanden 
- zijn geanalyseerd op basis van ‘intention-to-treat’.
Resultaten Tussen oktober 2003 en januari 2006 wezen wij 664 patiënten 
gerandomiseerd toe aan de step-upbehandeling (n=341) of de step- 
downbehandeling (n=323). Op korte termijn (binnen een maand) had de step- 
downbehandeling meer effect, maar na zes maanden waren beide benaderingen 
even succesvol: de step-upbehandeling bij 238 (72%) patiënten, de step- 
downbehandeling bij 219 (70%) patiënten (oddsratio 0,92; 95%-betrouw- 
baarheidsinterval 0,7-1,3). In de step-upgroep waren in die zes maanden echter 
minder medische kosten - vooral medicijnkosten - gemaakt dan in de step- 
downgroep (€228 tegen €245; p=0,0008).
Conclusie De step-upbehandeling is bij patiënten met nieuw ontstane 
maagklachten na zes maanden even effectief als de step-downbehandeling, 
maar kost minder.
Effectiviteit en kosteneffectiviteit na zes maanden
INLEIDING
De optimale behandeling van maagklachten, in de internationale literatuur 
‘dyspepsie’ genoemd, blijft een uitdaging. Maagklachten verlagen de kwaliteit 
van leven van de patiënt, hebben grote maatschappelijke kosten en leiden tot 
een aanzienlijke werkdruk voor huisartsen.1,2 De wetenschappelijke 
onderbouwing voor de beste initiële behandelmethode is beperkt.3,4 De meeste 
onderzoeken tot nu toe vergeleken slechts de effectiviteit van medicijnen, werden 
vooral uitgevoerd in de tweede lijn bij patiënten met aanhoudende klachten of 
werden gefinancierd door de farmaceutische industrie. Er zijn verschillende 
meta-analyses en overzichtsartikelen verschenen over de beste behandeling 
voor patiënten met dyspeptische klachten,5-9 maar slechts enkele van de daarin 
opgenomen onderzoeken - meestal van matige kwaliteit - evalueren de optimale 
initiële behandeling.5 De reviewers concludeerden dat de kennis over de meest 
kosteneffectieve strategie voor niet nader onderzochte maagklachten 
tekortschiet. De richtlijnen voor de behandeling zijn daardoor inconsistent.
In tegenstelling tot verschillende internationale richtlijnen adviseren de 
Nederlandse richtlijnen10,11 alle patiënten met nieuw ontstane maagklachten 
empirisch te behandelen met antacida of H2-receptorantagonisten, en 
protonpompremmers te reserveren voor patiënten met aanhoudende 
refluxklachten. Voor alle andere patiënten met aanhoudende klachten adviseren 
zij een ‘test-en-behandelingsstrategie’ gericht op Helicobacter pylori (H pylon).1 
Endoscopie is alleen geïndiceerd voor patiënten met alarmsymptomen zoals 
dysfagie, onbedoeld gewichtsverlies, anemie en hematemese. In de praktijk 
starten huisartsen desalniettemin steeds vaker direct al met protonpompremmers 
vanwege de veronderstelde snellere klinische effectiviteit en de daaraan 
gekoppelde kosteneffectiviteit. Om meer inzicht te krijgen in de beste initiële 
behandeling van maagklachten in de eerstelijnszorg hebben wij in een 
dubbelblind, gerandomiseerd placebogecontroleerd onderzoek de step-up- 
vergeleken met de step-downbehandeling.
METHODE
Tussen oktober 2003 en januari 2006 heeft een representatieve groep van 312 
Nederlandse huisartsen12 uit de universitaire netwerken rond Nijmegen, 
Maastricht en Utrecht meegewerkt aan het DIAMOND-onderzoek (Dutch study 
on Initial Management Of Newly diagnosed Dyspepsia). Wij vatten hier de 
methodologische aspecten van het onderzoek kort samen; de details zijn elders 
beschreven.12,13 Het onderzoeksprotocol is uitgevoerd met goedkeuring van de 
medisch-ethische commissies van de betrokken universitaire ziekenhuizen. Alle
169
Addendum 1
deelnemers hebben een toestemmingsformulier ondertekend. Het onderzoek is 
geregistreerd bij ClinicalTrials.gov (NCT00247715).
Onderzoekspopulatie
Patiënten van 18 jaar en ouder die bij de huisarts kwamen met een nieuwe 
episode van maagklachten kwamen in aanmerking voor het onderzoek als ze in 
het voorafgaande jaar géén endoscopie hadden gehad en in de voorgaande drie 
maanden géén voorgeschreven maagzuurremmers hadden gebruikt. Patiënten 
met alarmsymptomen (dysfagie, onbedoeld gewichtsverlies, anemie, 
hematemese), zwangerschap of onvoldoende kennis van de Nederlandse taal 
werden uitgesloten van deelname. Als definitie van ‘maagklachten’ gebruikten 
wij: pijn of ongemak in de bovenbuik (epigastrium) die door de arts werd 
toegeschreven aan het bovenste maag-darmkanaal, en die mogelijk gepaard 
ging met oprispingen, zuurbranden, misselijkheid of een opgeblazen gevoel.14,15
Onderzoeksopzet
De huisartsen verrichtten de consulten op de gebruikelijke wijze en gaven zo
10nodig ook leefstijladviezen. Aanvullend kregen de patiënten informatie over het 
onderzoek. Patiënten die voor deelname in aanmerking kwamen, werden 
willekeurig toegewezen aan een step-up- of step-downbehandeling (figuur A1.1) 
door één van de identiek verpakte medicatiedoosjes te openen. Elk doosje 
bevatte reeds gerandomiseerde, afzonderlijk verpakte medicatiepakketjes voor 
elke behandelstap van vier weken. De patiënten, artsen en onderzoekers waren 
allen geblindeerd voor de toegewezen behandelingsstrategie tot zes maanden 
na randomisatie. De arts nam tijdens het inclusieconsult tevens bloed af, maakte 
een controleafspraak voor vier weken nadien en gaf aan de patiënt de medicatie 
van stap 1 mee plus een vragenlijst over symptomen en een over de kwaliteit 
van leven.16-18 Patiënten kregen de instructie deze vragenlijsten in te vullen vóór 
aanvang van de behandeling en de controleafspraak af te zeggen als ze na vier 
weken klachtenvrij waren - tenzij een controleafspraak gebruikelijk was bij de 
betreffende huisarts.
De patiënt ging alleen door naar de volgende behandelstap als de symptomen 
aanhielden of binnen vier weken na het beëindigen van een behandelstap 
terugkwamen. Kwamen de symptomen pas na meer dan vier weken terug, dan 
behandelde de huisarts zelf verder naar eigen inzicht. Patiënten mochten eerder 
doorgaan naar de volgende stap als hun symptomen verergerden of als er 
onaangename bijwerkingen optraden. De medicatiepakketjes bevatten, steeds 
voor een behandelstap van vier weken, een zuurneutraliserend of zuurremmend 
middel in toenemende (respectievelijk afnemende) potentie.5 De step-upgroep
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Figuur A1.1: Overzicht van de onderzoeksopzet
H2 RA= H2-receptorantagonist. PPI= protonpompremmer.
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kreeg in stap 1 een antacidum viermaal daags (aluminiumoxide 200 
mg/magnesiumhydroxide 400 mg), in stap 2 een H2-receptorantagonist tweemaal 
daags (ranitidine 150 mg), en in stap 3 een protonpompremmer éénmaal daags 
(pantoprazol 40 mg). De step-downgroep kreeg dezelfde pakketjes, met de 
medicatie in omgekeerde volgorde. Om de behandelingsstrategie te blinderen 
was aan de antacidumbehandeling een placebo protonpompremmer eenmaal 
daags toegevoegd, en aan de protonpompremmer een placebo antacidum 
viermaal daags. Ongebruikte medicatie werd geretourneerd.
Gegevensverzameling
Vóór aanvang van de behandeling maten wij met behulp van een valide 
klachtenvragenlijst16 de aard en ernst van gastro-intestinale klachten zoals 
oprispingen, zuurbranden, pijn in de bovenbuik, misselijkheid en opgeblazen 
gevoel. De kwaliteit van leven maten wij met EQ-5D.17,18 Direct na inclusie 
kregen de deelnemers een aanvullende vragenlijst toegestuurd met vragen over 
leeftijd, geslacht, etniciteit, leefstijl, werk en inkomen, medische geschiedenis en 
medicijngebruik. De follow-up duurde zes maanden. Twee weken na het begin 
van de behandeling, aan het einde van elke behandelingsstap en aan het eind 
van de follow-upperiode vroegen wij de deelnemers met behulp van vragenlijsten 
naar de mate van klachtenvermindering, aard en ernst van de gastro-intestinale
16 17,18klachten, kwaliteit van leven, , leefstijl, werkverzuim en medicatiegebruik, en 
naar eventuele uitgaven aan vervoer en een aangepast dieet (de zogeheten 
patiëntuitgaven). Huisartsconsulten, bijwerkingen, diagnostiek en verwijzingen 
werden gerapporteerd op een patiëntgegevensformulier en achteraf 
gecontroleerd aan de hand van gegevens uit het huisartseninformatiesysteem. 
Het bloed van de deelnemers werd onderzocht op H pylori; huisarts en patiënt 
kregen de uitslag van deze test pas na afloop van de follow-upperiode te horen.
Bij het berekenen van de kosten zijn wij uitgegaan van de Nederlandse 
richtlijnen voor (farmaco-)economische evaluaties in de gezondheidzorg. Daarbij 
zijn vanuit een zogeheten maatschappelijk perspectief zowel de direct medische 
kosten (medicatie, consulten, diagnostische tests en verwijzingen) als de niet- 
medische kosten (productiviteitsverlies voor betaalde en onbetaalde 
werkzaamheden, patiëntuitgaven) in aanmerking genomen. De methoden
13hebben wij elders in meer detail beschreven.
De primaire uitkomstmaten waren de effectiviteit (gemeten als dichotome 
uitkomst: ‘Zijn uw klachten voldoende verminderd sinds de start van het 
onderzoek?’)12,13 en de kosteneffectiviteit van de initiële behandeling na zes 
maanden. Wij namen het subjectieve oordeel van de patiënt over het 
behandelsucces als maat, omdat dit in de dagelijkse praktijk de basis is voor de 
keuze om de behandeling te stoppen. Secundaire uitkomstmaten waren
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Figuur A1.2: Verloop van de patiënten door het onderzoek
veranderingen in ernst van de symptomen (somscore van de ernst van de 
bovenste gastro-intestinale klachten, variërend van 0 tot 72 zoals gemeten op 
twaalf subschalen) en kwaliteit van leven (de algemene subjectieve 
gezondheidstoestand van de patiënt zoals aangegeven op een visuele analoge
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schaal van 0 (slechtst denkbaar) tot 100 (best denkbaar)) tussen baseline en zes 
maanden.
Gegevensanalyse
De gegevensanalyse vond plaats op basis van ‘intention-to-treat’. Voor de 
onderlinge vergelijking van de behandelresultaten gebruikten wij de 
chikwadraattoets en de Kaplan-Meieranalyse. Voor het vergelijken van de kosten 
gebruikten wij de Mann-Whitney-U-test. De kosteneffectiviteit bepaalden we op 
basis van een incrementele analyse tussen de beide benaderingen, met de step- 
upbenadering als referentie. Ook hebben we enkelzijdige sensitiviteitsanalyses 
uitgevoerd om het effect van verschillende kosten op de gemiddelde totale 
kosten per strategie te evalueren. Alle berekeningen zijn gedaan met SAS 
(versie 8.2) en p-waarden van 0,05 of lager (tweezijdig getoetst) zijn aangemerkt 
als statistisch significant.
RESULTATEN
Van de 312 huisartsen die deelnamen, meldden er 150 (48%) in totaal 664 
patiënten aan.12 Het verloop van de patiënten door het onderzoek is 
weergegeven in figuur A1.2. De step-upgroep telde 341 patiënten, van wie wij er 
na zes maanden 332 (97%) konden evalueren. De step-downgroep telde 323 
patiënten, van wie er uiteindelijk 313 (97%) evalueerbaar waren. In totaal zijn 
negentien patiënten (negen uit de step-upgroep en tien uit de step-downgroep) 
voortijdig uitgevallen. De patiëntkenmerken op het moment van inclusie zijn 
weergegeven in tabel A1.1, de gegevens na zes maanden follow-up in tabel 
A1.2. In de step-upgroep kregen 139 (41%) patiënten alleen de stap-1- 
onderzoeksmedicatie. Zeven patiënten in deze groep startten in het geheel niet 
met de medicatie. Vierentachtig (25%) patiënten kregen zowel stap 1 als stap 2 
en 118 (35%) patiënten kregen alle drie de behandelstappen. In de step- 
downgroep kregen 153 (47%) patiënten alleen stap 1, van wie er vier nooit 
gestart zijn. Zevenenvijftig (18%) patiënten kregen stap 1 en stap 2 en 113 (35%) 
patiënten kregen alle drie de behandelstappen.
In de step-upgroep meldden 94 (28%) patiënten één of meer bijwerkingen (zie 
tabel A1.2), in de step-downgroep 93 (29%) patiënten. Daarbij ging het om 
(andere) dyspeptische klachten (step-upgroep 59 patiënten, step-downgroep 66 
patiënten), diarree (step-upgroep 24, step-downgroep 15), constipatie (step- 
upgroep 15, step-downgroep 12), winderigheid (step-upgroep 12, step- 
downgroep 8), vieze of droge smaak (step-upgroep 4, step-downgroep 20), 
hoofdpijn (step-upgroep 5, step-downgroep 10), en huiduitslag of jeuk (step- 
upgroep 6, step-downgroep 7). Bij één deelnemer in de step-upgroep, een 60-
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Tabel A1.1: Patiëntkenmerken bij inclusie
Step-up (n=341)* Step-down (n=323)*
Geslacht
Man 157 (46%) 147 (46%)
Vrouw 184 (54%) 176 (54%)
Leeftijd
< 40 jaar 120 (35%) 108 (33%)
40 - 55 jaar 118 (35%) 108 (33%)
> 55 jaar 103 (30%) 107 (33%)
Etniciteit
Kaukasisch 317 (93%) 306 (95%)
Werk
Betaald werk 196 (63%) 173 (59%)
Roken
Huidige rokers 96 (30%) 79 (26%)
Aantal rookeenheden per dag
0 - 9 22 (25%) 20 (26%)
10 - 19 38 (43%) 30 (39%)
> 20 28 (32%) 27 (35%)
Alcohol gebruik
Huidige alcohol gebruikers 226 (70%) 234 (77%)
Aantal glazen per week
0 - 7 152 (70%) 153 (67%)
8 - 14 43 (20%) 56 (24%)
> 15 22 (10%) 20 (9%)
H py lo ri status
Positief 124 (38%) 107 (34%)
Symptomen1"
Oprispingen 201 (66%) 212 (72%)
Zuurbranden 216 (70%) 207 (70%)
Pijn in de bovenbuik 215 (74%) 204 (75%)
Misselijkheid 118 (38%) 134 (46%)
Opgeblazen gevoel 215 (70%) 208 (71%)
Dominante klacht
Dyspepsie 159 (51%) 161 (54%)
Dyspepsie en reflux gelijk 98 (32%) 85 (29%)
Reflux 54 (17%) 51 (17%)
Kwaliteit van leven5
EQ-5D score 0.76 (0.19) 0.79 (0.17)
EQ-5D VAS 54 (25) 54 (25)
*n (%), noemers hangen af van het aantal patiënten dat antwoord heeft gegeven op de betreffende vraag in 




jarige vrouw zonder alarmsymptomen, werd na 47 dagen maagkanker 
gediagnosticeerd en palliatieve behandeling gestart (figuur A1.2). De step- 
upbehandeling was bij haar na twaalf dagen in stap 1 en zeven dagen in stap 2 
zonder resultaat gebleven.
Na zes maanden meldden 238 (72%) patiënten in de step-upgroep en 219 
(70%) patiënten in de step-downgroep dat de behandeling succesvol verlopen 
was (oddsratio (OR) 0,92; 95%-betrouwbaarheidsinterval (95%-BI) 0,7-1,3; zie 
tabel A1.2 en figuur A1.3). Bij 80 (24%) step-uppatiënten en 78 (25%) step- 
downpatiënten was daarvoor slechts één behandelstap nodig geweest, bij 44 
(13%) step-uppatiënten en 26 (8%) step-downpatiënten twee stappen en bij 24 
(7%) step-uppatiënten en 20 (6%) step-downpatiënten alle drie de stappen. De 
overige 90 (27%) step-uppatiënten en 95 (30%) step-downpatiënten bij wie de 
symptomen na zes maanden voldoende verlicht waren, hadden gedurende de 
onderzoeksperiode een aanvullende - door de huisarts ingestelde - behandeling 
gekregen in de vorm van medicijnen, consulten, diagnostische tests of
13ziekenhuisopnames.
Aan het einde van de onderzoeksperiode gebruikten in totaal 111 (17%) 
deelnemers nog protonpompremmers (58 in de step-upgroep, 53 in de step- 
downgroep; p=0,84). Dit waren vaker patiënten bij wie de klachten na zes 
maanden niet of onvoldoende verminderd waren (51 (27%) van de 188 
patiënten, tegenover 60 (13%) van de 457 patiënten met voldoende 
klachtenvermindering, p<0,0001).
Tijdens de onderzoeksperiode kregen 12 patiënten eradicatietherapie voor H 
pylori (tabel A1.2). Aan het eind van de follow-upperiode maakten wij de uitslag 
van de test op H pylori bekend aan huisarts en patiënt. Daarop kregen nog eens 
minimaal 86 patiënten deze eradicatietherapie, waarmee het totaal behandelde 
patiënten uitkwam op 98, dat is 42% van de 231 patiënten die bij inclusie H pylori 
positief waren.
De step-downbenadering bracht op korte termijn vaker succes dan de step- 
upbenadering. Twee weken na inclusie meldden significant meer patiënten uit de 
step-downgroep (55%; 95%-BI 50-61%) een behandelsucces dan uit de step- 
upgroep (42%; 95%-BI 36-47%). Na een maand was het percentage succesvolle 
behandelingen gestegen tot 66% (95%-BI 61-71%) in de step-downgroep en tot 
55% (95%-BI 50-61%) in de step-upgroep (zie ook figuur A1.3). Het aantal 
patiënten met recidiefklachten verschilde niet significant in beide groepen: 104 
(34%) in de step-upgroep en 113 (40%) in de step-down groep (p=0,15). Ook de 
tijd tot het optreden van een recidief verschilde niet significant (p=0,16).
De aard en de ernst van de symptomen waren bij aanvang van het onderzoek 
in beide behandelgroepen vergelijkbaar, op basis van 608 ingevulde vragen­
lijsten met een opgetelde score van gemiddeld 20,8 (SD 9,1) op een maximum
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Tabel A1.2: Resultaten per behandelingsstrategie na zes maanden follow-up
Step-up (n=341 )* Step-down (n=323)* p-waarde
Medische uitkomsten
Behandelsucces
Ja 238 72% (66-77%) 219 70% (64-76%) 0.63
Nee 94 28% (19-37%) 94 30% (21-39%)
Naar H pylori status
Negatief 142 71% (63-78%) 142 70% (62-77%) 0.88
Positief 89 73% (64-82%) 72 69% (59-80%) 0.54
Symptomen1
Oprispingen 70 27% (17-38%) 77 32% (21-42%) 0.30
Zuurbranden 90 36% (26-45%) 86 36% (26-46%) 0.95
Pijn in de bovenbuik 54 22% (11-33%) 60 25% (14-36%) 0.38
Misselijkheid 39 15% (4-27%) 40 16% (5-28%) 0.74
Opgeblazen gevoel 93 36% (26-46%) 92 38% (28-47%) 0.75
Kwaliteit van leven5
Verslechterd (VAS) 36 15% (4-27%) 41 19% (7-31 %) 0.53
Onveranderd (VAS) 44 19% (7-30%) 35 16% (4-28%)
Verbeterd (VAS) 155 66% (59-73%) 144 65% (58-73%)
Bijwerkingen*
Stap 1 (nup=334 / ndown=319) 70 21% (11-30%) 65 20% (11-30%) 0.85
Stap 2 (nup=202 / ndown=170) 18 9% (0-22%) 30 18% (4-31 %) 0.01
Stap 3 (nup=118 / ndown= 113) 21 18% (1-34%) 20 18% (1 -34%) 0.98
Directe medische consumptie
Voorgeschreven onderzoeksmedicatie
Antacldum 341 100% (100-100%) 113 35% (26-44%) <0.0001
H2-receptorantagonist 202 59% (52-66%) 170 53% (45-60%) 0.09
Protonpompremmer 118 35% (26-43%) 323 100% (100-100%) <0.0001
Number o f patients taking additional drug treatments
Antacldum 54 16% (6-26%) 59 18% (8-28%) 0.40
H2-receptorantagonist 22 6% (0-17%) 30 9% (0-20%) 0.17
Protonpompremmer 98 29% (20-38%) 93 29% (20-38%) 0.99
H pylori eradicatie 6 2% (0-12%) 6 2% (0-13%) 0.92
Prokinetica 10 3% (0-13%) 6 2% (0-13%) 0.37
Overlg gastro-intestinaal 25 7% (0-18%) 26 8% (0-19%) 0.73
VAS=visuele analoge schaal. *n % (95%  CI), noemers hangen af van het aantal patiënten dat antwoord 
heeft gegeven op de betreffende vraag in de vragenlijst. f Ernst van de symptomen >2 op een schaal van 0 
tot 6. §De EQ-5D VAS was analyseerbaar voor 235 respectievelijk 220 patiënten. *n % (95%  CI) van het 
gerapporteerde aantal bijwerkingen per stap.
van 72. Ruim driekwart (77%) van de deelnemers rapporteerde naast 
maagklachten ook refluxklachten; slechts 1% (8 patiënten) rapporteerde alleen 
refluxklachten. Gemeten over de gehele onderzoeksduur van zes maanden
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verbeterden de klachten zowel in de step-upgroep als in de step-downgroep met 
gemiddeld 10,3 punten (95%-BI 9-11; p=0,99). De score op de honderdpunts 
VAS-schaal van EQ-5D verbeterde in die periode met respectievelijk 20 punten 
(95%-BI 16-24) in de step-upgroep en 19 punten (95%-BI 15-23) in de step- 
downgroep (p=0,70).
Figuur A1.3: Tijd to t behandelsucces
De medische consumptie verschilde tussen de beide benaderingen alleen waar
13het de zuurremmende medicatie betrof (tabel A1.2). Daardoor waren de direct 
medische kosten in de step-upgroep gemiddeld lager dan in de step-downgroep, 
zoals tabel A1.3 laat zien. Uit deze tabel blijkt ook dat de indirecte kosten 
(productiviteitsverlies en patiëntuitgaven) van dezelfde orde van grootte waren 
als de medische kosten en in beide benaderingen ongeveer even hoog uitvielen 
(p=0,56). Al met al hadden patiënten in de step-upgroep significant minder 
kosten gemaakt dan patiënten in de step-downgroep (€426 versus €460, 
p=0,02). Doordat de kosten van de step-downbenadering hoger zijn bij een gelijk 
succespercentage, is de verhouding tussen kosten en effectiviteit gunstiger voor 
de step-upbenadering (figuur A1.4). Deze verhouding - de kosteneffectiviteit - is 
echter afhankelijk van de prijs van medicijnen voor maagklachten. Als wij de 
kostenberekening maken op basis van generieke preparaten in plaats van 
specialités, dan blijft het verschil in medicatiekosten weliswaar statistisch
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significant (p=0,003), maar geldt dat niet voor de totale medische kosten 
(p=0,12) en de totale kosten (p=0,90).
Tabel A1.3: Gemiddelde kosten per behandelstrategie, in Euro
Grondslag Gemiddelde kosten per patiënt p-waarde 
Step-up (n=341) Step-down (n=323)
Direct medische kosten (n=644)
Voorgeschreven onderzoeksmedicatie
Antacid30 0.14 per tablet 23.51 (0) B.22 (0.62) <0.0001
H2-receptor antagonist31 0.25 per tabletT 13.02 (0.59) 11.57 (0.61) 0.09
Proton pump inhibitor31 1.29 per tabletT 15.6B (1.17) 45.30 (0) <0.0001
Additionele medicatie
Antacid30 0.14 per tablet 1.74 (0.29) 1.76 (0.29) 0.46
H2-receptor antagonist31 0.25 per tabletT 1.13 (0.2B) 1 .BB (0.35) 0.15
Proton pump inhibitor31 1.29 per tabletT 22.05 (2.44) 25.74 (3.02) 0.B2
H pylori eradication31 146.1 3t 3.59 (1.67) 2.B4 (1.15) 0.93
Alle medicatie B0.71 (3.91) 97.31 (3.BB) <0.0001
Consulten
Alle consulten 70.92 (2.42) 71.36 (2.63) 0.95
Diagnostische tests
Alle diagnostische tests 76.14 (11.75) 76.35 (10.B4) 0.B3
Totale medische kosten 227.77 (15.54) 245.01 (14.93) 0.000S
Indirecte kosten (n=606)§
Totale indirecte kosten .. 215.70 (34.22) 237.29 (43.66) 0.56
Totale kosten (n=664)
Gemiddelde per groepn .. 425.76 (36.70) 460.26 (43.31) 0.02
t Receptkosten (€6.71) niet inbegrepen in de prijs per tablet. §Indirecte kosten (werkverzuim en 
patiëntuitgaven) waren beschikbaar voor 313 respectievelijk 293 patiënten. "indirecte kosten=0 voor de 58 
patiënten met ontbrekende gegevens.
DISCUSSIE
Idealiter zou een behandeling voor maagklachten zo snel en doeltreffend 
moeten zijn dat het middelengebruik tot een minimum kan worden beperkt. Voor 
de behandeling van nieuw optredende maagklachten in de eerstelijns zorg 
hebben wij aangetoond dat een step-upstrategie, beginnend met antacida, 
kosteneffectiever is dan een step-downstrategie die begint met 
protonpompremmers. Bij gelijke klinische effectiviteit (gemeten als 
behandelsucces na zes maanden, ernst van de symptomen en kwaliteit van 




Figuur A1.4: Gemiddelde kosten en effectiv ite it (SE) per behandelingsstrategie
De totale kosten waren in dit onderzoek voornamelijk afhankelijk van de 
medicijnkosten. Zouden we voor de kostprijzen uitgaan van generieke 
zuurremmende medicatie en niet van spécialités, dan zou het verschil in 
kosteneffectiviteit tussen beide behandelingsstrategieën nagenoeg verdwijnen 
(onder aanname dat een generieke protonpompremmer even effectief is als een 
merkpreparaat en de prijzen van antacida en H2-receptorantagonisten 
ongewijzigd blijven). In dat geval zou de voorkeur kunnen verschuiven naar 
initiële behandeling met generieke protonpompremmers, doordat met de step- 
downstrategie soms sneller resultaat wordt geboekt. Stapsgewijze 
behandelingsstrategieën zijn al eerder vergeleken, maar de resultaten komen
19 23niet volledig overeen met die van ons onderzoek. - In eerdere onderzoeken 
bleek beginnen met protonpompremmers vaak effectiever te zijn bij 
maagklachten.19-21,23-25 Verschillende onderzoekers menen - in tegenstelling tot 
wat wij gevonden hebben - dat protonpompremmers bij refluxklachten effectiever 
zijn dan bij maagklachten.26 Deze tegenstrijdige resultaten zijn waarschijnlijk het 
gevolg van verschillen in de patiëntenpopulatie. Eerdere onderzoeken zijn 
meestal gebaseerd op patiënten met dominante refluxklachten, of op patiënten 
met dyspeptische klachten die voor endoscopie verwezen worden naar de 
tweede lijn. Dit sluit deelname uit van maagpatiënten die wél reageren op
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zuurremmende medicatie, en dat verklaart waarschijnlijk de conclusie dat 
protonpompremmers minder effectief zijn bij niet-refluxpatiënten. Onze 
onderzoekspopulatie is, door de minimale selectie, een meer realistische 
weergave van de patiëntenpopulatie met nieuwe maagklachten in de dagelijkse 
klinische huisartsenpraktijk. Onze bevindingen, bij patiënten die met een nieuwe 
episode maagklachten op het spreekuur van de huisarts komen, vullen daarom 
de bestaande literatuur goed aan.
27Ons onderzoek laat, net zoals het CADET-HN-onderzoek , zien dat 
zuurbranden een geïntegreerd onderdeel is van het complex van symptomen bij 
patiënten met niet nader onderzochte maagklachten in de eerste lijn, en dat deze 
klachten slechts bij een zeer klein deel (17%) van onze populatie overheersen. 
Daarnaast tonen onze resultaten opnieuw aan dat, zo er al een voor alle 
patiënten geldende, optimale strategie voor de behandeling van maagklachten 
mocht bestaan, het vinden van die strategie wordt bemoeilijkt door het ontbreken 
van een eenduidige definitie, door de heterogeniteit van de symptomen en door 
het grote aantal onderliggende oorzaken.8,28,29
De sterke punten van ons onderzoek zijn het grote aantal patiënten, de 
gerandomiseerde dubbelblinde onderzoeksopzet, de directe vergelijking van de 
step-up- en de step-downbenadering, en de evaluatie van verschillende 
uitkomsten, inclusief de kosten. Dit klinische onderzoek heeft echter ook 
beperkingen. Ondanks alle moeite die we gedaan hebben om het onderzoek zo
pragmatisch mogelijk op te zetten, ontstonden er onvermijdelijk verschillen
12tussen het onderzoeksprotocol en de klinische praktijk. In de praktijk zou een 
huisarts waarschijnlijk geen step-downbenadering hanteren als de patiënt niet 
reageert op protonpompremmers, die in het algemeen worden beschouwd als 
een nuttige strategie om onderliggende reflux te identificeren. Bovendien kunnen 
wij niet beoordelen of er sprake is geweest van selectiebias, omdat de registratie 
hiervan te veel tijd zou vergen van de deelnemende huisartsen. Ten slotte blijft 
het onduidelijk of een periode van zes maanden - wat al langer is dan in de 
meeste onderzoeken - toereikend is voor een evaluatie van de kosteneffectiviteit 
bij een chronisch recidiverende aandoening als dyspepsie.
Kortom, de step-upbenadering is na zes maanden kosteneffectiever dan een 
step-downbenadering bij patiënten met een nieuwe episode van maagklachten. 
Initiële empirische behandeling met een protonpompremmer (step-down) geeft 
echter vaak eerder behandelsucces, met name in de kleine subgroep met 
dominante refluxklachten. Bovendien neemt het verschil in kosteneffectiviteit af 
wanneer men de berekeningen baseert op de prijzen van generieke medicatie. 
Deze resultaten geven op zichzelf echter geen aanleiding om de Nederlandse 
richtlijnen van het NHG en het CBO, die gebaseerd zijn op de step- 
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Behandeling van maagklachten door huisartsen - Visies op 




Doel De multidisciplinaire behandelrichtlijn maagklachten (CBO/NHG 2004) 
adviseert huisartsen een step-upbenadering (antacida, H2-receptorantagonist, 
protonpompremmer) te volgen bij patiënten met een eerste episode 
maagklachten. Dit is volgens resultaten uit het DIAMOND-onderzoek ook 
kosteneffectiever. In dit artikel beschrijven we de resultaten van een 
inventarisatie onder huisartsen naar de visie op, en het gebruik van deze 
behandelrichtlijnen.
Methode Huisartsen werkzaam in het midden en zuiden van Nederland 
ontvingen een korte vragenlijst waarin zij hun voorkeur voor behandelmethoden 
voor maagklachten konden aangeven en hun mening konden geven over de 
CBO-richtlijn en NHG-standaard maagklachten.
Resultaten In totaal hebben 191 huisartsen de vragenlijst ingevuld 
geretourneerd (139 mannen, 51 vrouwen, gemiddelde leeftijd 51 jaar). De 
meerderheid (62%) van deze huisartsen geeft aan te beginnen met een 
protonpompremmer bij een eerste episode maagklachten, en dus niet step-up 
te behandelen volgens het advies van de CBO en NHG. Hoewel het merendeel 
(83%) van de huisartsen de behandelrichtlijnen duidelijk vindt, geven vooral 
huisartsen met een voorkeur voor starten met een protonpompremmer aan ze 
moeilijk toepasbaar te vinden en minder wetenschappelijk onderbouwd. 
Ongeveer 38% van de huisartsen (n=69) vindt dat de behandelrichtlijn veran­
derd moet worden. Tweeënvijftig huisartsen (46%) geven aan dat de behandel­
richtlijnen niet veranderd hoeven te worden ondanks dat zij aangeven niet 
volgens die behandelrichtlijn te behandelen.
Conclusie De meerderheid van de huisartsen geeft aan de behandelrichtlijnen 
voor maagklachten niet op te volgen. Betere toepasbaarheid en meer 
wetenschappelijke onderbouwing worden genoemd als verbeterpunten.
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INLEIDING
Maagklachten komen vaak voor onder de Nederlandse bevolking en zijn 
verantwoordelijk voor circa 3-4% van alle consulten in de eerstelijnszorg. De 
CBO-richtlijn (2004) en de NHG-Standaard (2003) voor maagklachten adviseren 
huisartsen om bij patiënten met een eerste episode maagklachten een step- 
upbenadering te volgen: starten met lichte maagzuur beïnvloedende medicatie 
(antacida of H2-receptorantagonist) en bij aanhoudende klachten verder gaan 
met sterkere medicatie (protonpompremmers).1,2 In de praktijk wordt echter vaak 
gestart met de sterkste maagzuurremmers.3,4
Tot voor kort was het nog onduidelijk welke behandelmethode, 'step-up' of 
'step-down', het meest kosteneffectief was. Daarom zijn het UMC St Radboud, 
UMC Utrecht en de Universiteit van Maastricht in 2003 het DIAMOND-onderzoek 
gestart waarin deze behandelmethoden met elkaar vergeleken werden 
(Bijlage/Tekstvak A2.1). Aan dit gerandomiseerde onderzoek hebben meer dan 
300 huisartsen en 664 patiënten meegedaan. Door toevoeging van placebo’s 
wist noch de patiënt noch de behandelaar welke behandelmethode werd 
toegepast.5-7
Uit de resultaten bleek dat de patiënten die begonnen met een 
protonpompremmer eerder klachtvrij waren dan de patiënten die step-up werden 
behandeld. Echter, na de eerste maand waren verschillen tussen beide groepen 
verdwenen en na een half jaar was 71% van de patiënten klachtenvrij (step-up 
72% en step-down 70%, Bijlage/Tekstvak A2.1). Patiënten die ingedeeld waren 
in de step-upbenadering bleken echter minder kosten gemaakt te hebben, 
waardoor deze benadering kosteneffectiever was. Dit verschil was voornamelijk 
toe te schrijven aan het verschil in kostprijs van gebruikte maagzuurremmers.6,7
Hoewel de door de behandelrichtlijnen geadviseerde step-upbenadering bij een 
eerste episode maagklachten recent ook door onderzoek wetenschappelijk wordt 
onderbouwd, is nog niet duidelijk in hoeverre huisartsen dit advies opvolgen. 
Daarom zijn wij in 2008 een vervolgonderzoek gestart om de voorkeuren in 
behandelmethoden van maagklachten door huisartsen in kaart te brengen. 
Tevens konden de huisartsen hun mening geven over de behandelrichtlijnen 
voor maagklachten. De resultaten uit dit onderzoek kunnen meer inzicht geven in 
de implementatie van behandelrichtlijnen voor huisartsen, en eventuele 
verbeterpunten kunnen worden aangehaald.
METHODE
Voor dit onderzoek is er een korte vragenlijst verstuurd naar 2759 huisartsen, 
voornamelijk werkzaam in het midden en zuiden van Nederland. Bij de vragenlijst
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is ook een ‘fact sheet’ bijgevoegd (Bijlage/Tekstvak A2.1) met daarop de 
belangrijkste conclusies uit het DIAMOND-onderzoek.
Voor het versturen van de vragenlijst in de regio Zuid-Nederland is er een 
recent adressenbestand van huisartsen van de Universiteit Maastricht gebruikt. 
Voor de regio’s Nijmegen en Utrecht werden er vanwege privacyoverwegingen 
geen recente adresgegevens verstrekt. Daardoor is het adresbestand gebruikt, 
dat in 2003-2004 is gebruikt om huisartsen te werven voor het DIAMOND- 
onderzoek. De vragenlijst kon per fax of per post naar een Antwoordnummer 
geretourneerd worden en was volledig anoniem. Uiteindelijk zijn 124 (4.5%) 
enveloppen geretourneerd vanwege foutieve adressering (verhuizing, huisarts 
gestopt e.d.).
In de vragenlijst zijn een viertal vragen aan de huisartsen voorgelegd. De 
eerste vraag was: ‘In het algemeen, welke behandeling heeft uw voorkeur voor 
patiënten met een eerste episode maagklachten en waarom?’. De 
antwoordmogelijkheden waren: a] starten met een antacidum of een H2- 
receptorantagonist en bij aanhoudende klachten opbouwen naar een 
protonpompremmer (step-upbenadering) of b] starten met een 
protonpompremmer. De tweede vraag was: ‘Wat schrijft u voor bij een patiënt 
met een eerste episode maagklachten die een antacidum zoals Rennies heeft 
geprobeerd, maar zegt dat deze onvoldoende effect hebben?’. De 
antwoordmogelijkheden waren: a] een ander antacidum, b] een H2- 
receptorantagonist of c] een protonpompremmer. Bij de derde vraag konden de 
huisartsen op een vijfpuntsschaal aangeven in welke mate ze de 
behandelrichtlijnen ‘onduidelijk - duidelijk’, ‘moeilijk - makkelijk toepasbaar’, 
‘onvoldoende - voldoende evidence-based’ vonden. Tenslotte werd gevraagd: ‘In 
het licht van de DIAMOND resultaten (Bijlage/Tekstvak A2.1), vindt u dat de 
aanbevelingen voor behandeling bij een eerste episode maagklachten in 
behandelrichtlijnen (CBO richtlijn en NHG Standaard) veranderd moeten 
worden? Zo ja, wat moet er dan veranderd worden?’, waarop de volgende 
antwoordmogelijkheden volgden: a] Nee, er hoeft niets aan de richtlijnen 
veranderd te worden, b] Ja, de aanbevelingen moeten veranderd worden, 
namelijk ...).
De antwoorden op geretourneerde vragenlijsten zijn ingevoerd in een database 
en de resultaten zijn in frequentietabellen en staafdiagrammen weergegeven. Bij 
het analyseren van de data zijn de volgende scores van de vijfpuntsschaal 




Tekstvak A2.1: Fact Sheet (voorkant)







Na vier weken waren 191 ingevulde vragenlijsten geretourneerd. De vragenlijst 
is door 139 mannen en 51 vrouwen ingevuld (n=1 onbekend) met een 
gemiddelde leeftijd van 51 jaar (SD=7).
Voorkeur behandeling maagklachten
Op de vraag met welke medicijnen gestart wordt bij behandeling van een 
eerste episode maagklachten geven 117 (62%) huisartsen aan te beginnen met 
een protonpompremmer (step-down) en 72 huisartsen (38%) starten met een 
antacidum of een H2-receptorantagonist (step-up), zoals de huidige 
behandelrichtlijnen aanbevelen. De belangrijkste argumenten, die door 
huisartsen gegeven werden om hun voorkeur te onderbouwen, zijn weergegeven 
in tabel A2.1. Mannelijke huisartsen kiezen relatief vaker voor het starten met 
een protonpompremmer (65%) dan vrouwelijke huisartsen (52%).
Tabel A2.1: Overzicht van argumenten om te starten met protonpompremmers o f antacida/H2- 
receptorantagonisten
Starten protonpompremmers Starten antacida/H2-receptorantagonisten
• heeft snel effect •  zwaarder middel vaak niet (meteen) nodig
• verhoogde kans op therapietrouw • lichtere middelen vaak net zo effectief en
• gebruik als diagnostisch hulpmiddel minder of even duur
• kosten generieke protonpompremmers • de richtlijnen bevelen dit aan
verbeterd en vergoed door verzekeraars • afbouwen is vaak moeilijk
•  sluit aan bij adviezen gastroprotectie
• geadviseerd door MDL-artsen
Voor behandeling van aanhoudende klachten na/tijdens antacidumgebruik 
kiest het merendeel (65%) van de huisartsen voor een protonpompremmer en 
31% voor H2-receptorantagonist. De keuze voor een protonpompremmer of H2- 
receptorantagonist hangt daarbij sterk samen met de voorkeur voor 
behandelmethode. Huisartsen met een voorkeur voor step-up schrijven namelijk 
vaker eerst een H2-receptorantagonist voor (72%), in plaats van direct over te 
gaan op protonpompremmers, terwijl van de huisartsen met een voorkeur voor 
een step-downbenadering slechts een klein gedeelte met H2-receptorantagonist 




Evaluatie CBO richtlijn en NHG-standaard
Het merendeel van de huisartsen vindt de huidige behandelrichtlijnen duidelijk 
(figuur A2.1). Huisartsen met een voorkeur voor het starten met een 
protonpompremmer vinden de behandelrichtlijnen vaker onduidelijk dan 
huisartsen die een voorkeur hebben voor step-up behandelen (7% voor step- 
down vs 3% voor step-up).
Figuur A2.1: Huisartswaardering van de duidelijkheid van de richtlijn
Verder vindt 42% van alle huisartsen de behandelrichtlijnen moeilijk 
toepasbaar en 11% vindt de behandelrichtlijnen onvoldoende evidence-based 
(figuren A2.2 en A2.3). Ook hier zien we grote verschillen tussen huisartsen met 
een voorkeur voor step-up en huisartsen met een voorkeur voor starten met 
protonpompremmer: deze laatste groep vindt de behandelrichtlijnen minder vaak 
makkelijk toepasbaar (step-down: 59% vs step-up: 14%) en minder vaak 
evidence-based (step-down: 17% vs step-up: 2%).
Figuur A2.2: Huisartswaardering van de toepasbaarheid van de richtlijn
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Figuur A2.3: Huisartswaardering van de ‘evidence-base’ van de richtlijn
Ongeveer 38% van de huisartsen (n=72) vindt dat de behandelrichtlijn 
veranderd moet worden. Daarbij geven degenen met een voorkeur voor starten 
met een protonpompremmer aan dat de behandelrichtlijnen dienovereenkomstig 
veranderd moeten worden (n=60), terwijl de voorstanders voor step-up (n=12) 
aangeven dat de behandelrichtlijnen duidelijker moet beschrijven wat de waarde 
van de step-upbenadering is. Twee huisartsen geven aan dat de stap met 
antacidum kan vervallen. Van de huisartsen die starten met een 
protonpompremmer (n=112, 5 missing) geven 52 huisartsen (46%) aan dat de 
behandelrichtlijn niet veranderd hoeven te worden, ondanks dat hun voorkeur 
uitgaat naar een andere benadering dan de geadviseerde step-upbenadering 
(figuur A2.4).
Figuur A2.4: Mening van huisartsen over aanpassen van de richtlijn
DISCUSSIE
Uit de resultaten van dit onderzoek kunnen we concluderen dat de
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meerderheid van de huisartsen bij behandeling van eerste episode 
maagklachten de CBO-richtlijn en de NHG-standaard niet opvolgen. Meer dan de 
helft van de huisartsen gaven bij behandeling van eerste episode maagklachten 
aan te starten met een protonpompremmer, terwijl de behandelrichtlijnen 
voorschrijven te starten met antacida of H2-receptorantagonist. Een groot deel 
van de huisartsen die starten met een protonpompremmer zijn dan ook van 
mening dat de behandelrichtlijnen in overeenstemming met hun handelen 
veranderd moeten worden. Opmerkelijk is echter dat nagenoeg de helft van de 
huisartsen die starten met een protonpompremmer niet vond dat de 
behandelrichtlijn veranderd hoeft te worden.
Enige terughoudendheid ten aanzien van onze onderzoeksresultaten dient in 
acht genomen te worden. in dit onderzoek is het namelijk niet duidelijk of 
huisartsen voornamelijk gericht zijn op Nederlandse behandelrichtlijnen of dat 
internationale behandelrichtlijnen ook opgevolgd worden. De Amerikaanse (AGA 
en ACG), Britse (NiCE) en Canadese (CanDys) behandelrichtlijnen wijken 
aanzienlijk af van de Nederlandse behandelrichtlijn. Zij adviseren om de 
behandeling te starten met een H pylori ‘test-en-behandelstrategie’ of een 
protonpompremmer (of volgens de CanDys een protonpompremmer, H2- 
receptorantagonist of prokinetica), afhankelijk van de H pylori prevalentie of de 
dominante symptomen.8-11 Vergelijkbaar met de Nederlandse behandelrichtlijn 
adviseert de Schotse (SIGN) behandelrichtlijn om te starten met leefstijladviezen, 
antacida of H2-receptorantagonisten. Gebruik van een protonpompremmer wordt
echter pas geadviseerd indien symptomen aanhouden na een H pylori ‘test-en-
12
behandelstrategie’. Dit kan een verklaring zijn waarom een deel van de 
huisartsen zich niet houdt aan Nederlandse behandelrichtlijnen en niet 
gemakkelijk hun perceptie bijstelt.
Waarschijnlijk spelen financiën ook een rol. Sinds de CBO richtlijn 
maagklachten in 2004, zijn er verschillende protonpompremmers uit patent 
geraakt en als generiek product op de markt gekomen. Dit heeft ervoor gezorgd 
dat de kosten voor een protonpompremmer drastisch zijn gedaald. Dit zou ook 
kunnen leiden tot een andere interpretatie van de behandelrichtlijn, maar ook van 
de kosteneffectiviteit resultaten van het DIAMOND-onderzoek. Deze waren 
namelijk gebaseerd op pantoprazol, wat ten tijde van de studie nog een 
spécialité geneesmiddel was. Er worden op dit moment regionaal, maar ook 
landelijk, programma’s aangestuurd waarin het gebruik van generieke 
protonpompremmers wordt aangemoedigd. Patiënten die op dit moment de 
duurdere spécialité geneesmiddelen gebruiken, worden actief overgezet naar 
generieke middelen. Dit zal leiden tot minder geneesmiddelenkosten, maar een 
groot Canadees onderzoek heeft aangetoond, dat substitutie in totaal veel méér 
kosten met zich meebrengt.13 Patiënten die waren omgezet naar goedkopere
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protonpompremmers bezochten vaker opnieuw de arts en kregen vaker een 
endoscopisch onderzoek.
Daarnaast dient ook vermeld te worden, dat de respons in ons onderzoek laag 
is. Doordat slechts een verouderd huisartsadressenbestand tot onze beschikking 
stond, zullen mogelijk veel vragenlijsten niet zijn aangekomen. Daarnaast was er 
geen mogelijkheid om herinneringen te versturen om de respons te verhogen, 
omdat de vragenlijst anoniem was. Hoewel het niet uitgesloten is dat de groep 
respondenten niet geheel representatief is voor alle huisartsen in Nederland, 
geven onze resultaten de visie van huisartsen, die hun mening hebben willen 
geven over de behandelrichtlijn, weer. Op basis van deze gegevens is echter niet 
aan te geven hoe het voorschrijfgedrag van Nederlandse huisartsen werkelijk is. 
De resultaten van deze enquête kunnen desalniettemin goede input geven voor 
het eventueel aanpassen of verduidelijken van de behandelrichtlijn en geeft een 
beeld van de belangrijkste argumenten voor het huidige handelen. Dit kan 
gebruikt worden om de behandelrichtlijn te verbeteren, beter te implementeren, 
en zo uiteindelijk het ‘evidence-based’ handelen te verbeteren.
In het algemeen kunnen we concluderen dat een groot deel van de huisartsen 
de behandelrichtlijnen niet opvolgen. Bij herziening van de behandelrichtlijnen 
dienen beleidsmakers beter rekening te houden met de toepasbaarheid ervan. 
Tevens zal er meer uitleg moeten komen over de gemaakte keuzes voor een 
bepaalde behandelmethode aan de hand van wetenschappelijk onderzoek en 
dienen tegenargumenten weerlegd te worden. De resultaten van deze studie 
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Stellingen behorend bij het proefschrift
Initial m anagem ent of dyspepsia in primary care
effectiveness, efficiency, and quality of life
Corine J van Marrewijk, 8 februari 2011
1. De step-up benadering verd ient de voorkeur boven de step-down 
benadering in de behandeling van patiënten met nieuw ontstane 
maagklachten. (dit proefschrift)
2. Verm indering van sym ptom en is de belangrijkste, m aar niet de enige, 
onafhankelijke voorspe lle r van verbetering van kwaliteit van leven. (dit 
proefschrift)^ >
3. Naast betere wetenschappelijke onderbouw ing en toepasbaarheid van 
behandelrichtlijnen, zal de naleving ervan gestim uleerd en gehandhaafd 
moeten worden om te zorgen dat behandelrichtlijnen daadwerkelijk  kun­
nen bijdragen aan zorgvuld ige besteding van m iddelen in de gezond­
heidszorg. (dit proefschrift)
■ 4. De subjectieve observatie door een patiënt is w aardevoller dan een
objectieve klinische maat in de behandeling van m aagklachten.
5. Er is onvoldoende toegevoegde waarde voo r huisartsen om de status 
van het m aagslijm vlies serologisch te testen voorafgaand aan de behan­
deling van m aagklachten. (dit proefschrift)
6 . De ideale behandeling voor dyspepsie bestaat (nog) niet.
7. Zuurbranden is onderdeel van het dyspeptische sym ptoom  com plex in 
patiënten met nieuw ontstane m aagklachten in de eerste lijns gezond­
heidszorg. (dit proefschrift)
k  8. Het schrijven van een proefschrift naast een baan en m oederschap is
P  als koorddansen: je  moet continu zorgen dat je  in balans blijft.
9. Luister naar ieders kritiek, m aar behoud uw eigen oordeel. (William 
Shakespeare)
/
10. De charm e van de wetenschap is: dat je  van mening mag verschillen.
11. De m eest waardevolle kennis is zelfkennis.
■ 12. A chte r de wolken schijnt de zon.
13. Het is effectiever om je  energie te steken in leuke dingen, w ant
verve lende dingen kosten alleen energie, terw ijl de leuke dingen je  ju is t 
energie geven.
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